

WEST**End of Result Set**

Generate Collection

Print

L1: Entry 1 of 1

File: USPT

May 23, 2000

US-PAT-NO: 6066474DOCUMENT-IDENTIFIER: US 6066474 A

TITLE: Y2H56 A strong IKK binding protein

DATE-ISSUED: May 23, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Marcu; Kenneth B.	Stony Brook	NY		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE	CODE
The Research Foundation of State University of New York	Albany	NY			02	

APPL-NO: 09/ 195286 [PALM]

DATE FILED: November 18, 1998

INT-CL: [07] C12 P 21/06, C12 N 1/20, C07 H 21/04, C07 H 21/02, C07 H 1/00

US-CL-ISSUED: 435/69.1; 536/23.5, 536/23.1, 530/350, 435/252.3, 435/320.1

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 530/350, 536/23.1, 536/23.5

FIELD-OF-SEARCH: 435/69.1, 435/320.1, 435/252.3, 536/23.1, 536/23.5

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>5776717</u>	July 1998	Cao	435/15
<input type="checkbox"/>	<u>5804374</u>	September 1998	Baltimore et al.	435/6

OTHER PUBLICATIONS

THIS PAGE BLANK (USPTO)

Mock et al., "CHUK, a Conserved Helix-Loop-Helix Ubiquitous Kinase, Maps to Human Chromosome 10 and Mouse Chromosome 19", Genomics 27:348-351 (1995).

Margery A. Connelly and Kenneth B. Marcu, "CHUK, a New Member of the Helix-Loop-Helix and Leucine Zipper Families of Interacting Proteins, Contains a Serine-Threonine Kinase Catalytic Domain", Cellular and Molecular Biology Research 41:537-549 (1995).

Garkavtsev, et al., "Suppression of the novel growth inhibitor p33.sup.ING1 promotes neoplastic transformation", Nature Genetics 14:415-420 (1996).

DiDonato et al., "A Cytokine-Responsive I.kappa.B Kinase That Activates the Transcription Factor NF-.kappa.B", Nature 388:548-554 (1997).

Regnier et al., "Identification and Characterization of an I.kappa.B Kinase", Cell 90:373-383 (1997).

Ilana Stancovski and David Baltimore, "NF-.kappa.B Activation: The I.kappa.B Kinase Revealed?", Cell 91:299-302 (1997).

Woronicz et al., "I.kappa.B Kinase-.beta.: NF-.kappa.B Activation and Complex Formation with I.kappa.B Kinase-.alpha. and NIK", Science 278:866-869 (1997).

Zandi et al., "The I.kappa.B Kinase Complex (IKK) Contains Two Kinase Subunits, IKK.alpha. and IKK.beta., Necessary for I.kappa.B Phosphorylation and NF-.kappa.B Activation", Cell 91:243-252 (1997).

Garkavtsev, et al., "The candidate tumour suppressor p33.sup.ING1 cooperates with p53 in cell growth control", Nature 391:295-298 (1998).

Moshe Oren, "Teaming up to restrain cancer", Nature 391:233-234 (1998).

ART-UNIT: 162

PRIMARY-EXAMINER: Prouty; Rebecca E.

ASSISTANT-EXAMINER: Monshipouri; Maryam

ABSTRACT:

The present invention provides an isolated I.kappa.B kinase binding protein designated Y2H56 and functional equivalents thereof. The amino acid sequence of Y2H56, the nucleotide sequence encoding Y2H56, and other related protein and nucleic acid molecules are also provided.

8 Claims, 0 Drawing figures

Exemplary Claim Number: 1

BRIEF SUMMARY:

1 BACKGROUND OF THE INVENTION

2 Extracellular stimuli associated with immune responses, inflammatory responses, and apoptosis activate kinases through receptor mediated processes. Ashkenazi and Dixit, Science 281, 1305-1308 (1998). For example,

THIS PAGE BLANK (USPTO)

inflammatory cytokines such as tumor necrosis factor .alpha. (TNF.alpha.) or interleukin-1 (IL-1), activate kinases which in turn activate NF-.kappa.B by phosphorylating inhibitory proteins known as I.kappa.Bs. Phosphorylation of I.kappa.Bs is a key regulatory step for NF-.kappa.B mediated processes. See, for example, Baeuerle and Henkel, *Annu. Rev. Immunol.* 12, 141-179 (1994); Baldwin, *Annu. Rev. Immunol.* 14, 649-683 (1996); Siebenlist et al., *Annu. Rev. Cell Biol.* 12, 405-455 (1994); and Verma et al, *Genes Dev.* 9, 2723-2735 (1995). The kinases that phosphorylate I.kappa.Bs are called I.kappa.B kinases (IKKs).

- 3 The determination and characterization of kinases involved in signaling pathways leading to, for example, immune, inflammatory, and apoptotic responses is important for understanding and controlling these processes. Recently, an I.kappa.B kinase, designated IKK.alpha. but also referred to as CHUK (conserved helix-loop-helix ubiquitous kinase), was identified in a yeast-two-hybrid screen with NIK as bait. Regnier et al., *Cell* 90, 373-383 (1997). IKK.alpha. was determined to be responsible for the major I.kappa.B kinase activity induced by TNF stimulation of HeLa cells. DiDonato et al., *Nature* 388, 548-554 (1997). The identification of IKK.alpha. as a cytoplasmic kinase which phosphorylates I.kappa.B family members at their physiologically relevant sites and targets them for proteasome-mediated degradation was a major breakthrough.
- 4 The IKK.alpha. gene encodes a 745 amino-acid polypeptide (having a molecular mass of approximately 85 kDa). Murine and human IKK.alpha. cDNA clones were found to be almost identical. Connelly and Marcu, *Cellular and Molecular Biology Research* 41, 537-549 (1995).
- 5 Another kinase, termed IKK.beta., homologous to IKK.alpha., has also been reported. Stancovski and Baltimore, *Cell* 91, 299-302 (1997); Woronicz et al., *Science* 278, 866-869 (1997); and Zandi et al., *Cell* 91, 243-252 (1997). IKK.alpha. and IKK.beta. have 52% overall similarity to each other and 65% identity in the kinase domain. Zandi et al., *Cell* 91, 243-252 (1997). An I.kappa.B kinase termed T2K has also been described in U.S. Pat. No. 5,776,717 to Cao.
- 6 The known I.kappa.B protein kinases generally phosphorylate I.kappa.Bs at specific serine residues. For example, they specifically phosphorylate serines 32 and 36 of I.kappa.B.alpha.. Phosphorylation of both sites is required to efficiently target I.kappa.B.alpha. for destruction in vivo. Moreover, activation of IKK.alpha. and IKK.beta. occurs in response to NF-.kappa.B activating agents and mutant IKK.alpha. and IKK.beta. that are catalytically inactive block NF-.kappa.B stimulation by cytokines. These results highlight the important role played by I.kappa.B protein kinases in NF-.kappa.B activation processes. See Stancovski and Baltimore, *Cell* 91, 299-302 (1997) for a recent discussion of I.kappa.B kinases.
- 7 IKK.alpha. and IKK.beta., have structural motifs characteristic of the IKK kinases. This includes an amino terminal serine-threonine kinase domain separated from a carboxyl proximal helix-loop-helix (H-L-H) domain by a leucine zipper domain. These structural characteristics are unlike other kinases, and the domains are thought to be involved in protein-protein interactions.
- 8 Numerous proteins are involved in the signaling pathways that lead to immune, inflammatory, and apoptotic responses. A complete elucidation of these processes requires the identification of additional proteins that are involved and a determination of the protein interactions.
- 9 The discovery of additional proteins involved in these processes is important for controlling immune, apoptotic, and inflammatory processes. Thus, there is a great need for the identification and characterization of additional proteins involved in IKK mediated cellular processes.

THIS PAGE BLANK (USPTO)

10 SUMMARY OF THE INVENTION

11 The present invention provides an isolated IKK binding protein comprising the amino acid sequence set forth in SEQ ID NO:1 and functional equivalents thereof. Also included are isolated nucleic acid molecules that encode the IKK binding protein comprising the amino acid sequence set forth in SEQ ID NO:1 and its functional equivalents, methods of making the IKK binding proteins comprising expressing nucleic acid molecules encoding the proteins, and antibodies directed to the IKK binding proteins.

12 DETAILED DESCRIPTION OF THE INVENTION

13 The invention is directed to an IKK binding protein, designated Y2H56, and its functional equivalents. Y2H56 will hereinafter refer to the protein defined by SEQ ID NO:1, which is found in humans.

14 In this specification, functional equivalents are proteins or fragments that are substantially homologous to SEQ ID NO:1 and that specifically bind to an IKK protein, such as IKK.alpha. or IKK.beta.. The term IKK is used herein to refer to all kinases that phosphorylate any I.kappa.B and that have helix-loop-helix and leucine zipper domains. Y2H56 and its functional equivalents bind to the region of the IKK proteins made up of the contiguous helix-loop-helix and leucine zipper domains.

15 In order to determine whether the sequence of a first protein, or fragment thereof, is substantially homologous to the sequence of a second protein, such as Y2H56, or fragment thereof, the sequences are first aligned so as to optimize the percent of amino acid residues that are identical, or that are identical or equivalent, at corresponding positions. Gaps may be introduced in the sequences, if necessary, to achieve optimization.

16 Amino acids generally considered to be equivalent are indicated below in separate rows (a) through (e):

17 (a) Ala (A), Ser (S), Thr (T), Pro (P), Gly (G)

18 (b) Asn (N), Asp (D), Glu (E), Gln (Q)

19 (c) His (H), Arg (R), Lys (K)

20 (d) Met (M), Leu (L), Ile (I), Val (V)

21 (e) Phe (F), Tyr (Y), Trp (W)

22 The amino acid sequences of highly homologous proteins can usually be aligned by visual inspection. If visual inspection is insufficient, the proteins are aligned in accordance with any of the methods described by George, D. G. et al, in *Macromolecular Sequencing and Synthesis, Selected Methods and Applications*, pages 127-149, Alan R. Liss, Inc. (1988), such as the formula described at page 137 using a match score of 1, a mismatch score of 0, and a gap penalty of -1.

23 In a first embodiment, the sequence of a protein or fragment thereof is considered substantially homologous to the sequence of Y2H56 or a fragment thereof if the amino acid sequences, after alignment, are at least about 25% identical, preferably at least about 35% identical, more preferably at least about 50% identical, even more preferably at least about 65% identical, still more preferably at least about 75% identical, most preferably at least about 85% identical, and, ideally at least about 95% identical.

24 In a second embodiment, the sequence of a protein or fragment thereof is considered substantially homologous to the sequence of Y2H56 or a fragment thereof if the amino acid sequences, after alignment, are at least about 50%

THIS PAGE BLANK (USPTO)

identical or equivalent, preferably at least about 65% identical or equivalent, most preferably at least about 85% identical or equivalent, and ideally at least about 95% identical or equivalent.

- 25 Functional equivalents include all modifications of the polypeptide set forth in SEQ ID NO:1. These modifications may be introduced deliberately, as by site-directed mutagenesis, or may be natural variations and mutations. Such modifications include substitutions, additions, and/or deletions in the protein sequences as long as substantial homology and specific binding to IKK proteins are maintained.
- 26 For example, functional equivalents include variant Y2H56 proteins that are expressed by naturally occurring alleles. Alleles are alternative forms of a gene that occupy a given locus of a chromosome within a species.
- 27 Functional equivalents of Y2H56 also include proteins from non-human mammalian species (species orthologs) as well as proteins expressed by alleles of such species orthologs. Non-human mammals include, for example, primates, pet animals such as dogs and cats, laboratory animals such as rats and mice, and farm animals such as horses, sheep, and cows.
- 28 The proteins of the invention that do not occur in nature are isolated. The term "isolated" as used herein, in the context of proteins, refers to a polypeptide which is unaccompanied by at least some of the material with which it is associated in its natural state. The isolated protein constitutes at least 0.5%, preferably at least 5%, more preferably at least 25% and still more preferably at least 50% by weight of the total protein in a given sample.
- 29 Most preferably the "isolated" protein is substantially free of other
- 30 proteins, lipids, carbohydrates or other materials with which it is naturally associated, and yields a single major band on a non-reducing polyacrylamide gel. Substantially free means that the protein is at least 75%, preferably at least 85%, more preferably at least 95% and most preferably at least 99% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
- 31 ~~The invention also provides novel and/or isolated nucleic acid molecules that encode SEQ ID NO:1 and the functional equivalents thereof. Nucleic acid molecules (nucleic acids) of the invention include deoxyribonucleic acid (DNA), complementary DNA (cDNA), and ribonucleic acid (RNA) sequences.~~
- 32 ~~For example, the invention includes an isolated nucleic acid molecule as set forth in either SEQ ID NO:2 or SEQ ID NO:3, isolated nucleic acid molecules that are substantially homologous with SEQ ID NO:2 or SEQ ID NO:3, isolated nucleic acid molecules that hybridize with SEQ ID NO:2 or SEQ ID NO:3 under stringent conditions, nucleic acid sequences that are degenerate as a result of the genetic code, and the complements and fragments thereof.~~
- 33 In order to determine whether the sequence of a first nucleic acid molecule, or fragment thereof, is substantially homologous to the sequence of a second nucleic acid molecule, such as SEQ ID NO:2, or fragment thereof, the sequences are first aligned so as to optimize the percent of nucleotides that are identical at corresponding positions. Gaps may be introduced in the sequences if necessary to achieve optimization.
- 34 The nucleic acid sequences of highly homologous nucleic acid molecules can usually be aligned by visual inspection. If visual inspection is insufficient, the nucleic acid molecules are aligned in accordance with any of the methods described by George, D. G. et al, in *Macromolecular Sequencing and Synthesis, Selected Methods and Applications*, pages 127-149, Alan R. Liss, Inc. (1988), such as the formula described at page 137 using a

THIS PAGE BLANK (USPTO)

match score of 1, a mismatch score of 0, and a gap penalty of -1.

- 35 In the present specification, the sequence of a nucleic acid molecule or fragment thereof is considered substantially homologous to SEQ ID NO:2, or a fragment thereof, if the nucleic acid sequences, after alignment, are at least about 40% identical, preferably at least about 50% identical, more preferably at least about 60% identical, even more preferably at least about 70% identical, still more preferably at least about 80% identical, most preferably at least about 90% identical, and, ideally at least about 95% identical.
- 36 The invention also includes nucleic acid molecules that hybridize to SEQ ID NO:2 or SEQ ID NO:3, a fragment of SEQ ID NO:2, a complement of SEQ ID NO:2, or a complement of a fragment of SEQ ID NO:2 under stringent conditions. Also included in the invention are a preferred group of protein functional equivalents of SEQ ID NO:1 encoded by nucleic acid molecules that hybridize under stringent conditions to a sequence complementary to SEQ ID NO:2 or a fragment of SEQ ID NO:2.
- 37 The term "stringent conditions," as used herein, is equivalent to "high stringent conditions" and "high stringency." These terms are used interchangeably in the art.
- 38 Stringent conditions are defined in a number of ways. In one definition, stringent conditions are selected to be about 50.degree. C. lower than the thermal melting point ($T_{sub}m$) for a specific sequence at a defined ionic strength and pH. The $T_{sub}m$ is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched sequence. Typical stringent conditions are those in which the salt concentration is about 0.02 M at pH 7 and the temperature is at least about 60.degree. C. Further examples of stringent conditions can be found in U.S. Pat. No. 5,789,550 to Goeddel et al. (1998). The description of stringent conditions in U.S. Pat. No. 5,789,550 is herein incorporated by reference.
- 39 Stringent conditions, in the nucleic acid hybridization context, include a combination of conditions, such as the nature and concentration of salts and organic solvents, temperature, and other parameters that are typically known to control hybridization reactions. The combination of parameters is more important than the measure of any single parameter. See U.S. Pat. No. 5,786,210; Wetmur and Davidson, J. Mol. Biol. 31, 349-370 (1968). Generally, stringent conditions are obtained at higher temperatures and lower ionic strength. Control of hybridization conditions, and the relationships between hybridization conditions and degree of homology are understood by those skilled in the art. See, for example, Bej, A. K., Nucleic Acid Hybridizations: Principles and Strategies, in Dangler, C. A. ed, Nucleic Acid Analysis:
- 40 Principles and Bioapplications, Wiley-Liss, Inc., pp. 1-29 (1996); Adams et al., The Biochemistry of the Nucleic Acids, pp. 605-606, Chapman & Hall (1992); Sambrook J, Fritsch EF, and Maniatis T, Molecular Cloning. A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor (1989).
- 41 Fragments of nucleic acid molecules of the invention include primers and probes which are useful as tools in molecular biology and biotechnology. The fragment may or may not encode a polypeptide that binds to IKK.alpha. or IKK.beta.. Even if the encoded polypeptide does not bind, the fragment can be used; for example, as a primer ("amplimer") to selectively amplify nucleic acid, such as genomic DNA or total RNA. Primers can also be used in nucleic acid amplification procedures such as the polymerase chain reaction (PCR), ligase chain reaction (LCR), repair chain reaction (RCR), PCR oligonucleotide ligation assay (PCR-OLA), and the like.

THIS PAGE BLANK (USPTO)

- 42 Fragments of the nucleic acid molecules of the invention can also be oligonucleotides complementary to a target nucleic acid molecule, i.e., the fragment can be a probe. Such oligonucleotides can be DNA or RNA. Oligonucleotides useful as probes in hybridization studies, such as in situ hybridization, can also be constructed.
- 43 The length of the oligonucleotide probe is not critical, as long as it is capable of hybridizing to the target molecule. The oligonucleotide should contain at least 6 nucleotides, preferably at least 10 nucleotides, and more preferably, at least 15 nucleotides. There is no upper limit to the length of the oligonucleotide probes. Longer probes are more difficult to prepare and require longer hybridization times. Therefore, the probe should not be longer than necessary. Normally, the oligonucleotide probe will not contain more than 50 nucleotides, preferably not more than 40 nucleotides, and, more preferably, not more than 30 nucleotides.
- 44 Numerous methods for detectably labeling such probes with radioisotopes, fluorescent tags, enzymes, binding moieties (e.g., biotin), and the like are known, so that the probes of the invention can be adapted for easy detectability. Methods for making and using nucleic acid probes are understood by those skilled in the art. See, for example, Keller G H and Manak M M, DNA Probes, 2d ed., Macmillan Publishers Ltd., England (1991) and Hames B D and Higgins S J, eds., Gene Probes I and Gene Probes II, IRL Press, Oxford (1995).
- 45 The nucleic acid molecules may contain synthetic sequences that do not occur in nature and/or they are isolated. The term "isolated," as used herein, in the context of nucleic acids, includes nucleic acid molecules unaccompanied by at least some of the material with which they are associated in their natural state. The isolated nucleic acid may constitute at least 0.5%, preferably at least 5%, more preferably at least 25% and still more preferably at least 50% by weight of the total nucleic acid in a given sample.
- 46 Most preferably the "isolated" nucleic acid is substantially free of other nucleic acids, proteins, lipids, carbohydrates or other materials with which it is naturally associated. Substantially free means that the nucleic acid is at least 75%, preferably at least 85%, more preferably at least 95% and most preferably at least 99% free of other nucleic acids, proteins, lipids, carbohydrates or other materials with which it is naturally associated. The nucleic acid molecules of the invention can also be recombinant, meaning that they comprise a non-natural sequence or a natural sequence joined to nucleotide(s) other than those in which they are joined on the natural chromosome.
- 47 Y2H56 was shown, using yeast two-hybrid screens, to bind to the carboxyl terminal domain regions of IKK.alpha. and IKK.beta.. See example 1. Y2H56 specifically binds with the region of the IKK proteins made up of the contiguous helix-loop-helix and leucine zipper domains. The binding of the Y2H56 protein to the IKKs is stronger than the binding of IKK.alpha. to a natural substrate of IKK.alpha., viz. I.kappa.BP.beta.2.
- 48 The Y2H56 protein and the other IKK.alpha. binding proteins described in example 1 are useful for elucidating and controlling pathways leading to inflammation and apoptosis. These processes are mediated by receptors such as tumor necrosis factor (TNF) receptors. The IKK binding proteins can also be used to detect IKK complexes and modulate IKK activity in cells undergoing signalling by inflammatory mediators such as TNF.alpha. and Il-1.
- 49 The Y2H56 protein and its functional equivalents are also useful for identifying therapeutically active agents that modulate the binding or interaction of Y2H56 and either IKK.alpha. or IKK.beta.. Such agents can either prevent the formation of Y2H56/IKK complexes or prevent or inhibit the dissociation of Y2H56/IKK complexes. Molecules that prevent the

THIS PAGE BLANK (USPTO)

formation of Y2H56/IKK complexes or inhibit the dissociation of these complexes are useful for boosting the immune system, or as immunosuppressants, or as antiinflammatory agents.

- 50 Complex formation or dissociation can be determined by methods well known in the art. Such methods include, for example, gel filtration, sucrose density gradient centrifugation, crosslinking, and immunoprecipitation.
- 51 The proteins and variants of the proteins can be prepared by methods known in the art. Such methods include isolating the protein directly from cells, and synthesizing the protein chemically from individual amino acids. Preferably, the proteins of the invention can be prepared by providing DNA that encodes the protein, amplifying or cloning the DNA, expressing the DNA in a suitable host, and harvesting the protein.
- 52 DNA encoding the proteins of the invention can be synthesized or isolated. The DNA of the invention can be synthesized chemically from the four nucleotides in whole or in part by methods known in the art. Such methods include those described by Caruthers, Science 230, 281-285 (1985). DNA can also be synthesized by preparing overlapping double-stranded oligonucleotides, filling in the gaps, and ligating the ends together. See, generally, Sambrook et al. (1989) and Glover D M and Hames B D, eds., DNA Cloning, 2d ed., Vols. 1-4, IRL Press, Oxford (1995).
- 53 DNA expressing functional homologs of the protein can be prepared from wild-type DNA by site-directed mutagenesis. See, for example, Zoller and Smith, Nucleic Acids Res 10, 6487-6500 (1982); Zoller, Methods Enzymol 100, 468-500 (1983); Zoller, DNA 3(6), 479-488 (1984); and McPherson, ed., Directed Mutagenesis: A Practical Approach, IRL Press, Oxford (1991).
- 54 DNA encoding the protein of the invention can be isolated from different species by using the human sequence, SEQ ID NO:2, to prepare one or more oligonucleotide probes. The probe is labeled and used to screen a genomic or cDNA library in a suitable vector, such as phage lambda. The homology between the DNA of the Y2H56 of the species being screened and that of the human DNA is taken into account in determining the conditions of hybridization. The cDNA library may be prepared from mRNA by known methods, such as those described in Gubler and Hoffman, Gene 25, 263-270 (1983). Oligonucleotide probes can be used to screen cDNA libraries from different species and tissues. The oligonucleotide probe should be labeled so that it can be detected upon hybridization to DNA in the library being screened. These methods are well known in the art.
- 55 The DNA isolated is sequenced, and the sequence used to prepare additional oligonucleotide probes. This procedure may be repeated to obtain overlapping fragments until a complete open reading frame is produced.
- 56 The nucleic acids of the invention may be amplified by methods known in the art. One suitable method is the polymerase chain reaction (PCR) method described by Saiki et al., Science 239, 487 (1988), Mullis et al in U.S. Pat. No. 4,683,195 and by Sambrook et al. (1989). It is convenient to amplify the clones in the lambda-gt10 or lambda-gt11 vectors using lambda-gt10 or lambda-gt11-specific oligomers as the amplimers (available from Clontech, Palo Alto, Calif.). Other amplification procedures that are well known in the art such as ligase chain reaction (LCR), repair chain reaction (RCR), and PCR oligonucleotide ligation assay (PCR-OLA) can also be used to amplify the nucleic acids of the invention.
- 57 DNA encoding the proteins of the invention, or unique fragments thereof, may also be cloned in a suitable host cell and expressed by methods well known in the art. The DNA and protein may be recovered from the host cell. See, generally, Sambrook et al. (1989), for methods relating to the manufacture and manipulation of nucleic acids. The entire gene or additional fragments of the gene can be isolated by using the known DNA sequence or a fragment

THIS PAGE BLANK (USPTO)

thereof as a probe. To do so, restriction fragments from a genomic or cDNA library may be identified by Southern hybridization using labeled oligonucleotide probes derived from SEQ ID NO:2.

- 58 The amplified or cloned DNA can be expressed in a suitable expression vector by methods known in the art. See, generally, Sambrook et al. (1989).
- 59 A variety of expression vectors and host cell systems can be used. These include, for example, microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA containing the Y2H56 coding region. Other expression vectors and host cell systems that can be used include yeast transformed with recombinant yeast expression vectors containing the Y2H56 coding sequence, insect cells infected with recombinant virus expression vectors containing the Y2H56 coding sequence, plant cells infected with recombinant virus expression vectors containing the Y2H56 coding sequence, or animal cells infected with recombinant virus expression vectors (e.g., retroviruses, adenovirus, vaccinia virus) containing the Y2H56 coding sequence.
- 60 The expression vectors useful in the present invention contain at least one expression control sequence that is operatively linked to the DNA sequence or fragment to be expressed. The control sequence is inserted in the vector in order to control and to regulate the expression of the cloned DNA sequence. Examples of useful expression control sequences are the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the glycolytic promoters of yeast, e.g., the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast alpha-mating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters or SV40, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses or combinations thereof.
- 61 Useful expression hosts include well-known prokaryotic and eukaryotic cells. Some suitable prokaryotic hosts include, for example, *E. coli*, such as *E. coli* SG-936, *E. coli* HB 101, *E. coli* W3110, *E. coli* X1776, *E. coli* X2282, *E. coli* DHI, and *E. coli* MRC1, *Pseudomonas* sp., *Bacillus* sp., such as *B. subtilis*, and *Streptomyces* sp. Suitable eukaryotic cells include yeasts and other fungi, insect, animal cells, such as COS cells and CHO cells, human cells and plant cells in tissue culture.
- 62 Preferably, Y2H56 is expressed using baculoviral vectors in insect cell cultures. In general, the transformation of insect cells and production of foreign proteins therein is disclosed in Guarino et al., U.S. Pat. No. 5,162,222.
- 63 Proteins can be isolated from a solubilized fraction by standard methods. Some suitable methods include precipitation and liquid chromatographic protocols such as ion exchange, hydrophobic interaction, and gel filtration. See, for example, *Methods Enzymol* (Guide to Protein Chemistry, Deutscher, ed., Section VII) pp. 182:309 (1990) and *Scopes, Protein Purification*, Springer-Verlag, New York (1987), which are herein incorporated by reference.
- 64 Alternatively, purified material is obtained by separating the protein on
- 65 preparative SDS-PAGE gels, slicing out the band of interest and electroeluting the protein from the polyacrylamide matrix by methods known in the art. The detergent SDS is removed from the protein by known methods, such as by dialysis or the use of a suitable column, such as the Extracti-Gel column from Pierce. Mixtures of proteins can be separated by, for example, SDS-PAGE in accordance with the method of Laemmli, *Nature* 227, 680-685 (1970). Such methods are well known in the art.

THIS PAGE BLANK (USPTO)

- 66 The proteins of the invention can also be chemically synthesized by methods known in the art. Suitable methods for synthesizing proteins are described by Stuart and Young, *Solid Phase Peptide Synthesis*, 2d ed., Pierce Chemical Company (1984).
- 67 The invention also includes antibodies or antibody fragments that specifically bind to epitopes of the proteins of the invention defined by the amino acid sequence set forth in SEQ ID NO:1. An "antibody" in accordance with the present specification is defined broadly as a protein that binds specifically to an epitope. The antibodies of the invention can be monoclonal antibodies, polyclonal antibodies, chimerized antibodies, humanized antibodies, single chain antibodies, or a fragment thereof. For use in in vivo applications with human subjects, the antibody is preferably chimerized or humanized, containing an antigen binding region from, e.g., a rodent, with the bulk of the antibody replaced with sequences derived from human immunoglobulin.
- 68 Antibodies further include recombinant polyclonal or monoclonal Fab fragments prepared in accordance with the method of Huse et al., *Science* 246, 1275-1281 (1989).
- 69 Polyclonal antibodies are isolated from mammals that have been inoculated with the protein or a functional analog in accordance with methods known in the art. Briefly, polyclonal antibodies may be produced by injecting a host mammal, such as a rabbit, mouse, rat, or goat, with the protein or a fragment thereof capable of producing antibodies that distinguish between mutant and wild-type protein. The peptide or peptide fragment injected may contain the wild-type sequence or the mutant sequence. Sera from the mammal are extracted and screened to obtain polyclonal antibodies that are specific to the peptide or peptide fragment.
- 70 The antibodies are preferably monoclonal. Monoclonal antibodies may be produced by methods known in the art. These methods include the immunological method described by Kohler and Milstein, *Nature* 256:495-497 (1975) and by Campbell, in Burdon et al., eds, *Laboratory Techniques in Biochemistry and Molecular Biology*, Vol. 13, Elsevier Science Publishers, Amsterdam (1985); as well as the recombinant DNA method described by Huse et al. (1989).
- 71 To produce monoclonal antibodies, a host mammal is inoculated with a peptide or peptide fragment as described above, and then boosted. Spleens are collected from inoculated mammals a few days after the final boost. Cell suspensions from the spleens are fused with a tumor cell in accordance with the general method described by Kohler and Milstein (1975). See also Campbell (1985). To be useful, a peptide fragment must contain sufficient amino acid residues to define the epitope of the molecule being detected.
- 72 If the fragment is too short to be immunogenic, it may be conjugated to a carrier molecule. Some suitable carrier molecules include keyhole limpet hemocyanin and bovine serum albumin. Conjugation may be carried out by methods known in the art. One such method is to combine a cysteine residue of the fragment with a cysteine residue on the carrier molecule.
- 73 Methods for making chimeric and humanized antibodies are also known in the art. For example, antibodies can be engineered using genetic techniques to produce chimeric antibodies including protein components from two or more species.
- 74 For example, methods for making chimeric antibodies include those described in U.S. patents by Boss (Celltech) and by Cabilly (Genentech). See U.S. Pat. Nos. 4,816,397 and 4,816,567, respectively. Methods for making humanized antibodies are described, for example, in Winter, U.S. Pat. No. 5,225,539, Co et al., *Nature* 351, 501-502 (1992); Queen et al., *Proc. Natl. Acad. Sci.*

THIS PAGE BLANK (USPTO)

86, 10029-1003 (1989) and Rodrigues et al., Int. J. Cancer, Supplement 7, 45-50 (1992).

- 75 Methods are also known for inducing expression of engineered antibodies in various cell types, such as mammalian and microbial cell types. Numerous techniques for preparing engineered antibodies are described, for example, in Owens and Young, "The genetic engineering of monoclonal antibodies," J. Immunol. Meth. 168, 149-165 (1994).
- 76 Methods for making single chain antibodies are also known in the art. Some suitable examples include those described by Wells et al. in European patent application 502 812 and Int. J. Cancer 60, 137-144 (1995).
- 77 Assays for directly detecting the presence of Y2H56 and its functional equivalents with antibodies follow known formats, such as, fluorescent activated flow cytometry, fluorescent microscopy, and immuno-electron microscopy. Moreover, assays for detecting the presence of proteins with antibodies have been previously described and follow known formats, such as standard blot and ELISA formats. These formats are normally based on incubating an antibody with a sample suspected of containing the protein and detecting the presence of a complex between the antibody and the protein. The antibody is labeled either before, during, or after the incubation step. The protein is preferably immobilized prior to detection. Immobilization may be accomplished by directly binding the protein to a solid surface, such as a microtiter well, or by binding the protein to immobilized antibodies.
- 78 Suitable assays are known in the art, such as the standard ELISA protocol described by R. H. Kenneth, "Enzyme-linked antibody assay with cells attached to polyvinyl chloride plates" in Kenneth et al., Monoclonal Antibodies, Plenum Press, New York, pp. 376 et seq. (1981).

DETAILED DESCRIPTION:

1 EXAMPLES

2 Example 1

3 Y2H56 Binds IKKs

4 ~~A yeast two hybrid screen was undertaken with IKK.alpha. as a bait in an attempt to identify interacting proteins which could represent in vivo regulators of the cytokine induced kinase cascade.~~ Full length IKK.alpha. and smaller fragments in the Field's pGTB9c bait vector (see Fields and Sternglanz, Trends Genet. 10, 286-292 (1994)) met with technical problems owing to its inherent in vivo transactivation properties. These problems were overcome by incorporating a high dose of an inhibitor of the product of the His3 selection gene thereby severely restricting yeast colony growth. (Triazole or 3-AT (3-amino-1, 2, 4-triazole or aminotriazole) has been reported to competitively inhibit the product of the yeast His3 gene in a dose dependent manner (Klopotoski et al., Arch. Biochem. Biophys. 112, 562-566 (1965)). The bait vector's insert was a 937 bp SnaBI/XhoI fragment of the murine IKK.alpha. clone encoding the protein's leucine zipper, helix-loop-helix and carboxyl terminus. The latter bait vector was transfected into the Y153 yeast strain and a colony that grew on agar without tryptophan was selected for further transfections according to standard protocols (Yeast Matchmaker manual, Clontech Inc., Palo Alto, Calif.). Yeast harboring the bait grew on histidine-minus plates. However, this non-specific growth was abrogated by the inclusion of 50 .mu.M (3-AT) that would also yield the strongest interactors. Y153 cells harboring the bait vector were transfected with a B lymphoblast cDNA library (0.6.times.10.sup.9 cfu, ATCC #87003) (Durfee et al., Genes Dev 7, 555-569 (1993)) sub-cloned into plasmid BNN132 (for a final transfection frequency

THIS PAGE BLANK (USPTO)

of 10.sup.5 clones), which were spread onto 30 agar plates (His-, Trp-, Leu-, 50 mM 3-AT). 126 clones showing a faster growth rate compared to background colonies were picked after 3 and 6 days incubation at 30.degree. C. and replated. 70 clones were selected for plasmid isolation based on their growth on His-, Trp-, Leu-, 50 .mu.M 3-AT plates. From these 70 picks secondary picks, 16 clones remained positive after multiple rounds of purification and rescreening (14 of these sixteen were unique and two were isolated twice).

TABLE 1

Results of a Yeast Two-Hybrid Screen with IKK.alpha. Helix-Loop-Helix and Leucine Zipper Domains as Bait
Relative Interaction

		Insert	
Y2h Clones	Strength	Length	Identity
11	+	0.8 kB	RanBP5
52.sup.#	++	0.9 kB	CoA Reductase
21	++	1.3 kB	TRIP9/HuI.kappa.B.beta.2
29.sup.#	++	1.1 kB	HuTCP-1
31	++	1.5 kB	Hsp40
37	+	2.3 kB	BS4 (Interferon Induced Protein)
67	+	1.5 kB	Phospholipase A2
71	+	0.8 kB	Calmodulin
70	+	1.5 kB	HuSgn3
14*	++	1.2 kB	HuAD3 Locus
35*	+++	1.2 kB	Cosmid near Btk
56*	+++	0.9 kB	p33ING1-like
53*	+++	1.2 kB	Unknown
61**	+	0.7 kB	Unknown

Legend:

Fourteen yeast two hybrid clones obtained from a human B lymphoblastoid cell cDNA library which specifically interact with the contiguous helixloop-helix and leucine zipper domains of the IKK.alpha. protein. M clones (Y2h11,21,29, 70,14,35,56 and 53) also bound to an analogous IKK.beta. bait with similar or even greater strength except for Hsp40 which only specifically bound to the IKK.alpha. bait. All clones reproducibly failed to significantly interact with an empty bait vector and #two other bait vectors harboring either the IKK.alpha. Leucine Zipper or HelixLoop-Helix domains. The relative interaction strengths are based on the growth rates (i.e., colony size) of each clone.

.sup.# Isolated Twice;

*Unknown strong interacting proteins;

**Unknown weak interacting protein.

- 5 The fourteen clones are shown in Table 1. These results demonstrate the presence of a family of IKK.alpha. binding proteins. Nine of the 14 clones are known proteins and the remaining five specify novel proteins: three of which interact with the bait more strongly than IKK.alpha.'s I.kappa.B.beta. substrate (Y2h35, 53 and 56), one in a comparable fashion to I.kappa.B.beta. (Y2h14) and one exhibited weaker binding (Y2h61). Several of the known proteins are involved in either signaling and/or molecular trafficking pathways in cells. RanBP5 was isolated as a Ran binding protein and Ran is a small GTP-binding and- hydrolyzing protein predominantly located in the nucleus (Deane et al., Mol. Cell Biol. 17, 5087-5096 (1998). RanBP5 is related to importin-.beta., a mediator of nuclear localization signal (NLS)-dependent nuclear transport. TRIP9/HuI.kappa.B.beta.2 is the predominant isoform of I.kappa.B.beta. in human cells and a known physiological substrate of the IKK.alpha. kinase (Lee et al., Mol.

THIS PAGE BLANK (USPTO)

Endocrinol. 9, 243-254 (1995); Hirano et al., Mol. Cell. Biol. 18, 2596-2607 (1998)). The presence of I.kappa.B.beta. amongst these IKK.alpha. interacting proteins validates the specificity of the screen and also demonstrates the I.kappa.Bs do not require the IKK.alpha. amino terminal kinase domain for binding. Hsp40 and TCP-1 are chaperone proteins which might bind to the bait due to a partially unfolded conformation (in the context of a Gal4dbd chimera). A database of frequently isolated clones in yeast two hybrid screens does contain several hsp proteins but Hsp40 and TCP1 are not represented amongst these frequently isolated, presumably false positive genes. Alternatively, they may also be natural interactors of IKK.alpha. that might be involved in its in vivo cytoplasmic trafficking. HuSgn3 was recently described as a component of a 450 kDa protein complex that also possesses an I.kappa.B kinase activity. Seeger et al., FASEB J. 12, 469-478 (1998). Sgn3 also exhibited sequence similarities to regulatory components of the 26S proteasome complex. Calmodulin is the principal calcium sensor in the cell, which when complexed to two calcium ions, acts as a regulator for a variety of intracellular enzymes including kinases such as CaM-kinase II, the serine/threonine specific phosphatase, Calcineurin and proteins which maintain the cytoskeletal architecture.

- 6 Y2H56 is highly homologous with the p33-ING1 tumor suppressor protein having about 45% identity and about 70% overall similarity. The p33-ING1 tumor suppressor protein has been shown to functionally interact with the p53 tumor suppressor protein to arrest cellular growth and induce apoptosis. Garkavtsev et al., Nature Genetics 14, 415-420 (1996).

```

#          SEQUENCE LISTING
- - - - <160> NUMBER OF SEQ ID NOS: 3
- - <210> SEQ ID NO 1
<211> LENGTH: 226
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
- - <400> SEQUENCE: 1
- - Met Ala Thr Ala Met Tyr Leu Glu His Tyr Le - #u Asp Ser Ile Glu
Asn
1          5 - #          10 - #          15
- - His Pro Cys Glu Leu Gln Arg Asn Phe Gln Le - #u Met Arg Glu Leu Asn
20          - #          25          - #          30
- - Gln Arg Thr Glu Asp Lys Lys Ala Glu Ile As - #p Ile Leu Ala Ala Glu
35          - #          40          - #          45
- - Tyr Ile Ser Thr Val Lys Thr Leu Ser Pro As - #p Gln Arg Val Glu Arg
50          - #          55          - #          60
- - Leu Gln Lys Ile Gln Asn Ala Tyr Ser Lys Cy - #s Lys Glu Tyr Ser Asp
65          - # 70          - # 75          - # 80
- - Asp Lys Val Gln Leu Ala Met Gln Thr Tyr Gl - #u Met Val Asp Lys His
85 - #          90 - #          95
- - Ile Arg Arg Leu Asp Ala Asp Leu Ala Arg Ph - #e Glu Ala Asp Leu Lys
100          - #          105          - #          110
- - Asp Lys Met Glu Gly Ser Asp Phe Gln Ser Se - #r Gly Gly Arg Gly Leu
115          - #          120          - #          125
- - Lys Lys Gly Arg Gly Gln Lys Glu Lys Arg Gl - #y Ser Arg Gly Arg Gl
130          - #          135          - #          140
- - Arg Arg Thr Ser Glu Glu Asp Thr Pro Lys Ly - #s Lys Lys His Lys Gl
145          1 - #50          1 - #55          1 -
#60
- - Gly Ser Glu Phe Thr Asp Thr Ile Leu Ser Va - #l His Pro Ser Asp
Val
165 - #          170 - #          175
- - Leu Asp Met Pro Val Asp Pro Asn Glu Pro Th - #r Tyr Cys Leu Cys His
180          - #          185          - #          190
- - Gln Val Ser Tyr Gly Glu Met Ile Gly Cys As - #p Asn Pro Asp Cys Pro
195          - #          200          - #          205

```

THIS PAGE BLANK (USPTO)

```

- - Ile Glu Trp Phe His Phe Ala Cys Val Asp Le - #u Thr Thr Lys Pro Ly:
    210                - #    215                - #    220
- - Gly Lys
225
- - - - <210> SEQ ID NO 2
<211> LENGTH: 699
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
- - <400> SEQUENCE: 2
- - ccgagccggc cgcgagcga gatggcgacc gccatgtact tgcagcacta tc -
#tggacagt      60
- - atcgagcacc atccctgcga acttcagagg aacttcagc tgatgcgaga gc -

```

```

#tggaccag     120
- - aggacggaag ataagaaagc agagattgac atcctggctg cagagtacat ct -
#ccacggtg     180
- - aagacgctgt ctccagacca gcgcgtggag cgctgcaga agatccagaa cg -
#cctacagc     240
- - aagtgcgaag aatacagtga cgacaaagtg cagctggcca tgcagaccta cg -
#agatggtg     300
- - gataaacaca ttcgaaggct tgatgcagac ctggcgcgct ttgaagcaga tc -
#tgaaggac     360
- - aagatggagg gcagtgattt tcaaagctcc ggagggcgag ggtaaaaaaa ag -
#gccgggggt    420
- - cagaaagaaa aaagagggtc ccggggccga ggaggagga catcagagga ag -
#acacacca     480
- - aagaaaaaga agcaciaaag agggctctgag ttactgaca ccactcgtgc cg -
#tgcacccc     540
- - tctgatgtgc tggacatgcc cgtggacca aacgaacca cgtactgcct gt -
#gccaccag     600
- - gtctcctatg gggagatgat tggctgtgac aatccagact gtccaattga gt -
#ggtttcac     660
- - tttgcctgcg tggaccttac cagaaaccc aaaggaaaa - #
- #    699

```

```

- - - - <210> SEQ ID NO 3
<211> LENGTH: 678
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
- - <400> SEQUENCE: 3
- - atggcgaccg ccatgtactt gcagcactat ctggacagta tcgagcacca tc -
#cctgcgaa     60
- - cttcagagga acttcagct gatgcgagag ctggaccaga ggacggaaga ta -
#agaaagca     120
- - gagattgaca tcctggctgc agagtacatc tccacggtga agacgctgtc tc -
#cagaccag     180
- - cgctggagc gcctgcagaa gatccagaac gcctacagca agtgcaggga at -
#acagtgc      240
- - gacaaagtgc agctggccat gcagacctac gagatgggtg ataaacacat tc -
#gaaggctt     300
- - gatgcagacc tggcgcgctt tgaagcagat ctgaaggaca agatggaggg ca -
#gtgatttt     360
- - caaagctccg gagggcgagg gttaaaaaaa ggccggggtc agaaagaaaa aa -
#gaggggtc     420
- - cggggccgag gcaggaggac atcagaggaa gacacaccaa agaaaaagaa gc -
#acaaagga     480
- - gggctctgagt tcaactgacac catcctgtcc gtgcaccct ctgatgtgct gg -
#acatgccc     540
- - gtggacccaa acgaaccac gtactgcctg tgccaccagg tctcctatgg gg -
#agatgatt     600
- - ggctgtgaca atccagactg tccaattgag tggtttcact ttgcctgcgt gg -
#accttacc     660

```

THIS PAGE BLANK (USPTO)

- - acgaaaccca aaggaaaa
- # 678

- #

- #

CLAIMS:

What is claimed is:

1. An isolated nucleic acid molecule comprising a sequence that encodes an IKK binding protein having SEQ ID NO:1 or its allelic variants.
2. An isolated nucleic acid molecule according to claim 1 comprising SEQ ID NO:2, SEQ ID NO:3, or sequences that have at least 85% identity thereto.
3. An isolated nucleic acid molecule according to claim 1 comprising SEQ ID NO:2 or SEQ ID NO:3.
4. An isolated nucleic acid molecule encoding an IKK binding protein that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NO:2, and SEQ ID NO:3.
5. An isolated nucleic acid molecule fully complementary to the nucleic acid molecule of either SEQ ID NO:2 or SEQ ID NO:3.
6. A method of making an IKK binding protein or its allelic variants, comprising:

incorporating into a host cell a nucleic acid molecule that encodes an IKK binding protein comprising a sequence as set forth as SEQ ID NO:1 or its allelic variants;

expressing the nucleic acid molecule; and

isolating the IKK binding protein or its allelic variants.
7. A method according to claim 6, wherein the nucleic acid molecule that encodes an IKK binding protein comprising a sequence set forth as SEQ ID NO:1 or its allelic variants comprises either SEQ ID NO:2 or SEQ ID NO:3.
8. A method of making an IKK binding protein, comprising:

incorporating into a host cell a nucleic acid molecule that encodes an IKK binding protein wherein the nucleic acid molecule that encodes an IKK binding protein or its allelic variants comprises a nucleic acid molecule that is at least 85% identical to either the nucleic acid molecule of SEQ ID NO:2 or SEQ ID NO:3.

THIS PAGE BLANK (USPTO)

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 22, 2003, 19:12:58 ; Search time 2252 Seconds
(without alignments)
6889.554 Million cell updates/sec

Title: US-09-442-013-7
Perfect score: 958
Sequence: 1 ttgtcgtacactcagccctgc.....cgtgtactactagtaacaa 958

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues
Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 100%

Maximum Match 0%

Database :

EST: *
1: em_estbda:*
2: em_esthum:*
3: em_estlin:*
4: em_estlun:*
5: em_estlov:*
6: em_estlpl:*
7: em_estro:*
8: em_hlc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hlc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_mam:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	787.2	82.2	925	14 B0684820	B0684820 AGENCOURT
2	745	77.8	995	14 B0679158	B0679158 AGENCOURT
3	735.8	76.8	904	14 B0686855	B0686855 AGENCOURT
4	723	75.5	879	14 B0687622	B0687622 AGENCOURT
5	714.6	74.6	941	14 B0877416	B0877416 AGENCOURT
6	711	74.2	989	14 B0883988	B0883988 AGENCOURT

7	690.6	72.1	874	14 B0688356	B0688356 AGENCOURT
8	685.2	71.5	905	14 B0683118	B0683118 AGENCOURT
9	669.4	69.9	719	12 BG753113	BG753113 AGENCOURT
10	653.6	68.2	952	14 B0678481	B0678481 AGENCOURT
11	642.8	67.1	720	12 BG749339	BG749339 AGENCOURT
12	635.8	66.4	951	14 B0675901	B0675901 AGENCOURT
13	613.2	64.0	913	14 B0677883	B0677883 AGENCOURT
14	612	63.9	911	14 B0682571	B0682571 AGENCOURT
15	589.6	61.5	1871	11 AK007536	AK007536 Mus muscu
16	583.2	60.9	958	11 BB611904	BB611904 Mus muscu
17	566	59.1	919	11 AK006421	AK006421 Mus muscu
18	562.6	58.7	803	12 BG170225	BG170225 AGENCOURT
19	505.4	52.8	1127	14 B0682900	B0682900 AGENCOURT
20	502	52.4	676	10 BB609787	BB609787 AGENCOURT
21	488	50.9	714	9 AV018921	AV018921 AGENCOURT
22	467	48.7	721	9 AV018921	AV018921 AGENCOURT
23	461	48.1	715	9 AV018921	AV018921 AGENCOURT
24	458.4	47.8	627	10 BB658097	BB658097 AGENCOURT
25	428.6	44.7	695	12 BF321053	BF321053 AGENCOURT
26	387.2	40.4	459	9 A1087819	A1087819 AGENCOURT
27	381.8	39.9	649	14 BQ770942	BQ770942 AGENCOURT
28	360.8	39.7	638	12 BF532779	BF532779 AGENCOURT
29	373.8	39.0	879	12 BF691977	BF691977 AGENCOURT
30	361.6	37.7	548	12 BF573681	BF573681 AGENCOURT
31	353.6	36.9	668	12 BG176984	BG176984 AGENCOURT
32	348.8	36.4	652	12 BE961079	BE961079 AGENCOURT
33	314.6	32.8	464	10 BB852285	BB852285 AGENCOURT
34	300	31.3	502	9 A1675196	A1675196 AGENCOURT
35	300	31.3	506	9 A1337313	A1337313 AGENCOURT
36	298.8	31.2	854	9 AL533224	AL533224 AGENCOURT
37	298.2	31.1	984	14 BM804671	BM804671 AGENCOURT
38	298	31.1	499	10 AM195045	AM195045 AGENCOURT
39	266.8	31.0	535	10 BE46370	BE46370 AGENCOURT
40	236.4	30.9	422	11 AK009312	AK009312 AGENCOURT
41	296.4	30.9	890	9 AJ456490	AJ456490 AGENCOURT
42	291	30.4	526	9 A1091362	A1091362 AGENCOURT
43	287.8	30.0	509	9 A1312128	A1312128 AGENCOURT
44	287.6	30.0	1618	11 AK009267	AK009267 AGENCOURT
45	287.2	30.0	1062	13 BM549218	BM549218 AGENCOURT

ALIGNMENTS

RESULT 1
B0684820
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

B0684820 925 bp mRNA linear EST 15-JUL-2002
AGENCOURT 8343534 NIH_MGC_110 Homo sapiens cDNA clone IMAGE1550307
5', mRNA sequence.
B0684820
B0684820.1 GI:21810136
EST.
human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
NIH-MGC <http://mgc.ncl.nih.gov/>.
1 (bases 1 to 925)
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgaps-remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
<http://image.lnl.gov>
Plate: L10M2393 row: C column: 12
High quality sequence stop: 727.
Location/Qualifiers
1. .925

FEATURES

source

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:6250307"
/clone_lib="NIH_MGC_110"
/tissue_type="ductal carcinoma, cell line"
/lab_host="DH10B (phage-resistant)"
/note="Organ: pancreas; Vector: pORF7; Site:1: XhoI;
Site:2: EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(G). Library constructed by
ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC Library."

BASE COUNT 260 a 221 c 268 g 174 t 2 others
ORIGIN

Query Match 82.2%; Score 787.2; DB 14; Length 925;

Best Local Similarity 98.9%; Pred. No. 1.6e-189;

Matches 792; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 156 CTGATAGTATCGAAGACCTTCCCTCGAAGCTTCAGAGAACTTCAGCTGATGCGAG 215

Db 60 CTGACAGATTCAGAAACCTTCCCTCGAAGCTTCAGAGAACTTCAGCTGATGCGAG 119

QY 216 CTGACAG 275

Db 120 CTGACAG 179

QY 276 TCCACGGTGAAGAGCGTGTCTCCAGACACGCGGTGAGCGCTGCAGAGATCCAGAC 335

Db 180 TCCACGGTGAAGAGCGTGTCTCCAGACACGCGGTGAGCGCTGCAGAGATCCAGAC 239

QY 336 GCCTACAG 395

Db 240 GCCTACAG 299

QY 396 GAGATGGTGAATTAACACATTTGAGAGCGCTTGTATGACAGCTGGCGGCTTTGAAGCAGAT 455

Db 300 GAGATGGTGAATTAACACATTTGAGAGCGCTTGTATGACAGCTGGCGGCTTTGAAGCAGAT 359

QY 456 CTGACAG 515

Db 360 CTGACAG 419

QY 516 GGCAGGGGTGAG 575

Db 420 GGCAGGGGTGAG 479

QY 576 GACACACCAAG 635

Db 480 GACACACCAAG 539

QY 636 GTGACACCCCTGTATGTCTGACATGCCGTGGACCCCAAGCAACCCAGTACTGCTG 655

Db 540 GTGACACCCCTGTATGTCTGACATGCCGTGGACCCCAAGCAACCCAGTACTGCTG 599

QY 696 TGGCACCAGGTCTCTATGGGAGATGATGGCTGTGACAAATCGAGCTGCAATTGAG 755

Db 600 TGGCACCAGGTCTCTATGGGAGATGATGGCTGTGACAAATCGAGCTGCAATTGAG 659

QY 756 TGGTTTCACTTTGCTGCGGTGACCTTACACAGAAACCCCAAGAGAAATGTTCTGTCA 815

Db 660 TGGTTTCACTTTGCTGCGGTGACCTTACACAGAAACCCCAAGAGAAATGTTCTGTCA 719

QY 816 CGGTGTGTCCAG 875

Db 720 CGGTGTGTCCAG 779

QY 876 GCAAGTAAATCTGCTTCCCTTATCGTGTGCAATATTTCCCTTCTTTAAACTACCTT 935

Db 780 GCAAGTAAATCTGCTTCCCTTATCGTGTGCAATATTTCCCTTCTTTAAACTACCTT 839

QY 936 GTTCGGTGTACTAGTAAAC 956

Db 840 GTTCGGTGTACTAGTAAAC 860

RESULT 2

BO679158

LOCUS

DEFINITION

AGENCY

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

1 (bases 1 to 956)

NIH-MGC

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished (1999)

Contact: Robert Strausberg, Ph.D.

Email: cgraphs-remail.nih.gov

Tissue Procurement: DCTD/DRP

cDNA Library Preparation: Rubin Laboratory

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

Plate: LLM2380 row: e column: 09

High quality sequence stop: 638.

Location/Qualifiers

1..995

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:6213872"

/clone_lib="NIH_MGC_112"

/tissue_type="melanotic melanoma, cell line"

/lab_host="DH10B (phage-resistant)"

/note="Organ: skin; Vector: pORF7; Site:1: XhoI; Site:2:

EcoRI; cDNA made by oligo-dT priming. Directionally cloned

into EcoRI/XhoI sites using the following 5' adaptor:

GGCACGAG(G). Library constructed by ling Hong in the

laboratory of Gerald M. Rubin (University of California,

Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and

Superscript II RT (Life Technologies). Note: this is a

NIH_MGC Library."

BASE COUNT 268 a 260 c 287 g 180 t

ORIGIN

Query Match 77.8%; Score 745; DB 14; Length 995;

Best Local Similarity 98.0%; Pred. No. 8.6e-179;

Matches 765; Conservative 0; Mismatches 15; Indels 1; Gaps 1;

QY 156 CTGATAGTATCGAAGACCTTCCCTCGAAGCTTCAGAGAACTTCAGCTGATGCGAG 215

Db 46 CTGACAGATTCAGAAACCTTCCCTCGAAGCTTCAGAGAACTTCAGCTGATGCGAG 105

QY 216 CTGACACAG 275

Db 106 CTGACACAG 165

QY 276 TCCACGGTGAAGAGCGTGTCTCCAGACACGCGGTGAGAGCGCTGCAGAAATCCAGAAC 335

Db 166 TCCACGGTGAAGAGCGTGTCTCCAGACACGCGGTGAGAGCGCTGCAGAAATCCAGAAC 225

QY 336 GCCTACAGCAAGTGAAGAGATACAGTGAAG 395

Db 226 GCCTACAGCAAGTGAAGAGATACAGTGAAG 285

QY 396 GAGATGGTGAATTAACACATTTGAGAGCGCTTGTATGACAGCTGGCGGCTTTGAAGCAGAT 455

Db 286 GAGATGATGATAAACAATTCGAAAGGCTTGATGACGAGCTGGCGGCTTTGAACGAGT 345
Qy 456 CTGAAGGACAAGATGGAGGCGATGATTTTGAAGCTCCGGAGGCGGATTAATAAAA 515
Db 346 CTGAAGGACAAGATGGAGGCGATGATTTTGAAGCTCCGGAGGCGGATTAATAAAA 405
Qy 516 GGCCGGGGTCAAGAAAAGAAAAGAGGTCGCGGGCCGAGGAGGAGACATCAGAGAA 575
Db 406 GGCCGGGGTCAAGAAAAGAAAAGAGGTCGCGGGCCGAGGAGGAGACATCAGAGAA 465
Qy 576 GACACACCAAGAAAAGAAAAGAGGTCGAGGAGGTCGAGTTCACAGACATCCTGTC 635
Db 466 GACACACCAAGAAAAGAAAAGAGGTCGAGGAGGTCGAGTTCACAGACATCCTGTC 525
Qy 636 GTGCACCCCTCTGATGTCGTGACACATGCCCCGTGACCCAAACGAGACCTGCTG 695
Db 526 GTGCACCCCTCTGATGTCGTGACACATGCCCCGTGACCCAAACGAGACCTGCTG 585
Qy 696 TGCCACACGATCTCTATGGGAGATGATGGCTGTGACCAATCCAGACTGTCATTTGAG 755
Db 586 TGCCACACGATCTCTATGGGAGATGATGGCTGTGACCAATCCAGACTGTCATTTGAG 645
Qy 756 TGTTTCACTTTGCTGCGTGACCTTACACAGAAACCAAGAAAATGTTCTGTCCA 815
Db 646 TGTTTCACTTTGCTGCGTGACCTTACACAGAAACCAAGAAAATGTTCTGTCCA 705
Qy 816 CGGTGTCTCCAGAAAAGAAAAGAGTAAAGAGAGAGCTGTGTCG -CCCGATCCGAG 874
Db 706 CGGTGTCTCCAGAAAAGAAAAGAGTAAAGAGAGAGCTGTGTCG -CCCGATCCGAG 765
Qy 875 AGCAAGTAAATCTGTCCTTCATTCGTCGTCATATTTCCCTTTTAAACTACT 934
Db 766 GAGCAGGATATCTGTCCTTTCTTCTGTCGTCATATTTCCCTTTTAAACTACT 825
Qy 935 T 935
Db 826 T 826

RESULT 3
B0686855
LOCUS
DEFINITION B0686855 904 bp mRNA linear EST 15-JUL-2002
5', mRNA sequence. IMAGE:6248487
ACCESSION B0686855
VERSION B0686855.1 GI:21812171
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 904)
AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgabs-remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Rubin Laboratory
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/MLN at:
<http://image.llnl.gov>
Plate: L10M238 row: 9 column: 16
High quality sequence stop: 664.
Location/Qualifiers
1. 904

FEATURES
source
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:6248487"
/clone_id="NIH_MGC_110"
/tissue_type="ductal carcinoma, cell line"

/lab_host="DH10B (phage-resistant)"
/note="Organ: pancreas; Vector: pOTB7; Site:1: XhoI;
Site:2: EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACAG(G). Library constructed by
ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-CDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC Library."

BASE COUNT 252 a 215 c 265 g 170 t 2 others
ORIGIN

Query Match 76.8%; Score 735.8; DB:14; Length 904;
Best Local Similarity 97.8%; Pred. No. 1.9e-176;
Matches 787; Conservative 0; Mismatches 14; Indels 4; Gaps 4;

Qy 156 CTGATAGTATCGAGAACCTTCCTCGCAACTCTGAGAGAACTTCACAGTATCGAGAG 215
Db 60 CTGAGACATATCGAAGAACCTTCCTCGCAACTCTGAGAGAACTTCACAGTATCGAGAG 119
Qy 216 CTGACACAGAGAGCGGAAGATAGAAAGCAGAGATTCAGTCTGGCTGCAGATACATC 275
Db 120 CTGACACAGAGAGCGGAAGATAGAAAGCAGAGATTCAGTCTGGCTGCAGATACATC 179
Qy 276 TCCACGGTGAAGAGCGCTGCTCCAGACAGCGCGTGGAGCGCTGACAGATCCAGAAC 335
Db 180 TCCACGGTGAAGAGCGCTGCTCCAGACAGCGCGTGGAGCGCTGACAGATCCAGAAC 239
Qy 336 GCGTACACAGTGCAGAAATACAGTACAGACAAAGTGCAGCTGGCCATGCAGACCTAC 395
Db 240 GCGTACACAGTGCAGAAATACAGTACAGACAAAGTGCAGCTGGCCATGCAGACCTAC 299
Qy 396 GAGATGTGATTAACACATTCGAAAGCTTGATGACAGACTGGCGGCTTTGAAGCAGAT 455
Db 300 GAGATGTGATTAACACATTCGAAAGCTTGATGACAGACTGGCGGCTTTGAAGCAGAT 359
Qy 456 CTGAAGGACAAGATGAGAGGCGAGTATTTGAAGCTCCGGAAGGCGGAGTTAAAAAA 515
Db 360 CTGAAGGACAAGATGAGAGGCGAGTATTTGAAGCTCCGGAAGGCGGAGTTAAAAAA 419
Qy 516 GGCCGGGGTCAAGAAAAGAAAAGAGGTCGCGGGCCGAGGAGGAGACATCAGAGAA 575
Db 420 GGCCGGGGTCAAGAAAAGAAAAGAGGTCGCGGGCCGAGGAGGAGACATCAGAGAA 479
Qy 576 GACACACCAAGAAAAGAAAAGAGGAGGTCGAGTTCACAGACATCCTGTC 635
Db 480 GACACACCAAGAAAAGAAAAGAGGAGGTCGAGTTCACAGACATCCTGTC 539
Qy 636 GTGCACCCCTCTGATGTCGTGACATGCCCCGTGGAGCCCAAGCAACCAAGTACTGCTG 695
Db 540 GTGCACCCCTCTGATGTCGTGACATGCCCCGTGGAGCCCAAGCAACCAAGTACTGCTG 599
Qy 696 TGCCACACGATCTCTATGGGAGATGATGGCTGTGACCAATCCAGACTGTCATTTGAG 755
Db 600 TGCCACACGATCTCTATGGGAGATGATGGCTGTGACCAATCCAGACTGTCATTTGAG 659
Qy 756 TGTTTCACTTTGCTGCGTGACCTTACACAGAAACCAAGAAAATGTTCTGTCCA 815
Db 660 TGTTTCACTTTGCTGCGTGACCTTACACAGAAACCAAGAAAATGTTCTGTCCA 719
Qy 816 CGGTGTCTCCAGAAAAGAAAAGAGTAAAGAGAGAGCTGTGTCG -GGATCCGAG 873
Db 720 CGGTGTCTCCAGAAAAGAAAAGAGTAAAGAGAGAGCTGTGTCG -CCCGGATCCGAG 779
Qy 874 GAGCAAGTAAATCTGT -CCCTTCATTCGTGTCGCAATATTTCCCTTCTTTAAAAACTAC 932
Db 780 GAGCAAGTAAATCTGTCCCTCTTCTGTCGCAATATTTCCCTTCTTTAAAAACTAC 839
Qy 933 CTGTTTC -GGTTGATCTTAGTAAC 956
Db 840 CTGTTTCGGGTGATCTTAAAAAC 864

```

FEATURES             SOURCE
LOCUS                B0687622
DEFINITION           B0687622      879 bp      mRNA      linear      EST 15-JUL-2002
                        AGENCOURT_8171406 NIH_MGC_110 Homo sapiens CDNA clone IMAGE70251931
                        5', mRNA sequence.
ACCESSION            B0687622
VERSION              B0687622.1   GI:21812938
KEYWORDS              EST.
SOURCE               human.
ORGANISM             Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 879)
NIH-MGC http://mgc.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgapds@email.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: L16CM2397 row: g column: 04
High quality sequence stop: 645.
Location/Qualifiers
1..879

```

Query Match	Best Local Similarity	75.5%	Score 723;	DB 14;	Length 879;
Matches 773;	Conservative	0;	Mismatches 10;	Indels 4;	Gaps 4;
Db	156	CTGATAGGTATCGAAGACCTTCCCTCGGACCTTCAGAGAACTTCACCTGATGCGAGAG	215		
QY	40	CTGGACATATTCGAGAACCTTCCCTCGGACCTTCAGAGAACTTCACCTGATGCGAGAG	99		
Db	216	CTGGACCGAGAGAGAGAAAGATTAAGAAACAGAGATTGACATCCCGGCGAGAGATATTC	275		
QY	100	CTGGACCGAGAGAGAGAGAAAGATTAAGAAACAGAGATTGACATCCCGGCGAGAGATATTC	159		
Db	276	TCACAGGTGAAGACGCTGCTTCACAGACCAGCGCGCTGAGCGCTTCAGAGATCCAGAAC	335		
QY	160	TCACAGGTGAAGACGCTGCTTCACAGACCAGCGCGCTGAGCGCTTCAGAGATCCAGAAC	219		
Db	336	GCCATACAGCAGTGCAGAGGATATACAGTACAGCAAAAGCGAGCGTGGCCATCAGACCTAC	395		
QY	220	GCCATACAGCAGTGCAGAGGATATACAGTACAGCAAAAGCGAGCGTGGCCATCAGACCTAC	279		
Db	396	GAGATGTGTGATTAACAACATTTCGAAGGCTTGATATCGACACTCGCGCGCTTTTGAACAGAT	455		
QY	280	GAGATGTGTGATTAACAACATTTCGAAGGCTTGATATCGACACTCGCGCGCTTTTGAACAGAT	339		
Db	456	CTGAAGGACAGAGATGAGAGGCGAGTGTATTTTGAAGGCTCCGAGAGGCGAGGGTTAAAAAA	515		
QY	340	CTGAAGGACAGAGATGAGAGGCGAGTGTATTTTGAAGGCTCCGAGAGGCGAGGGTTAAAAAA	399		

QY	516	GGCCGGGGTCAAGAAAGAAAAAGAGGGTCCCGGGCCGAGCGAGAGAGCATCAGAGAA	575
Db	400	GGCCGGGGTCAAGAAAGAAAAAGAGGGTCCCGGGCCGAGCGAGAGAGCATCAGAGAA	459
QY	576	GACACACCAAGAAAAAGAGCACAAGAGAGGGTCTGATGTTCACTGACACCATCTGTCC	635
Db	460	GACACACCAAGAAAAAGAGCACAAGAGAGGGTCTGATGTTCACTGACACCATCTGTCC	519
QY	636	GTGACCCCTCTGATGTGATGCGAGCATGCCGTGGACCCAAAGCAACCATCGTACTGCTG	695
Db	520	GTGACCCCTCTGATGTGATGCGAGCATGCCGTGGACCCAAAGCAACCATCGTACTGCTG	579
QY	696	TGCACACGAGTCTCTATGGGGAGATGATTGGCTGTGACAAATCCAGACTGTCCAAATTGAG	755
Db	580	TGCACACGAGTCTCTATGGGGAGATGATTGGCTGTGACAAATCCAGACTGTCCAAATTGAG	639
QY	756	TGGTTTCACTTGGCTCGCT - GGAACCTTACCAGCAAAACCAAGGAAAAATGGTCTGTCC	814
Db	640	TGGTTTCACTTGGCTCGCTCGTGGACCTTACCAGCAAAACCAAGGAAAAATGGTCTGTCC	699
QY	815	ACGGTGTGTCCAGAGAAAAAG - GGAAGAAGAAATGAGAGAGACTGTGTGCCCGGATCGA -	872
Db	700	ACGGTGTGTGTCCAGAGAAAAAGGAGGAAGAAAGTATGAGAGAGCTGTGTGCCCGGATCGAG	759
QY	873	GGAGCAAGTTAATCTGTGCC - TTCAATTCGTGTGCAATATTTCCTCTCTTTAAAACTA	931
Db	760	GGAGCAAGTTAATCTGTGCCCTTCTTCGTGTGCAATATTTCCTCTCTTTAAAACTA	819
QY	932	CCCTGTT 938	
Db	820	CCTTGGT 826	

FEATURES	source
LOCUS	BO877416
DEFINITION	BO877416 941 bp mRNA linear EST 16-Aug-2002
ACCESSION	AGNCOURT_8071188 NIH_MGC_112 Homo sapiens cDNA clone IMAGE:6090578
VERSION	5, mRNA sequence.
KEYWORDS	BO877416 GI:22269424
ORGANISM	EST. human.
REFERENCE	Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
AUTHORS	1 (bases 1 to 941)
TITLE	NIH-MGC http://mgc.nci.nih.gov/ .
JOURNAL	National Institutes of Health, Mammalian Gene Collection (MGC)
COMMENT	Unpublished (1999) Contact: Robert Strausberg, Ph.D. Email: cgaps@email.nih.gov Tissue Procurement: DCTD/DTF cDNA Library Preparation: Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL) DNA Sequencing by: Agencourt Bioscience Corporation Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at: http://lmcw.llnl.gov plate: LCM2332 row: d column: 03 High quality sequence stop: 556. Location/Qualifiers 1. 941 /organism="Homo sapiens" /db_xref="taxon:9606" /clone="IMAGE:6090578" /clone_id="NIH_MGC_112" /tissue_type="melanotic melanoma, cell line" /lab_host="DH10B (phage-resistant)" /note="Organ: skin; Vector: pOTB7; Site_1: XhoI; Site_2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGGACGGG(5). Library constructed by Ling Hong in the

Laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies). Note: this is a NIH-MGC Library."

BASE COUNT 262 a 238 c 266 g 175 t

Query Match 74.6%; Score 714.6; DB 14; Length 941;
Best Local Similarity 98.3%; Pred. No. 4.6e-171;
Matches 764; Conservative 0; Mismatches 9; Indels 4; Gaps 4;

QY 156 CTGATAGTATGAGAACCTTCCTCGCAACTTCAGAGAACTTCAGCTGATGCGAGAG 215
DB 46 CTGACAGATGAGAACCTTCCTCGCAACTTCAGAGAACTTCAGCTGATGCGAGAG 105
QY 216 CTGACACGAGAGAGCGAAGATAGAAAGCAGATTGACATCTGCTGCGAGATCATC 275
DB 106 CTGACACGAGAGAGCGAAGATAGAAAGCAGATTGACATCTGCTGCGAGATCATC 165
QY 276 TCCACGGTGAAGAGCTGTCTCCAGACCGCGTGGAGCGCTGACAGAAATCCAGAAC 335
DB 166 TCCACGGTGAAGAGCTGTCTCCAGACCGCGTGGAGCGCTGACAGAAATCCAGAAC 225
QY 336 GCCTACAGCAAGTGCAGAGGAATATACAGTACGACAAAGTGCAGCTGGCATGACAGACTAC 395
DB 226 GCCTACAGCAAGTGCAGAGGAATATACAGTACGACAAAGTGCAGCTGGCATGACAGACTAC 285
QY 396 GAGATGTGTGATTAACACATTCGAAAGCTTGATGACAGACCTGGCGCTTTGAGCAGAT 455
DB 286 GAGATGTGTGATTAACACATTCGAAAGCTTGATGACAGACCTGGCGCTTTGAGCAGAT 345
QY 456 CTGAAGGACAAAGATGAGAGGCGATTTGAAAGCTCCGAGGCGAGAGGTTAAAGAA 515
DB 346 CTGAAGGACAAAGATGAGAGGCGATTTGAAAGCTCCGAGGCGAGAGGTTAAAGAA 405
QY 516 GGCCGGGGGTTCAGAAAGAAAGAGGGTCCCGGGCCGAGAGGAGAGCATCAGAGAA 575
DB 406 GGCCGGGGGTTCAGAAAGAAAGAGGGTCCCGGGCCGAGAGGAGAGCATCAGAGAA 465
QY 576 GACACACCAAGAAAGAAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 635
DB 466 GACACACCAAGAAAGAAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 525
QY 636 GTGCACCCCTCTGATGTGTGACATGCGCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 695
DB 526 GTGCACCCCTCTGATGTGTGACATGCGCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 585
QY 696 TGCCACACAGGCTCTCTATGGGAGATGATGGCTGTGACAAATCCAGACTGTCCAAATTGAG 755
DB 586 TGCCACACAGGCTCTCTATGGGAGATGATGGCTGTGACAAATCCAGACTGTCCAAATTGAG 645
QY 756 TGGTTTCACTTTGCTGCGGTGAGCTTACACAGAAACCAAGAAATGTTTGTGTGCA 815
DB 646 TGGTTTCACTTTGCTGCGGTGAGCTTACACAGAAACCAAGAAATGTTTGTGTGCA 705
QY 816 CGGTGTGTCACAGG-AAAAGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 873
DB 706 CGGTGTGTCACAGGAG 765
QY 874 GAGCAAGTTAATCT-GTCCCTTCATTCGT-GTGCATATTTTCCCTCTTTTAAAA 928
DB 766 GAGCAAGTTAATCTGTGCTCCTTCATTCGTGTCCTCAATTTTCCCTTTTAAAA 822

RESULT 6
BO883988 989 bp mRNA linear EST 16-AUG-2002
LOCUS AGENCOURT.8073788 NIH_MGC_110 Homo sapiens cDNA clone IMAGE6089499
DEFINITION 5' mRNA sequence.
ACCESSION BO883988
VERSION BO883988.1 GI:22275996
KEYWORDS EST.
SOURCE human.

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 989)
AUTHORS NIH-MGC <http://mgc.ncl.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgabs-remail.nih.gov
Tissue Procurement: ATCC

cDNA Library Preparation: Rubin Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNLN at:
<http://image.lnl.gov>
Plate: L10M2313 row: 1 column: 21
High quality sequence start: 21
High quality sequence stop: 589.

FEATURES
source location/Qualifiers
1..989
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:6083492"
/clone_lib="NIH-MGC_110"
/tissue_type="ductal carcinoma, cell line"
/lab_host="DH10B (phage-resistant)"
/note="Organ: pancreas; Vector: pOTB7; Site_1: XhoI;
Site_2: EcoRI; cDNA made by oligo-dT priming.
Directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCAGAG(G). Library constructed by
Ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH-MGC Library."

BASE COUNT 260 a 257 c 288 g 184 t

Query Match 74.2%; Score 711; DB 14; Length 989;
Best Local Similarity 95.3%; Pred. No. 3.8e-170;
Matches 765; Conservative 0; Mismatches 35; Indels 3; Gaps 3;

QY 156 CTGATAGTATGAGAACCTTCCTCGCAACTTCAGAGAACTTCAGCTGATGCGAGAG 215
DB 69 CTGACAGATGAGAACCTTCCTCGCAACTTCAGAGAACTTCAGCTGATGCGAGAG 128
QY 216 CTGACACGAGAGAGCGAAGATAGAAAGCAGATTGACATCTGCTGCGAGATCATC 275
DB 129 CTGACACGAGAGAGCGAAGATAGAAAGCAGATTGACATCTGCTGCGAGATCATC 188
QY 276 TCCACGGTGAAGAGCTGTCTCCAGACGAGCGGTGGAGCGCTTCAGAAAGTCCAGAAC 335
DB 189 TCCACGGTGAAGAGCTGTCTCCAGACGAGCGGTGGAGCGCTTCAGAAAGTCCAGAAC 248
QY 336 GCCTACAGCAAGTGCAGAGGAATATACAGTACGACAAAGTGCAGCTGGCATGACAGACTAC 395
DB 249 GCCTACAGCAAGTGCAGAGGAATATACAGTACGACAAAGTGCAGCTGGCATGACAGACTAC 308
QY 396 GAGATGTGTGATTAACACATTCGAAAGCTTGATGACAGACCTGGCGCTTTGAAAGCAGAT 455
DB 309 GAGATGTGTGATTAACACATTCGAAAGCTTGATGACAGACCTGGCGCTTTGAAAGCAGAT 368
QY 456 CTGAAGGACAAAGATGAGAGGCGAGTATTTGAAAGCTCCGAGGCGAGAGGTTAAAGAA 515
DB 369 CTGAAGGACAAAGATGAGAGGCGAGTATTTGAAAGCTCCGAGGCGAGAGGTTAAAGAA 428
QY 516 GGCCGGGGGTTCAGAAAGAAAGAGGGTCCCGGGCCGAGAGGAGAGGAGGAGGAGGAGGAG 575
DB 429 GGCCGGGGGTTCAGAAAGAAAGAGGGTCCCGGGCCGAGAGGAGGAGGAGGAGGAGGAGGAG 488
QY 576 GACACACCAAGAAAGAAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 635
DB 489 GACACACCAAGAAAGAAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 548

Qy	636	GTGCACCCCTTGATGTCTGTGGACATGTGCCGCGTGACCCAAAGAACCCACGACTGACCTG	695
Dp	549	GTTCACCCCTTGATGTCTGTGGACATGTGCCGCGTGACCCAAAGAACCCACGACTGACCTG	608
Qy	696	TGCCACAGAGTCCTCTATGGGGAGATGATGTGGCTTGCACATCCAGACTGTCCAAATTGAG	755
Dp	609	TGCCACAGAGTCCTCTATGGGGAGATGATGTGGCTTGCACATCCAGACTGTCCAAATTGAG	668
Qy	756	TGCTTTCACTTTGCCCTGCGGTGACCTTACACGAAACCCAAAGGAAAATGGTTCTGTCCA	815
Dp	669	TGCTTTCCCTTTGCCCTGCGGTGACCTTACACAAAAACC - AAGGAAATGGTTCGTGCCA	727
Qy	816	CGGTGTGTTCACGAAAAGAGAGAAAGAATG - GGAGAGCTGTGTG - CCGGATCCGAG	873
Dp	728	CCGGGTGTGCCCCGGAAGAAAGAGAAAGATGAGGAGAGCTGTGTGCCCCCGGACCCGAG	787
Qy	874	GAGCAAGTTAATCTGTGCTCCCTTCATCTCGTGTGCGCAATTTTCCCTCTTTTAAACTACC	933
Dp	788	GAGCAAGTTAATCTGTGCCCCCTTCTTTCGCGCGCAATATTTTCCCTCTTTTAAACTACC	847
Qy	934	TTGTTCGGTGTGATCTTAGTAAC	956
Dp	848	TTGTTCGGGTGATCTTAGTAAC	870

RESULT 7				
B0688356				
LOCUS	B0688356	874 bp	mRNA	linear EST 15-JUL-2002
DEFINITION	AGNCSCURT_8064337 NIH_MGC_110 Homo sapiens CDNA clone IMAGE:6207958 5' mRNA sequence.			

ACCESSION	BQ688356
VERSION	BQ688356.1
KEYWORDS	GI:21813672
SOURCE	EST.
ORGANISM	human.
REFERENCE	Homo sapiens
AUTHORS	Euharyota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE	1 (bases 1 to 874)
JOURNAL	NIH-MGC http://mgc.nci.nih.gov/ .
COMMENT	National Institutes of Health, Mammalian Gene Collection (MGC) Unpublished (1999)
CONTACT	Contact: Robert Strausberg, Ph.D.

Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Rubin Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
<http://image.lnl.gov>
Plate: LCM2364 row: n column: 23
High quality sequence stop: 649.

FEATURES	location/qualifiers
source	1. .874

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:6207956"
/clone_1ib="NH_MGC_110"
/tissue_type="ductal carcinoma, cell line"
/lab_host="DH10B (phage-resistant)"
/ncore="Organ: pancreas; Vector: pOTB1; Site_1: XhoI;
Site_2: EcoRI; cDNA made by oligo-dT priming.
directionally cloned into EcoRI/XhoI sites using the
following 5' adaptor: GGCACGAG(G). Library constructed
by Ling Hong in the laboratory of Gerald M. Rubin (University
of California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NH_MGC library"

```

BASE COUNT	ORIGIN
246 a	209 c
255 g	164 t

Query Match 72.1%; Score 690.6; DB 14; Length 874;

Best Local Similarity 97.18; Pred. No. 5.8e-165;
Matches 768; Conservative 0; Mismatches 14; Indels 9; Gaps 6;

[illegible]

RESULT	8
B0683118	
LOCUS	B0683118
DEFINITION	B0683118 905 bp mRNA
	AGNCNCOURT_8208770 NIH_MGC_112 Homo sapiens cdna linear EST_15-JUL-2002
	5', mRNA sequence.

ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM
BO683118	BO683118.1	GI:21795797	EST.	human.
				Homo sapiens
				Eumetazoa; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
REFERENCE				
1	(bases 1 to 905)			


```

Db 145 TCCACGGTGAAGACGCTGTCTCCAGACACGCGGTGGAGCGCTGCAGAAATCCAGAAC 208
QY 336 GCCTACAGCAAGTGCAGAAATACAGTACAGACAAATGTCAGCTGGCCATGCAGACCTAC 395
Db 209 GCCTACAGCAAGTGCAGAAATACAGTACAGACAAATGTCAGCTGGCCATGCAGACCTAC 268
QY 396 GAGATGGTGAATTAACACATCTTGAAGGCTTGCAGACCTGGCGCGCTTTGAAGCAGAT 455
Db 269 GAGATGGTGAATTAACACATCTTGAAGGCTTGCAGACCTGGCGCGCTTTGAAGCAGAT 328
QY 456 CTGACGACAAAGATGAGGAGGAGGAGTGTGAAAGCTCCGAGAGGCGAGGCTTAAAAAA 515
Db 329 CTGACGACAAAGATGAGGAGGAGGAGTGTGAAAGCTCCGAGAGGCGAGGCTTAAAAAA 388
QY 516 GCGCGGGGTGAGAAAGAAAGAGGCTCCGAGGCGCGAGGAGGAGATCAGAGAA 575
Db 389 GCGCGGGGTGAGAAAGAAAGAGGCTCCGAGGCGCGAGGAGGAGATCAGAGAA 448
QY 576 GACACACAAAGAAAGAAAGAGGCTCTGAGTTCACTGACACCATCTGCTCC 635
Db 449 GACACACAAAGAAAGAAAGAGGCTCTGAGTTCACTGACACCATCTGCTCC 508
QY 636 GTGCACCCCTCTGATGCTGTCGACATGCCGTCGACCCCAACGACCATCTGCTCC 695
Db 509 GTGCACCCCTCTGATGCTGTCGACATGCCGTCGACCCCAACGACCATCTGCTCC 568
QY 696 TGCACACAGGTCTCTATGGG-GAGATGATTGGCTGTGACATTCACATCTGCAATTTGA 754
Db 569 TGCACACAGGTCTCTATGGGCGAGATGATTGGCTGTGACATTCACATCTGCAATTTGA 628
QY 755 GTGGTTTCACTTTGCTGCTGCTGACCTTACACGAAACCAAGAAATGTTCTGCTCC 814
Db 629 GTGGTTTCACTTTGCTGCTGCTGACCTTACACGAAATGTTCTGCTCC 688
QY 815 AGCGTGTCTCAGAAAGAGAGAGAGAG 845
Db 689 AGCGTGTCTCAGAAAGAGAGAGAGAG 719

```

```

RESULT 10
LOCUS B0678481 952 bp mRNA linear EST 15-JUL-2002
DEFINITION AGENCOUT_8208766 NIH_MGC_112 Homo sapiens cDNA clone IMAGE:589982
5', mRNA sequence.
ACCESSION B0678481
VERSION B0678481.1 GI:21791160
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 952)
AUTHORS NIH-MGC http://mgc.ncl.nih.gov/
TITLES National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgrabs-r@mail.nih.gov
Tissue Procurement: DCTD/DPD
cDNA Library Preparation: Rubin Laboratory
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LINL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LINL at:
http://image.llnl.gov
Plate: L1CM2419 row: C column: 03
High quality sequence stop: 592.
Location/Qualifiers
1..952
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:6260282"
/clone_1lb="NIH_MGC_112"
/tissue_type="melanotic melanoma, cell line"

```

```

FEATURES
source

```

```

/lab_host="DH10B (phage-resistant)"
/note="Organ: skin; Vector: pOTB7; Site_1: XhoI; Site_2:
EcoRI; cDNA made by oligo-dT priming. Directionally cloned
into EcoRI/XhoI sites using the following 5' adaptor:
GGCAGCAGC(G). Library constructed by Ling Hong in the
Laboratory of Gerald M. Rubin (University of California,
Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and
Superscript II RT (Life Technologies). Note: this is a
NIH_MGC Library."
BASE COUNT 234 a 297 c 257 g 163 t 1 others
ORIGIN

```

```

Query Match 68.2%; Score 653.6; DB 14; Length 952;
Best Local Similarity 95.8%; Pred. No. 1.5e-155;
Matches 682; Conservative 0; Mismatches 29; Indels 1; Gaps 1;

```

```

QY 156 CTGATAGTATCGAAGAACTTCCCTGGAACCTTCAGAGAACTTCCAGCTGATGCCAGAG 215
Db 46 CTGGACAGATCGAAGAACTTCCCTGGAACCTTCAGAGAACTTCCAGCTGATGCCAGAG 105
QY 216 CTGGACAGAGAGAGAGAGATTAAGAAAGAGAGATTGACATCTGCTGAGAGTACATC 275
Db 106 CTGGACAGAGAGAGAGAGATTAAGAAAGAGAGATTGACATCTGCTGAGAGTACATC 165
QY 276 TCCACGGTGAAGAGCTGTCTCCAGACACAGCGGTGGAGCGCTGCAGAAATCCAGAAC 335
Db 166 TCCACGGTGAAGAGCGTGTCTCCAGACACAGCGGTGGAGCGCTGCAGAAATCCAGAAC 225
QY 336 GCCTACAGCAAGTGCAGAAATACAGTACAGACAAATGAGAGTGGCCATGACAGACTAC 395
Db 226 GCCTACAGCAAGTGCAGAAATACAGTACAGACAAATGAGAGTGGCCATGACAGACTAC 285
QY 396 GAGATGGTGAATTAACACATCTTCAAGGCTTGATGACAGACTGGCGGCTTTGAAGCAGAT 455
Db 286 GAGATGGTGAATTAACACATCTTCAAGGCTTGATGACAGACTGGCGGCTTTGAAGCAGAT 345
QY 456 CTGAAGAGCAAGATGAGAGGAGTATTTGAAAGCTCCGAGAGCGAGGCTTAAAAAA 515
Db 346 CTGAAGAGCAAGATGAGAGGAGTATTTGAAAGCTCCGAGAGCGAGGCTTAAAAAA 405
QY 516 GCGCGGGGTGAGAAAGAAAGAGGTCCTCCGAGGCGCGAGGAGAGCATAGAGGAA 575
Db 406 GCGCGGGGTGAGAAAGAAAGAGGTCCTCCGAGGCGCGAGGAGAGCATAGAGGAA 465
QY 576 GACACACAAAGAAAGAAAGAGGAGGAGGCTGAGTTCACTGACACCATCTGCTCC 635
Db 466 GACACACAAAGAAAGAAAGAGGAGGAGGCTGAGTTCACTGACACCATCTGCTCC 525
QY 636 GTGCACCCCTCTGATGCTGTCGACATGCCGTCGACCCAAAGACCCACGTACTGCTCC 695
Db 526 GTGCACCCCTCTGATGCTGTCGACATGCCGTCGACCCAAAGACCCACGTACTGCTCC 585
QY 696 TGCACACAGGTCTCTATGGGAGATGATGCTGTGACAAATCCACATCTCCAAATTTGAG 755
Db 586 TGCACACAGGTCTCTATGGGAGATGATGCTGTGACAAATCCACATCTCCAAATTTGAG 645
QY 756 TGGTTTCACTTTGCTGCTGCTGACCTTACACGAAACCAAGAAATGTTCTGCTCA 815
Db 646 TGGTTTCCCTTTGCTGCTGCTGACCTTACACGAAACCAAGAAATGTTCTGCTCC 705
QY 816 CGGTGTGTCCAGAG-AAAAGAGAGAAAGATGAGAGAGCTGTGCTCCGG 866
Db 706 CGGTGTGTCCAGAG-AAAAGAGAGAAAGATGAGAGAGCTGTGCTCCGG 757

```

```

RESULT 11
LOCUS BG749339 720 bp mRNA linear EST 15-MAY-2001
DEFINITION 602707806F1 NIH_MGC_43 Homo sapiens cDNA clone IMAGE:187664-5
5', mRNA sequence.
ACCESSION BG749339
VERSION BG749339.1 GI:14059992
KEYWORDS EST.

```

SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 720)
AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Ling Hong/Rubin Laboratory
DNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
<http://image.lnl.gov>
Plate: LNCM1682 row: k column: 01
High quality sequence stop: 713.
Location/Qualifiers
1..720
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:4844664"
/clone_lib="NIH-MGC.43"
/tissue_type="normal pigmented retinal epithelium"
/lab_host="DH10B (phage-resistant)"
/note="Organ: eye; Vector: pOTB7; Site_1: XhoI; Site_2:
EcoRI; CDNA made by oligo-dt priming. Directionally
cloned into EcoRI/XhoI sites using the following 5'
adaptor: GGCACGAG(G). Library constructed by Ling Hong
in the laboratory of Gerald M. Rubin (University of
California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH-MGC Library." 1"
BASE COUNT 209 a 177 c 212 g 122 t
ORIGIN
Query Match 67.1%; Score 642.8; DB 12; Length 720;
Best Local Similarity 98.4%; Pred. No. 8.1e-153;
Matches 681; Conservative 0; Mismatches 7; Indels 4; Gaps 3;
QY 156 CTGATAGTATGAGAGACCTTCCCTGCGAAGCTTCAGAGAACTTCAGCTGATGCGAGAG 215
DB 29 CTGACAGATATGAGAACTTCCCTGCGAAGCTTCAGAGAACTTCAGCTGATGCGAGAG 88
QY 216 CTGACACAGAGAGCGAAGATAGAAAGCAGAGATTGACATCTGGCTGCGAGATACATC 275
DB 89 CTGACACAGAGAGCGAAGATAGAAAGCAGAGATTGACATCTGGCTGCGAGATACATC 148
QY 276 TCCACAGTGAAGAGCTCTCTCCAGACAGCGCTGGAGCGCTTCAGAAAGATCCAGAAC 335
DB 149 TCCACAGTGAAGAGCTCTCTCCAGACAGCGCTGGAGCGCTTCAGAAAGATCCAGAAC 208
QY 336 GCGTACACAGAGTGCAGAGATACAGTACGACAAAGTGCAGACTGGCCATGCGAGACTAC 395
DB 209 GCGTACAGAGTGCAGAGAAATACAGTACGACAAAGTGCAGACTGGCCATGCGAGACTAC 268
QY 366 GAGATGTGTGATTAACACATTCGAAAGCTTGATGCGACAGCTGGCGCGCTTTGAACAGAT 455
DB 269 GAGATGTGTGATTAACACATTCGAAAGCTTGATGCGACAGCTGGCGCGCTTTGAACAGAT 328
QY 456 CTGAGGACAAGATGAGAGGCGATGATTTGAAGCTCCGAGGCGGAGGCTTAAGAAAA 515
DB 329 CTGAGGACAAGATGAGAGGCGATGATTTGAAGCTCCGAGGCGGAGGCTTAAGAAAA 388
QY 516 GCGCGGGGTACAG--AAAGAAAAAGAGGGTCCCGGGCGGAGAGCGAGAGATCAGAGG 573
DB 389 GCGCGGGGTACAGCAGCAAGAAAAAGAGGGTCCCGGGCGGAGAGCGAGAGATCAGAGG 448
QY 574 AAGACACACAAAGAAAAAGAGCAAGAGAGGGTCTGAGTTCACTGACACCATCTGCT 633
DB 449 AAGACACACAAAGAAAAAGAGCAAGAGAGGGTCTGAGTTCACTGACACCATCTGCT 508

QY 634 CCGTGACCCCTCTGATGATGCTGACATGCCCGGTGACCCAAAGACACAGCTACTGCC 693
DB 509 CCGTGACCCCTCTGATGATGCTGACATGCCCGGTGACCCAAAGACACAGCTACTGCC 568
QY 694 TGTGCCACCAAGGTCTCTATGAGGAGATGATGGCTGTGACAAATCCAGACTGTCCAAATGG 753
DB 569 TGTGCCACCAAGGTCTCTATGAGGAGATGATGGCTGTGACAAATCCAGACTGTCCAAATGG 628
QY 754 AGTGTTCACCTTTCCTGCGTGGACCTTACACGAAACCAAGCA--AAATGTTCTGT 812
DB 629 AGTGTTCACCTTTCCTGCGTGGACCTTACACGAAACCAAGCAACATGATGTTCTGT 688
QY 813 CCAGGTGTGTCAGAGAA--AAGAGAGAGAGA 843
DB 689 CCAGGTGTGTCAGAGAAAGAGAGAGAGA 720
RESULT 12
LOCUS B0675901 951 bp mRNA linear EST 15-JUL-2002
DEFINITION AGENCOURT_8297255 NIH-MGC_112 Homo sapiens cDNA clone IMAGE:6274178
5', mRNA sequence.
ACCESSION B0675901
VERSION B0675901.1 GI:21788593
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
REFERENCE 1 (bases 1 to 951)
AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: DCTD/DMP
CDNA Library Preparation: Rubin Laboratory
DNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
<http://image.lnl.gov>
Plate: LNCM2455 row: f column: 03
High quality sequence stop: 574.
Location/Qualifiers
1..951
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:6274178"
/clone_lib="NIH-MGC.112"
/tissue_type="melanotic melanoma, cell line"
/lab_host="DH10B (phage-resistant)"
/note="Organ: skin; Vector: pOTB7; Site_1: XhoI; Site_2:
EcoRI; CDNA made by oligo-dt priming. Directionally cloned
into EcoRI/XhoI sites using the following 5' adaptor:
GGCACGAG(G). Library constructed by Ling Hong in the
laboratory of Gerald M. Rubin (University of California,
Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and
Superscript II RT (Life Technologies). Note: this is a
NIH-MGC Library." 1"
BASE COUNT 249 a 243 c 304 g 155 t
ORIGIN
Query Match 66.4%; Score 635.8; DB 14; Length 951;
Best Local Similarity 93.6%; Pred. No. 5.1e-151;
Matches 697; Conservative 0; Mismatches 42; Indels 6; Gaps 3;
QY 156 CTGATAGTATGAGAGACCTTCCCTGCGAAGCTTCAGAGAACTTCAGCTGATGCGAGAG 215
DB 46 CTGACAGATATGAGAACTTCCCTGCGAAGCTTCAGAGAACTTCAGCTGATGCGAGAG 105
QY 216 CTGACACAGAGAGCGAAGATAGAAAGCAGAGATTGACATCTGGCTGCGAGATACATC 275

Db	106	CTGACCCGAGAGAGCGGAAGATATAGAAACAGAGATGATCTCTGGCTGCGAGAGTACATC	165
QY	276	TTCAACGGTGAAGACGCTGTCTTCCAGACACGCGCGTGAAGCCCTTGCAGAGAATCCAGAAC	335
Db	166	TTCCACGGGTGAAGAGCGCTGTCTTCCAGACACGCGCGTGAAGCCCTTGCAGAGAATCCAGAAC	225
QY	336	GGCTTACACGACGTCACAGATACAGTACAGTACAGTACAGTACAGTACAGTACAGTACAGTAC	395
Db	226	GGCTTACACGACGTCACAGATACAGTACAGTACAGTACAGTACAGTACAGTACAGTACAGTAC	285
QY	396	GAGATGATGATTAACACATTCGAAGCGCTTATGATGATGATGATGATGATGATGATGATGAT	455
Db	286	GAGATGATGATTAACACATTCGAAGCGCTTATGATGATGATGATGATGATGATGATGATGAT	345
QY	456	CTGAAGGACAGATGAGAGCGCATGATTTTGAAGCTCCGAGAGGCGGAGGTTAAAAAAA	515
Db	346	CTGAAGGACAGATGAGAGCGCATGATTTTGAAGCTCCGAGAGGCGGAGGTTAAAAAAA	405
QY	516	GGCGGGGTCAGAAAAAGAAAAAGAGGCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG	575
Db	406	GGCGGGGTCAGAAAAAGAAAAAGAGGCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG	465
QY	576	GACACACCAAGAAAAAGAACACACAAAGAGAGGCTGTGAGTTCACCTGACACCATCTGTCC	635
Db	466	GACACACCAAGAAAAAGAACACACAAAGAGAGGCTGTGAGTTCACCTGACACCATCTGTCC	525
QY	636	GTGCAACCCCTCTGATGTGTCTGAGCATGCGCGGTGAGCCCAACGAAACCCACGTACTGCTG	695
Db	526	GTGCAACCCCTCTGATGTGTCTGAGCATGCGCGGTGAGCCCAACGAAACCCACGTACTGCTG	585
QY	696	TGCCAACCAAGCTCTCTTATGAGGAGATGATGATGATGATGATGATGATGATGATGATGATG	755
Db	586	TGCCAACCAAGCTCTCTTATGAGGAGATGATGATGATGATGATGATGATGATGATGATGATG	645
QY	756	TGCTTCTACTTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGT	812
Db	646	TGCTTCTACTTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGTGCTGT	705
QY	813	CCACGCTGTGTCCAGAGAAAAAGAGAAAGAAG--TAGAGGAGAGCTGTGTG--CCCGATC	869
Db	706	CCGAGGAGGCTGTCCCGAGAAAAAGAGAGAGAGTAGAGAGGAGGCTGTGCGCGCGGATC	765
QY	870	CGAGAGCAAGTAATCTGTCTT 894	
Db	766	CGAGAGCAAGTAATCTGTCTT 790	

FEATURES	Source	Location/Qualifiers
1.	913	/organism="Homo sapiens"
/db_xref="taxon:9606"		
/clone="IMAGE:6264048"		
/clone_lib="NIH_MGC_112"		
/tissue_type="melanotic melanoma, cell line"		
/lab_host="DH10B (phage-resistant)"		
/note="Organ: skin; Vector: pORF7; site_1: XhoI; Site_2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCCAGAG(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using Zap-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies). Note: this is a NIH_MGC Library."		
BASE COUNT	238 a	251 c 293 g 131 t
ORIGIN		
Query Match	64.0%;	Score 613.2; DB 14; Length 913;
Best Local Similarity	93.9%;	Pred. No. 2.8e-145;
Matches 661;	Conservative 0;	Mismatches 38; Indels 5; Gaps 2;
QY	156	CTGATAGGTATTCGAAACCTTCCCTGGCAGACTTCGAGAGACTTCACCTGATGCGAGAG 215
Db	46	CTGGACATATTCGAAACCTTCCCTGGCAGACTTCGAGAGACTTCACCTGATGCGAGAG 105
QY	216	CTGGACACAGAGAGACGGAAGATTAAGAAGCAGAGATTGACATCTTGCTGCAGAGTACATC 275
Db	106	CTGGACACAGAGAGACGGAAGATTAAGAAGCAGAGATTGACATCTTGCTGCAGAGTACATC 165
QY	276	TCCACGGTGAAGACGCTGTCTCCAGACCAAGCGCGGTGAGAGCGCTTCAGAGATCCAGAAC 335
Db	166	TCCACGGTGAAGACGCTGTCTCCAGACCAAGCGCGGTGAGAGCGCTTCAGAGATCCAGAAC 225
QY	336	GCCTACACCAAGTGCAGAGATACAGTACAGCAAAATGACAGCTGGCCATGAGACCTAC 395
Db	226	GCCTACACCAAGTGCAGAGATACAGTACAGCAAAATGACAGCTGGCCATGAGACCTAC 285
QY	396	GAGATGGTGATTAACACATTCGAAAGGCTTGATGAGACCTGGCGCGCTTTGAAACAGAT 455
Db	286	GAGATGGTGATTAACACATTCGAAAGGCTTGATGAGACCTGGCGCGCTTTGAAACAGAT 345
QY	456	CTGAAGGACAAGATGGAGGGCAGTGATTTTGAAGCTCCGAGGGCGAGGGTTAAAAAAA 515
Db	346	CTGAAGGACAAGATGGAGGGCAGTGATTTTGAAGCTCCGAGGGCGAGGGTTAAAAAAA 405
QY	516	GGCCGGGGTCAAGAAAAAGAGGGTCCGGGGGCCGAGGCGAGGAGACATCAAGGAA 575
Db	406	GGCCGGGGTCAAGAAAAAGAGGGTCCGGGGGCCGAGGCGAGGAGACATCAAGGAA 465
QY	576	GACACACCAAGAAAAAGAGCACAAAGAGGGTGTGAGTTCTATCGACACCATCTCTGCC 635
Db	466	GACACACCAAGAAAAAGAGCACAAAGAGGGTGTGAGTTCTATCGACACCATCTCTGCC 525
QY	636	GTCACACCCCTCGATGATGCTGTGACATGCCCGCTGAGACCCCAAGCAACCCACGTACTGCTG 695
Db	526	GTCACACCCCTCGATGATGCTGTGACATGCCCGCTGAGACCCCAAGCAACCCACGTACTGCTG 585
QY	696	TGCCACCAAGGTCCTCTAATGGGAGA--TGATGGCTGTGACATTCAGACTGTCTCAATT 752
Db	586	TGCCACCAAGGTCCTCTAATGGGAGA--TGATGGCTGTGACATTCAGACTGTCTCAATT 645
QY	753	GAGTGGTTTCACTT--GCCTGCGTGGACCTTACACAGAAACCCAAAGAAATGGTCT 810
Db	646	GAGTGGTTTCTTTTGGCTTGCGGGGAGCTTACACAGAAACCCAAAGAAATGGTCT 705
QY	811	GTCACAGGTGTGTCCAGGAAAAAGAGAGAAAGATAGAGAGAG 854
Db	706	GTCACAGGGGGGTCCCCCAAAACGCCCGCAAGAAAGACGACGAGAG 749

RESULT	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
14	B0682571	B0682571 AGENCOURT_8212749 NIH_MGC_112 Homo sapiens CDNA clone IMAGE:6272913	911 bp	mRNA	linear	EST 15-JUL-2002						
		5'', mRNA sequence.										
		B0682571										
		B0682571.1 GI:21795250										
		EST.										
		human.										
		Homo sapiens										
		Eukaryote; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;										
		Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.										
		1 (bases 1 to 911)										
		NIH-MGC http://mgc.nci.nih.gov/										
		National Institutes of Health, Mammalian Gene Collection (MGC)										
		Unpublished (1999)										
		Contact: Robert Strausberg, Ph.D.										
		Email: cga@bts.fremail.nih.gov										
		Tissue Procurement: DCDN/DTP										
		CDNA Library Preparation: Rubin Laboratory										
		CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)										
		DNA Sequencing by: Agencourt Bioscience Corporation										
		Clone distribution: MGC clone distribution information can be										
		found through the I.M.A.G.E. Consortium/LNL at:										
		http://image.lnl.gov										
		plate: LICM2452 row: a column: 10										
		High quality sequence stop: 452.										
		Location/Qualifiers										
		1..911										
		/organism="Homo sapiens"										
		/db_xref="taxon:9606"										
		/clone="IMAGE:6272913"										
		/clone_lib="NIH_MGC_112"										
		/tissue_type="melanotic melanoma, cell line"										
		/lab_host="DH10B (phage-resistant)"										
		/note="Organ: skin; Vector: pOTB7; Site_1: XhoI; Site_2:										
		EcoRI; CDNA made by oligo-dT priming. Directionally cloned										
		into EcoRI/XhoI sites using the following 5' adaptor:										
		GGAACGAG(G). Library constructed by Ling Hong in the										
		Laboratory of Gerald M. Rubin (University of California,										
		Berkeley) using ZAP-CDNA synthesis kit (Stratagene) and										
		Superscript II RT (Life Technologies). Note: this is a										
		NIH_MGC Library."										
		BASE COUNT	229 a	227 c	326 g	128 t	1 others					
		ORIGIN										
		Query Match	63.9%	Score 612;	DB 14;	Length 911;						
		Best Local Similarity	95.1%;	Pred. No. 5.7e-145;								
		Matches 663; Conservative %	0; Mismatches 31; Indels 3; Gaps 3;									
OY	156	CTGATAGGTATTCGAAACCTCCCGGCAACTTCAGAGAACCTCCACTGATGGAGAAG	215									
Db	46	CTTGACACTATTTCGAAACCTTCCTCCGCCAACCCTTCAGAGAACTTCACACTGATGGAGAAG	105									
OY	216	CTGGACCGAGAGGAGCGAAGATTAAGAAACAAGATTGACATCTGGGCTGCAGAGATCATC	275									
Db	106	CTGGACCGAGAGGAGCGAAGATTAAGAAACAAGATTGACATCTGGGCTGCAGAGATCATC	165									
OY	276	TTCACGGTGAAGACGCTGTCTCCAGACCAAGCGCGCTGGAGCGCTTCAGAGAAGATCCAGAAC	335									
Db	166	TTCACGGTGAAGACGCTGTCTCCAGACCAAGCGCGCTGGAGCGCTTCAGAGAAGATCC										

Db	346	CTGAAGGACAAAGATGAGGGCGACGTATTTTGGAAAGCTCCGAGGGCCGAGGTTAAAAAA	405
Qy	516	GGCCGGGGGTGAGAAAAGAAAAAGAGGGTCCGGGGCCCGAGCGACGACATCAGAGGA	575
Db	406	GGCCGGGGGTGACAAAAGAAAAAGAGGGTCCGGGGCCCGAGCGACGACATCAAGAGGA	465
Qy	576	GACACACCAAGAAAAGAGAGCAAAAGAGAGGGTGTGAGTTCTCAGACACCTCTGTGCC	635
Db	466	GACACACCAAGAAAAGAGAGCAAAAGAGAGGGTGTGAGTTCTCAGACACCTCTGTGCC	525
Qy	636	GTGACCCCTCTGATGTGTGGACATGCCCGCTGAGACCCAAAGCAACCCAGCTACTGCC	695
Db	526	GTGACACCCCTCTGATGTGTGGACATGCCCGGGGAGCCAAAGCAACCCAGCTACTGCC	585
Qy	696	TGGCAACCGAGTCTCTAT-GGGGAATATAT-T-GCTGTGACAAATCCACATCTCCAAAT	753
Db	586	TGGCAACCGAGTCTCTATGAGGGGAATATGATTTGGCTGTGACATTCACATCTGCCATTG	645
Qy	754	AGTGGTTTCACATTTCTCCTGCGTGAGACCTTACCCACAAACCCAAAGAAATGGTCTGTCC	813
Db	646	GGGGGGGGTACATTTCTCTGGGGGGAGCCTTACACAGAAACCCCAAGGAAATGGTCCGCG	705
Qy	814	CAC-GGTGTGTCCAGAAAAGAGAGAAAGAAAGTGG	849
Db	706	CCCGGGGGGGTCCCGACAAATCAACAACAAGGGGG	742
RESULT	15		
LOCUS	AK007536	1871 bp	linear
DEFINITION	Mus musculus 10 day old male pancreas cDNA, RIKEN full-length enriched library, clone:1810018M11:homolog to CANDIDATE TUMOR SUPPRESSOR P33 INGI HOMOLOG, full insert sequence.		
ACCESSION	AK007536		
KEYWORDS	HTC, CAP trapper.		
SOURCE	Mus musculus (strain:C57BL/6J) 10 day old male pancreas cDNA to mRNA, clone:11b:RIKEN full-length enriched mouse cDNA library clone:1810018M11.		
ORGANISM	Mus musculus		
REFERENCE	Manuvela, Buthayar, Koenig, Schlegel, Muridae, Muridae, Mus. <i>Mammalia</i> , <i>Eutheria</i> , <i>Rodentia</i> , <i>Sitomorphi</i> , <i>Muridae</i> , <i>Muridae</i> , <i>Mus</i> .		
REFERENCE	1	Carninci, P. and Hayashizaki, Y.	
REFERENCE	2	High efficiency full-length cDNA cloning Meth. Enzymol. 303, 19-44 (1999)	
REFERENCE	3	Genome Res. 10 (10), 1617-1630 (2000)	
REFERENCE	4	Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P., Konno, H., Akiyama, J., Nishi, K., Kitsuana, T., Tashiro, H., Itoh, M., Suni, N., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Matshiki, M., Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kita, A., and Hayashizaki, Y.	
REFERENCE	5	RIKEN integrated sequence analysis (RISA) system-384-format sequencing pipeline with 384 multicapillary sequencer	
REFERENCE	6	Genome Res. 10 (11), 1757-1771 (2000)	
REFERENCE	7	Kawai, J., Shingawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Aizawa, K., Hara, A., Nishikishi, Y., Konno, H., Adachi, J., Fukuda, S., Alizawa, T., Izawa, M., Nishi, K., Kiyosawa, H., Kondo, S., Yamataka, I.,	

QY 935 TGTTCGTTGATTAAGTA 954
|||
DB 840 ATTTGACTGATATTAAATA 859

Search completed: February 22, 2003, 20:52:03
Job time : 2261 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 22, 2003, 19:25:28 : Search time 4159 Seconds
(without alignments)
5791.417 Million cell updates/sec

Title: US-09-442-013-7
Perfect score: 958
Sequence: 1 ttgtcgtacctcagccctgc.....cgttgtacttagtaacaa 958

Scoring table: IDENTITY-NUC
Gapop 10.0 , Gapext 1.0

Searched: 24791104 seqs, 12571243825 residues

Total number of hits satisfying chosen parameters: 49582208

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

Pending_Patents_NA_Main:*

```

1: /cgn2_6/ptodata/1/pna/PCrUS_COMB.seq:*
2: /cgn2_6/ptodata/1/pna/US06_COMB.seq:*
3: /cgn2_6/ptodata/1/pna/US07_COMB.seq:*
4: /cgn2_6/ptodata/1/pna/US080_COMB.seq:*
5: /cgn2_6/ptodata/1/pna/US081_COMB.seq:*
6: /cgn2_6/ptodata/1/pna/US082_COMB.seq:*
7: /cgn2_6/ptodata/1/pna/US083_COMB.seq:*
8: /cgn2_6/ptodata/1/pna/US084_COMB.seq:*
9: /cgn2_6/ptodata/1/pna/US085_COMB.seq:*
10: /cgn2_6/ptodata/1/pna/US086_COMB.seq:*
11: /cgn2_6/ptodata/1/pna/US087_COMB.seq:*
12: /cgn2_6/ptodata/1/pna/US088_COMB.seq:*
13: /cgn2_6/ptodata/1/pna/US089_COMB.seq:*
14: /cgn2_6/ptodata/1/pna/US090_COMB.seq:*
15: /cgn2_6/ptodata/1/pna/US091_COMB.seq:*
16: /cgn2_6/ptodata/1/pna/US092_COMB.seq:*
17: /cgn2_6/ptodata/1/pna/US093_COMB.seq:*
18: /cgn2_6/ptodata/1/pna/US094_COMB.seq:*
19: /cgn2_6/ptodata/1/pna/US095_COMB.seq:*
20: /cgn2_6/ptodata/1/pna/US095B_COMB.seq:*
21: /cgn2_6/ptodata/1/pna/US095C_COMB.seq:*
22: /cgn2_6/ptodata/1/pna/US095D_COMB.seq:*
23: /cgn2_6/ptodata/1/pna/US096A_COMB.seq:*
24: /cgn2_6/ptodata/1/pna/US096B_COMB.seq:*
25: /cgn2_6/ptodata/1/pna/US096C_COMB.seq:*
26: /cgn2_6/ptodata/1/pna/US096D_COMB.seq:*
27: /cgn2_6/ptodata/1/pna/US096E_COMB.seq:*
28: /cgn2_6/ptodata/1/pna/US097A_COMB.seq:*
29: /cgn2_6/ptodata/1/pna/US097B_COMB.seq:*
30: /cgn2_6/ptodata/1/pna/US097C_COMB.seq:*
31: /cgn2_6/ptodata/1/pna/US097C_COMB.seq:*
32: /cgn2_6/ptodata/1/pna/US098B_COMB.seq:*
33: /cgn2_6/ptodata/1/pna/US098C_COMB.seq:*
34: /cgn2_6/ptodata/1/pna/US099A_COMB.seq:*
35: /cgn2_6/ptodata/1/pna/US099B_COMB.seq:*
36: /cgn2_6/ptodata/1/pna/US099C_COMB.seq:*
37: /cgn2_6/ptodata/1/pna/US099D_COMB.seq:*
38: /cgn2_6/ptodata/1/pna/US100A_COMB.seq:*
39: /cgn2_6/ptodata/1/pna/US100B_COMB.seq:*
40: /cgn2_6/ptodata/1/pna/US101A_COMB.seq:*
41: /cgn2_6/ptodata/1/pna/US101B_COMB.seq:*
42: /cgn2_6/ptodata/1/pna/US102A_COMB.seq:*
43: /cgn2_6/ptodata/1/pna/US102B_COMB.seq:*

```

Result No.	Score	% Match	Query Length	DB ID	Description
1	958	100.0	958	18 US-09-442-013-7	Sequence 7, Appl1
2	936.4	97.7	1300	30 US-09-799-451-403	Sequence 403, App
3	798.4	83.3	1108	18 US-09-442-013-1	Sequence 1, Appl1
4	794.6	82.9	1073	28 US-09-716-972-4875	Sequence 4875, Ap
5	794.6	82.9	1073	29 US-09-721-588-5351	Sequence 5351, Ap
6	794.6	82.9	69	US-60-250-830-3236	Sequence 3236, Ap
7	794.6	82.9	2537	76 US-60-323-966-3236	Sequence 3, Appl1
8	787.4	82.2	807	18 US-09-442-013-3	Sequence 5, Appl1
9	787.4	82.2	807	18 US-09-442-013-5	Sequence 43, Appl1
10	771	80.5	1082	1 PCT-US02-25465-43	Sequence 9, Appl1
11	647.4	67.6	958	18 US-09-442-013-9	Sequence 652, App
12	645.6	67.4	1275	62 US-60-184-797-652	Sequence 16936, A
13	645.6	67.4	71	US-60-278-258-16936	Sequence 646, App
14	641.8	67.0	1465	1 PCT-US01-04098A-646	Sequence 298, Appl
15	641.8	67.0	1465	24 US-09-620-325-298	Sequence 18, Appl
16	622	64.9	1011	20 US-09-532-645-18	Sequence 924, Appl
17	622	64.9	1011	56 US-60-126-246-5	Sequence 2614, Ap
18	449.4	46.9	1199	1 PCT-US01-03800A-924	Sequence 7985, Ap
19	449.4	46.9	1199	18 US-09-496-914A-7985	
20	449.4	46.9	1199	18 US-09-496-914A-7985	
21	449.4	46.9	1199	22 US-09-560-875A-7985	

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

```
22 438.4 45.8 974 62 US-60-184-797-1099 Sequence 1099, Ap
23 434 44.3 466 25 US-09-649-164-5599 Sequence 5599, Ap
C 24 427.6 44.6 693 18 PCT-US01-03800A-709 Sequence 709, App
C 25 427.6 44.6 693 12 US-09-496-914A-5424 Sequence 5424, Ap
C 26 427.6 44.6 693 22 US-09-560-875A-5424 Sequence 5424, Ap
27 378 39.5 432 29 US-09-721-588-3653 Sequence 3653, Ap
28 376.6 39.3 456 16 US-09-234-611-9815 Sequence 9815, Ap
29 376.6 39.3 456 16 US-09-235-076-16047 Sequence 16047, A
30 376.6 39.3 456 17 US-09-248-797-32620 Sequence 32620, A
31 376.6 39.3 456 29 US-09-333-782-16047 Sequence 16047, A
32 376.6 39.3 456 29 US-09-737-223-16047 Sequence 16047, A
33 376.6 39.3 456 34 US-09-904-809-9815 Sequence 9815, Ap
34 376.6 39.3 456 34 US-09-918-995-16047 Sequence 16047, A
35 376.6 39.3 456 34 US-09-925-564-32620 Sequence 32620, A
36 361.2 37.7 443 29 US-09-758-472-2828 Sequence 2828, Ap
37 361.2 37.7 443 18 US-10-235-926-2828 Sequence 13363, A
38 351.6 36.7 428 36 US-09-975-673A-13363 Sequence 13363, A
39 351.6 36.7 428 36 US-09-975-673A-13363 Sequence 13363, A
40 351.6 36.7 435 18 US-09-496-911-13364 Sequence 13364, A
41 351.6 36.7 435 18 US-09-975-673A-13364 Sequence 13364, A
42 346 36.1 402 17 US-09-362-510-4047 Sequence 4047, Ap
43 346 36.1 402 17 US-09-362-510A-4047 Sequence 4047, Ap
44 346 36.1 402 34 US-09-904-013-4047 Sequence 2963, Ap
45 325.2 33.9 359 28 US-09-716-972-2963
```

ALIGNMENTS

```
RESULT 1
US-09-442-013-7
; Sequence 7, Application US/09442013
; GENERAL INFORMATION:
; APPLICANT: Lou, Ying
; APPLICANT: Xu, Xiang
; APPLICANT: Leo, Cindy
; APPLICANT: Huang, Betty
; APPLICANT: Shen, Mary
; TITLE OF INVENTION: NOVEL IAPS ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS
; TITLE OF INVENTION: AND METHODS OF USE
; FILE REFERENCE: A-68289/DIB/RMS/DAV
; CURRENT APPLICATION NUMBER: US/09/442, 013
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 7
; LENGTH: 958
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-442-013-7
```

```
Query Match 100.0%; Score 958; DB 18; Length 958;
Best Local Similarity 100.0%; Pred. No. 3.3e-247;
Matches 958; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 TTTGCTGACCTAGCCCTCGTGCGGTATGAGGGTCTGCGTGGCTGAGCATCCAGTGT 60
DB 1 TTTGCTGACCTAGCCCTCGTGCGGTATGAGGGTCTGCGTGGCTGAGCATCCAGTGT 60
QY 61 CCTTCCTACTGCCACTGAGAGGCTCAGGCTGATTTCCAGCACTGTCTGCCAGGACAA 120
DB 61 CCTTCCTACTGCCACTGAGAGGCTCAGGCTGATTTCCAGCACTGTCTGCCAGGACAA 120
QY 121 TGGAGCAGAGAGTCACTCCACGAGAGCTGAGAGGCTGATAGTATCGAGAACCTTCCCT 180
DB 121 TGGAGCAGAGAGTCACTCCACGAGAGCTGAGAGGCTGATAGTATCGAGAACCTTCCCT 180
QY 181 GCGAAGCTTCAAGAGACTTCCAGCTGATGAGAGCTGAGAGGCTGAGAGGAGGAGATAGA 240
DB 181 GCGAAGCTTCAAGAGACTTCCAGCTGATGAGAGCTGAGAGGCTGAGAGGAGGAGATAGA 240
QY 241 AAGCAGAGATGACATCTGCTGCTGAGAGTACTTCCAGGCTGGAAGACGCTGTCTCCAG 300
DB 241 AAGCAGAGATGACATCTGCTGCTGAGAGTACTTCCAGGCTGGAAGACGCTGTCTCCAG 300
```

```
DB 241 AAGCAGAGATGACATCTGCTGCTGAGAGTACTTCCAGGCTGGAAGACGCTGTCTCCAG 300
QY 301 ACCAGCGCGTGAGAGCGCTGTCAGAGATCCAGAGACGCTTACAGCAAGTCCAGGAATAGA 360
DB 301 ACCAGCGCGTGAGAGCGCTGTCAGAGATCCAGAGACGCTTACAGCAAGTCCAGGAATAGA 360
QY 361 GTGAGCAGCAAGAGTCAAGCTGAGGCGCATCCAGAGCTTACAGAGATGTGTAAACATTCGAA 420
DB 361 GTGAGCAGCAAGAGTCAAGCTGAGGCGCATCCAGAGCTTACAGAGATGTGTAAACATTCGAA 420
QY 421 GGTTCATGACAGACCTGGGCGCTTGAAGCAGATCTGGAAGGCAAGATGAGGGGAGAG 480
DB 421 GGTTCATGACAGACCTGGGCGCTTGAAGCAGATCTGGAAGGCAAGATGAGGGGAGAG 480
QY 481 ATTTTAAAGCTCCGAGAGGCGAGGCTTAAAAAAGCGGGGCTCAGAAAGAAAAAGAG 540
DB 481 ATTTTAAAGCTCCGAGAGGCGAGGCTTAAAAAAGCGGGGCTCAGAAAGAAAAAGAG 540
QY 541 GGTCCCGGGGCGAGGCGAGAGGACATCAGAGAGACACACCAAGAAAAAGAACACACA 600
DB 541 GGTCCCGGGGCGAGGCGAGAGGACATCAGAGAGACACACCAAGAAAAAGAACACACA 600
QY 601 AAGGAGGCTCTGATGCTCAGTACAGACATCTGCTGCGTGGACCCCTGTGATGTCTGGACA 660
DB 601 AAGGAGGCTCTGATGCTCAGTACAGACATCTGCTGCGTGGACCCCTGTGATGTCTGGACA 660
QY 661 TGCCCGTGAGACCAAGCAAGACCCAGCTAGCTGCTGTCACCAAGCTCTCTATGGGAGA 720
DB 661 TGCCCGTGAGACCAAGCAAGACCCAGCTAGCTGCTGTCACCAAGCTCTCTATGGGAGA 720
QY 721 TGATTTGGCTGTGACCAATTCAGACTGTCCAAATTTGATGTTTCACTTTCCTGCTGGACC 780
DB 721 TGATTTGGCTGTGACCAATTCAGACTGTCCAAATTTGATGTTTCACTTTCCTGCTGGACC 780
QY 781 TTACCAAGCAAGACCAAGCAAGAAATGTTCTGTCCAGAGTGTGCCAGAAAAAGAGAAACA 840
DB 781 TTACCAAGCAAGACCAAGCAAGAAATGTTCTGTCCAGAGTGTGCCAGAAAAAGAGAAACA 840
QY 841 AGAAGTAGAGAGAGAGTGTGTGCCGAGATCCAGAGCAAGTATATGTGCCCTTCTTTCG 900
DB 841 AGAAGTAGAGAGAGAGTGTGTGCCGAGATCCAGAGCAAGTATATGTGCCCTTCTTTCG 900
QY 901 TGTGCAATATATTCCTCTTTTAAACTATCCCTTGTGGTGTATGATTAAGTACAA 958
DB 901 TGTGCAATATATTCCTCTTTTAAACTATCCCTTGTGGTGTATGATTAAGTACAA 958
```

```
RESULT 2
US-09-799-451-403
; Sequence 403, Application US/09799451
; GENERAL INFORMATION:
; APPLICANT: Tang, Y. Tom
; APPLICANT: Zhou, Ping
; APPLICANT: Goodrich, Ryle
; APPLICANT: Asundi, Vinod
; APPLICANT: Ren, Feiyan
; APPLICANT: Zhang, Jie
; APPLICANT: Xue, Aidong J.
; APPLICANT: Zhao, Qing A.
; APPLICANT: Wang, Jian-Rui
; APPLICANT: Ma, Yuning
; APPLICANT: Yamazaki, Victoria
; APPLICANT: Chen, Rui-hong
; APPLICANT: Wang, Zhiwei
; APPLICANT: Yang, Yonghong
; APPLICANT: Wehrman, Tom
; APPLICANT: Ghosh, Reena
; APPLICANT: Drmanac, Radoje T.
; TITLE OF INVENTION: Novel Nucleic Acids and
; FILE REFERENCE: Polypeptides
; CURRENT APPLICATION NUMBER: US/09/799,451
```

;
; CURRENT FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 948
; SOFTWARE: pf_fl_genes Version 2.0
; SEQ ID NO 403
; LENGTH: 1300
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (188)..(913)
US-09-799-451-403

Query Match 97.7%; Score 936.4; DB 30; Length 1300;
Best Local Similarity 98.8%; Pred. No. 2,5e-241;
Matches 943; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OY 3 TGTGACCTCAGCCCTGCGTGGCGTATTGAGGGTCTGCGTGGCTGAGACATCAGTGTCC 62
DB 71 TGTGACCTCAGCCCTGCGTGGCGTATTGAGGGTCTGCGTGGCTGAGACATCAGTGTCC 130
OY 63 TTTCGACCTGACCTGACAGCCCTGAGCCCTGATTTCCAGACATCTGTCTCCAGAGCAATG 122
DB 131 TTTCGACCTGACCTGACAGCCCTGAGCCCTGATTTCCAGACATCTGTCTCCAGAGCAATG 190
OY 123 GGAGCAAGATGCTCCTCAGAGACTCTGGAGGCTGATGATGAGAGAACTTCCCTTC 182
DB 191 GGAGCAAGATGCTCCTCAGAGACTCTGGAGGCTGATGATGAGAGAACTTCCCTTC 250
OY 183 GAATCTCAGAGAACTTCCAGTGTGCGAGAGCTGGAGCAAGAGAGAGAGATTAAGAA 242
DB 251 GAATCTCAGAGAACTTCCAGTGTGCGAGAGCTGGAGCAAGAGAGAGAGATTAAGAA 310
OY 243 GGAGGATTTGACATCTGCTGCTCAGAGTACATCTCCAGGCTGAACCGTGTCTCCAGAC 302
DB 311 GGAGGATTTGACATCTGCTGCTCAGAGTACATCTCCAGGCTGAACCGTGTCTCCAGAC 370
OY 303 CAGCCGCTGAGAGCGCTGAGAGATCCAGAGCGCTACAGAGAGTGCAGAGAGATACAGT 362
DB 371 CAGCCGCTGAGAGCGCTGAGAGATCCAGAGCGCTACAGAGAGTGCAGAGAGATACAGT 430
OY 363 CAGCAGCAAAAGTGCAGCTGGCCATGCAAGACTTACAGAGTGTGATTAACATCTCGAAG 422
DB 431 CAGCAGCAAAAGTGCAGCTGGCCATGCAAGACTTACAGAGTGTGATTAACATCTCGAAG 490
OY 423 CTTGATGAGAGCTGGCGGCTTTGAAGAGATCTGAAGAGAAATGAGAGGCACTGAT 482
DB 491 CTTGATGAGAGCTGGCGGCTTTGAAGAGATCTGAAGAGAAATGAGAGGCACTGAT 550
OY 483 TTTGAAAGCTCCGAGAGGCGGTTAAAAAAGCCGCGGCTCAGAAAAAAGAGAGG 542
DB 551 TTTGAAAGCTCCGAGAGGCGGTTAAAAAAGCCGCGGCTCAGAAAAAAGAGAGG 610
OY 543 TCCCGGGGCGGAGGAGAGACATCAGAGAGAACACCAAAAGAAAAAAGAGACAAA 602
DB 611 TCCCGGGGCGGAGGAGGAGACATCAGAGAGAACACCAAAAGAAAAAAGAGACAAA 670
OY 603 GGAGGCTGAGATCTGACGACACATCTGTCTCCGTCACACCCCTCTGATGTGCTGCACATG 662
DB 671 GGAGGCTGAGATCTGACGACACATCTGTCTCCGTCACACCCCTCTGATGTGCTGCACATG 730
OY 663 CCGGTGAGACCCAAAGAACCCACGACTGTGCTGCTCCACAGAGTCTCCATATGGGAGATG 722
DB 731 CCGGTGAGACCCAAAGAACCCACGACTGTGCTGCTCCACAGAGTCTCCATATGGGAGATG 790
OY 723 ATTGCTGTGACATTCAGACTGTCCAAATGAGTGGTTTCACTTTGCTGCTGAGACCTT 782
DB 791 ATTGCTGTGACATTCAGACTGTCCAAATGAGTGGTTTCACTTTGCTGCTGAGACCTT 850
OY 783 ACCAGAAAACCCAAAGAAAATGTTCTGTCCACGCTGTCTCAGAGAAAAGAGAGAG 842
DB 851 ACCAGAAAACCCAAAGAAAATGTTCTGTCCACGCTGTCTCAGAGAAAAGAGAGAG 910
OY 843 AAGTAGAGAGAGCTGTGTGTCGGATCCGAGAGCAAGTAAATCTGTCCCTTCAATTCGTG 902

DB 911 AAGTAGAGAGAGCTGTGTGTCGGATCCGAGAGCAAGTAAATCTGTCCCTTCAATTCGTG 970
OY 903 TCGCAATATTTCCCTTCCCTTTTAAAGTACCTTTGCGTTGATACCTTAGTAC 956
DB 971 TCGCAATATTTCCCTTCCCTTTTAAAGTACCTTTGCGTTGATACCTTAGTAC 1024

RESULT 3
US-09-442-013-1
; Sequence 1, Application US/09442013
; GENERAL INFORMATION:
; APPLICANT: Lou, Yang
; APPLICANT: Xu, Xiang
; APPLICANT: Leo, Cindy
; APPLICANT: Huang, Betty
; APPLICANT: Shen, Mary
; TITLE OF INVENTION: NOVEL IAPS ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS
; FILE REFERENCE: A-68289/DJB/RMS/DAV
; CURRENT APPLICATION NUMBER: US/09/442.013
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 1108
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-442-013-1

Query Match 83.3%; Score 798.4; DB 18; Length 1108;
Best Local Similarity 99.3%; Pred. No. 3.8e-204;
Matches 802; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

OY 149 TGGAGCCTGATAGTATGAGAGACCTTCCCTGCACTTACAGAGAACTTCCAGCTGAT 208
DB 301 TGTCTGGATTTACAGATATGAGAGACCTTCCCTGCACTTACAGAGAACTTCCAGCTGAT 360
OY 209 GCGAAGCTGGACCCAGAGAGCGAAGATTAAGAAACAGAGATTTGATCTGCTGACGA 268
DB 361 GCGAAGCTGGACCCAGAGAGCGAAGATTAAGAAACAGAGATTTGATCTGCTGACGA 420
OY 269 GTACATCTCCAGGCTGAGAGACCTGTCTCAGACAGCGCGTGGAGCCCTGACAGAAAT 328
DB 421 GTACATCTCCAGGCTGAGAGACCTGTCTCAGACAGCGCGTGGAGCCCTGACAGAAAT 480
OY 329 CCAGAACGCTTACAGCAAGTGCAGAGAAATACAGTACGACAGCAAAAGTGCAGCTGCGCATCA 388
DB 481 CCAGAACGCTTACAGCAAGTGCAGAGAAATACAGTACGACAGCAAAAGTGCAGCTGCGCATCA 540
OY 389 GACCTACGAGATGTGATTAACACATTCGAAGGCTTGTATGACAGCTGCGGCTTTGA 448
DB 541 GACCTACGAGATGTGATTAACACATTCGAAGGCTTGTATGACAGCTGCGGCTTTGA 600
OY 449 ACCGATCTGAGAGGACCAAGATGAGAGGCGAGTATTTGAAAGCTCCGAGGCGGAGGTT 508
DB 601 ACCGATCTGAGAGGACCAAGATGAGAGGCGAGTATTTTGAAGCTCCGAGGCGGAGGTT 660
OY 509 AAAAAAGGCGGAGTCAAGAAAAAAGAGGTCGCCGCGGCGCAGAGGAGAGATC 568
DB 661 AAAAAAGGCGGAGTCAAGAAAAAAGAGGTCGCCGCGGCGCAGAGGAGAGATC 720
OY 569 AGAGAGAGACACCAAGAAAAAAGAGACAAAGAGAGGCTGTGATTCACTGACACAT 628
DB 721 AGAGAGAGACACCAAGAAAAAAGAGACAAAGAGAGGCTGTGATTCACTGACACAT 780
OY 629 CCGTCCGAGACCCCTCTGATGTGCTGAGACATGCGCGGAGACCAAGAGAGAGAGT 688
DB 781 CCGTCCGAGACCCCTCTGATGTGCTGAGACATGCGCGGAGACCAAGAGAGAGT 840
OY 689 CTGCTGTGACCAAGATCTCTTATGAGAGATGATGATGATGATGATGATGATGATGATGATGAT 748
DB 841 CTGCTGTGACCAAGATCTCTTATGAGAGATGATGATGATGATGATGATGATGATGATGATGAT 900

OY	749	AAAGATGGTTTACATTGCGCTGGACCTTACCAGAACCCAAGGAATAATGGTT 	808
Dd	901	AATTGATGGTTTCACCTTGCTGCCTGGAACCTTACCAGAACCCAAAGGAATAATGGTT 	960
OY	809	CTGTCCACGGTGTGTCCAGAAAAAGAGAAGAAAGTAGAGAGAGCTGTGTGCCGGAT 	868
Dd	961	CTGTCCACGGTGTGTCCAGAAAAAGAGAAGAAAGTAGAGAGAGCTGTGTGCCGGAT 	1020
OY	869	CCGAGGAGCCAAGTTAATCTGTCCCCTCATTTCTGTGCGCAATATTTTCCCTCCTTTAAA 	928
Dd	1021	CCGAGGAGCCAAGTTAATCTGTCCCCTCATTTCTGTGCGCAATATTTTCCCTCCTTTAAA 	1080
OY	929	CTACTCTGTGGTTGATTACTTAGTAAC 	956
Dd	1081	CTACTCTGTGGTTGATTACTTAGTAAC 	1108

```

RESULT 4
US-09-716-972-4875
: Sequence 4875, Application US/09716972
: GENERAL INFORMATION:
: APPLICANT: Hunter, John J.
: APPLICANT: Shyjan, Andrew W.
: APPLICANT: Vasicsek, Thomas
: APPLICANT: Lee, John
: TITLE OF INVENTION: NOVEL NUCLEIC ACID MOLECULES AND USES
: TITLE OF INVENTION: THEREFOR
: FILE REFERENCE: 1600, 2030-001
: CURRENT APPLICATION NUMBER: US/09/716, 972
: CURRENT FILING DATE: 2000-11-21
: PRIOR APPLICATION NUMBER: 60/166,948
: PRIOR FILING DATE: 1999-11-22
: NUMBER OF SEQ ID NOS: 5251
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 4875
: LENGTH: 1073
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-716-972-4875

```

Query Match	82.9%;	Score 794.6;	DB 28;	Length 1073;
Best Local Similarity	99.5%;	Pred. No. 4e-203;		
Matches 797; Conservative	0;	Mismatches 4;	Indels 0;	Gaps 0;

QY	156	CTGTAGGTATCCGAAACCTTCCCTGGCAATTCAGAGAACTCCAGCTGATCCGGAG	215
Db	38	CTGACACGTATCCGAACCTTCCCTGGCAATTCAGAGAACTTCCAGCTGATCCGGAG	97
QY	216	CTGACACGAGAGCGAAGATTAAGAAAGCAGAGATTGACATCTCTGCTGCAGATACATC	279
Db	98	CTGACACGAGAGCGAAGATTAAGAAAGCAGAGATTGACATCTCTGCTGCAGATACATC	157
QY	276	TCCACGGTGAAGACCGTGTCTCCAGACCAGCGCTGGACGGCTCTGCAGAAAGATCCAGAC	335
Db	158	TCCACGGTGAAGACCGTGTCTCCAGACCAGCGCTGGAGGGCTCTGCAGAAAGATCCAGAC	217
QY	336	GCTTACAGCAAGTGCAGGAATACATAGTACGACAAATGCGAGCTGGCATATGCAGACCTAC	395
Db	218	GCTTACAGCAAGTGCAGGAATACATAGTACGACAAATGCGAGCTGGCATATGCAGACCTAC	277
QY	396	GAGATGTTGATTAACACATTTGGAAGGCTTGATGCAGACCTGGGGCTTTTGAAGCGAT	455
Db	278	GAGATGTTGATTAACACATTTGGAAGGCTTGATGCAGACCTGGGGCTTTTGAAGCGAT	337
QY	456	CTGAAAGCAAGATGGAGGGCAGTGTATTTGAAAGCTCCGAGGGCGAGGCTTAAAAAA	515
Db	338	CTGAAAGCAAGATGGAGGGCAGTGTATTTGAAAGGCTCCGAGGGCGAGGCTTAAAAAA	397
QY	516	GGCCGGGTCAGAAAGAAAAAGGGTCCCGGGGGCCGAGGACAGAGACATCAGACGAA	579
Db	398	GGCCGGGTCAGAAAGAAAAAGGGTCCCGGGGGCCGAGGACAGAGACATCAGACGAA	457

Oy	576	GACACACCAAGAAAAAGAACACAAAGAGGGGCTGAGTTCACTGACACATCTCGTCC	635
Db	458	GACACACCAAGAAAAAGAACACAAAGAGGGGCTGAGTTCACTGACACATCTCGTCC	517
Oy	636	GTGCACCCCTCTGATGTGCTGGACATGCCGCTGGACCCAAAGCAACCCAGTACTCGCTG	695
Db	518	GTGCACCCCTCTGATGTGCTGGACATGCCGCTGGACCCAAAGCAACCCAGTACTCGCTG	577
Oy	696	TGCCACCAAGGTCTCTTATGGGAGATATTGGCTGTGACAATCCAGACNCTCCAAITTTGAG	755
Db	578	TGCCACCAAGGTCTCTTATGGGAGATATTGGCTGTGACAATCCAGACNCTCCAAITTTGAG	637
Oy	756	TGGTTTCACTTTGGCTGCGTGGAGCCTTACACGAAACCCAAAGGAAATGGTTCTGTCCA	815
Db	638	TGGTTTCACTTTGGCTGCGTGGAGCCTTACACGAAACCCAAAGGAAATGGTTCTGTCCA	697
Oy	816	CGGTGTCTCCAGSAAAGAGSAAAGAAAGTAGAGGAGCTGTGTGCCCGGATCCGAGGA	875
Db	698	CGGTGTCTCCAGSAAAGAGSAAAGAAAGTAGAGGAGCTGTGTGCCCGGATCCGAGGA	757
Oy	876	GCAAGTTAATCTGTGCCCTTCATTTCGTGCGCATATTTCCTTCCTTTTAAACTACTTT	935
Db	758	GCAAGTTAATCTGTGCCCTTCATTTCGTGCGCATATTTCCTTCCTTTTAAACTACTTT	817
Oy	936	GTCGGTTGATCTTAGTAAC	956
Db	818	GTCGGTTGATCTTAGTAAC	838

```
RESULT 5
US-09-721-588-5351
: SEQUENCE 5351, APPLICATION US/09721588
: GENERAL INFORMATION:
: APPLICANT: Gearling, David P.
: APPLICANT: Holtzman, Douglas A.
: APPLICANT: Villavejan, Jean-Luc
: TITLE OF INVENTION: NOVEL NUCLEIC ACID MO
: TITLE OF INVENTION: THEREFOR
: FILE REFERENCE: 1600.2046-001
: CURRENT APPLICATION NUMBER: 05/09/721,588
: CURRENT FILING DATE: 2000-11-22
: PRIOR FILING DATE: 1999-11-24
: PRIOR APPLICATION NUMBER: 60/167,381
: NUMBER OF SEQ ID NOS: 5410
: SOFTWARE: FastSeq for Windows Version 4.0.
: SEQ ID NO 5351
: LENGTH: 1073
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-721-588-5351
```

Query Match	82.9%;	Score 794.6;	DB 29;	Length 1073;
Best Local Similarity	99.5%;	Pred. No. 4e-203;		
Matches 797; Conservative	0;	Mismatches 4;	Indels 0;	Gaps 0;

Qy	156	CTGTAGGTATTCGAGAACCTTCCCTCGCACTTCAGAGAACTCCAGCTGATGCAGAG	215
Pb	38	CTGGACAGTATCGAGAACCTTCCCTCGCACTTCAGAGAACTCCAGCTGATGCAGAG	97
Qy	216	CTGTGACCAAGAGACCGGAAGATTAAGAAAGCAGACATTGACATCTCTGGCTCGAGAGTCAATC	275
Pb	98	CTGTGACCAAGAGACCGGAAGATTAAGAAAGCAGAGATTGACATCTCTGGCTCGAGAGTCAATC	157
Qy	276	TCCACGGGTGAAGACGCGTGTCTCCAGACACAGCGGTGGAGCGCCTCGCAGAAAGATCCAGAAC	335
Pb	158	TCCACGGGTGAAGACGCGTGTCTCCAGACACAGCGGTGGAGCGCCTCGCAGAAAGATCCAGAAC	217
Qy	336	GCCATACAGCAAGTCCAGAGGAATACAGTACGACACAAAGTGCAGTGGCCCATTCGACACTTAC	395
Pb	218	GCCATACAGCAAGTCCAGAGGAATACAGTACGACACAAAGTGCAGTGGCCCATTCGACACTTAC	277
Qy	396	GAGATGGTGGATTAACACATTCGAAAGGCTTGATGACACACTGGCGCGCTTTGAAAGCAGAT	455

Db 278 GAGATGTTGATTAACACATTCGAAAGCCTTATGTCAGACCTGCGCCGCTTTGAAGCAGAT 337
Qy 456 CTGAAGACCAAGATGAGGAGCGATGATTTTGAAGCTCCGGAGGGCGAGGGTTAAAGAA 515
Db 338 CTGAAGGCAAGATGAGGAGCGATGATTTTGAAGCTCCGGAGGGCGAGGGTTAAAGAA 397
Qy 516 GCGCGGGGTCAAGAAAAAGAGGGTCCCGGGGCCGAGGCGAGAGGACATCAGAGGAA 575
Db 398 GCGCGGGGTCAAGAAAAAGAGGGTCCCGGGGCCGAGGCGAGAGGACATCAGAGGAA 457
Qy 576 GACACACCAAGAAAAAGAGGACACAAAGAGGGTCTGAGTTCTACTGACACCATCCTGTCC 635
Db 458 GACACACCAAGAAAAAGAGGACACAAAGAGGGTCTGAGTTCTACTGACACCATCCTGTCC 517
Qy 636 GTGACACCCCTCTGATGTCCTGAGACATGCCGTTGAGCCCAAGCAAGCCACGACTGCTCG 695
Db 518 GTGACACCCCTCTGATGTCCTGAGACATGCCGTTGAGCCCAAGCAAGCCACGACTGCTCG 577
Qy 696 TGCCACACGTCCTCTATGGGAGATGATGTCGTCGACAAATCCAGACTGTCCAAATTGAG 755
Db 578 TGCCACACGTCCTCTATGGGAGATGATGTCGTCGACAAATCCAGACTGTCCAAATTGAG 637
Qy 756 TGGTTTCACTTTGCGTGGGTGACCTTACCAAGAAACCCAAAGAAAAATGTTCTGTCCA 815
Db 638 TGGTTTCACTTTGCGTGGGTGACCTTACCAAGAAACCCAAAGAAAAATGTTCTGTCCA 697
Qy 816 CGGTGTCTCCAGAAAAAGAGAAAGTAGAGGAGGAGTGTGTGCCCGGATCCGAGAGA 875
Db 698 CGGTGTCTCCAGAAAAAGAGAAAGTAGAGGAGGAGTGTGTGCCCGGATCCGAGAGA 757
Qy 876 GCAAGTTAATCTGTCCTTCATTCGTCGCAATATTCCCTTCTTTAAACTACCTT 935
Db 758 GCAAGTTAATCTGTCCTTCATTCGTCGCAATATTCCCTTCTTTAAACTACCTT 817
Qy 936 GTTCGGTTGATTAAGTAAC 956
Db 818 GTTCGGTTGATTAAGTAAC 838

RESULT 6
; Sequence 3236, Application US/60250830
; GENERAL INFORMATION:
; APPLICANT: Morris, Macdonald
; APPLICANT: Lal, Preeti
; APPLICANT: Diep, Dinh
; TITLE OF INVENTION: METHOD FOR THE IDENTIFICATION OF SEQUENCE POLYMORPHISMS USING
; TITLE OF INVENTION: POLYNUCLEOTIDE SEQUENCE DATABASES, AND SINGLE NUCLEOTIDE
; FILE REFERENCE: GX-0020 P
; CURRENT APPLICATION NUMBER: US/60/250,830
; CURRENT FILING DATE: 2000-11-04
; NUMBER OF SEQ ID NOS: 3246
; SOFTWARE: PERL Program
; SEQ ID NO 3236
; LENGTH: 2537
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: 121128.18
US-60-250-830-3236

Query Match 82.9%; Score 794.6; DB 69; Length 2537;
Best Local Similarity 99.5%; Pred. No. 5.3e-203;
Matches 797; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 156 CTGATAGTATCGAAGACTTCCTCGGAGCTTCGAGAGACTTCACACTGATGCGAGAG 215
Db 56 CTGACACTATCGAAGACTTCCTCGGAGCTTCGAGAGACTTCACACTGATGCGAGAG 115
Qy 216 CTGACACGAGAGCGAAGATAGAAAGCAGAGATTGACATCTGCGTCGACAGATACATC 275
|||||

Db 116 CTGACACGAGAGACGGAAGATAGAAACAGAGATTGACATCTGTGTCGACAGATACATC 175
Qy 276 TCCACGGTGAAGAGCGCTCTCCAGACAGCGCGTGGAGCGCTCGACAGATCCAGAAC 335
Db 176 TCCACGGTGAAGAGCGCTCTCCAGACAGCGCGTGGAGCGCTCGACAGATCCAGAAC 235
Qy 336 GCGTTCACCAAGTGCAGGAATATACAGTACAGCAAAAGTGCAGCTGCGCATCAGACCTAC 395
Db 236 GCGTTCACCAAGTGCAGGAATATACAGTACAGCAAAAGTGCAGCTGCGCATCAGACCTAC 295
Qy 396 GAGATGTGATTAACACATTCGAAAGCTTGATGACAGACTGCGCGCTTTGAAGCAGAT 455
Db 296 GAGATGTGATTAACACATTCGAAAGCTTGATGACAGACTGCGCGCTTTGAAGCAGAT 355
Qy 456 CTGAAGCAAGATGAGGAGCGATTTTGAAGCTCCGGAGGGCGAGGGTTAAAGAA 515
Db 356 CTGAAGCAAGATGAGGAGCGATTTTGAAGCTCCGGAGGGCGAGGGTTAAAGAA 415
Qy 516 GCGCGGGGTCAAGAAAAAGAGGGTCCCGGGGCCGAGGCGAGAGGACATCAGAGGAA 575
Db 416 GCGCGGGGTCAAGAAAAAGAGGGTCCCGGGGCCGAGGCGAGAGGACATCAGAGGAA 475
Qy 576 GACACACCAAGAAAAAGAGGACACAAAGAGGGTCTGAGTTCTACTGACACCATCCTGTCC 635
Db 476 GACACACCAAGAAAAAGAGGACACAAAGAGGGTCTGAGTTCTACTGACACCATCCTGTCC 535
Qy 636 GTGACACCCCTCTGATGTCCTGAGACATGCCGTTGAGCCCAAGCAAGCCACGACTGCTCG 695
Db 536 GTGACACCCCTCTGATGTCCTGAGACATGCCGTTGAGCCCAAGCAAGCCACGACTGCTCG 595
Qy 696 TGCCACACGTCCTCTATGGGAGATGATGTCGTCGACAAATCCAGACTGTCCAAATTGAG 755
Db 596 TGCCACACGTCCTCTATGGGAGATGATGTCGTCGACAAATCCAGACTGTCCAAATTGAG 655
Qy 756 TGGTTTCACTTTGCGTGGGTGACCTTACCAAGAAACCCAAAGAAAAATGTTCTGTCCA 815
Db 656 TGGTTTCACTTTGCGTGGGTGACCTTACCAAGAAACCCAAAGAAAAATGTTCTGTCCA 715
Qy 816 CGGTGTCTCCAGAAAAAGAGAAAGTAGAGGAGGAGTGTGTGCCCGGATCCGAGAGA 875
Db 716 CGGTGTCTCCAGAAAAAGAGAAAGTAGAGGAGGAGTGTGTGCCCGGATCCGAGAGA 775
Qy 876 GCAAGTTAATCTGTCCTTCATTCGTCGCAATATTCCCTTCTTTAAACTACCTT 935
Db 776 GCAAGTTAATCTGTCCTTCATTCGTCGCAATATTCCCTTCTTTAAACTACCTT 835
Qy 936 GTTCGGTTGATTAAGTAAC 956
Db 836 GTTCGGTTGATTAAGTAAC 856

RESULT 7
; Sequence 3236, Application US/60323966
; GENERAL INFORMATION:
; APPLICANT: Morris, Macdonald
; APPLICANT: Lal, Preeti
; APPLICANT: Diep, Dinh
; TITLE OF INVENTION: METHOD FOR THE IDENTIFICATION OF SEQUENCE POLYMORPHISMS USING
; TITLE OF INVENTION: POLYNUCLEOTIDE SEQUENCE DATABASES, AND SINGLE NUCLEOTIDE
; FILE REFERENCE: GX-0020-1 P
; CURRENT APPLICATION NUMBER: US/60/323,966
; CURRENT FILING DATE: 2001-09-21
; NUMBER OF SEQ ID NOS: 3246
; SOFTWARE: PERL Program
; SEQ ID NO 3236
; LENGTH: 2537
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No: 121128.18

US-60-323-966-3236

Query Match 82.9%; Score 794.6; DB 76; Length 2537;
Best Local Similarity 99.5%; Pred. No. 5.3e-203;
Matches 797; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 156 CTGATAGTATGAGAACCTTCCTGCGAACCTTCAGAGAACTTCAGCTGATGCGAGAG 215
DB 56 CTGGACAGTATCGAAGAACCTTCCTGCGAACCTTCAGAGAACTTCAGCTGATGCGAGAG 115
QY 216 CTGGACCAAGACGGAAGATTAAGAAAGAGAGATGATGATCTGCTGCTGAGTACATC 275
DB 116 CTGGACCAAGAGAGCGGAAGATTAAGAAAGAGAGATGATGATCTGCTGCTGAGTACATC 175
QY 276 TCCACGCTGAAGACGCTGCTCCAGACACGCGCTGGAGCGCTCGAGAAGATCCAGAC 335
DB 176 TCCACGCTGAAGACGCTGCTCCAGACACGCGCTGGAGCGCTCGAGAAGATCCAGAC 235
QY 336 GCGTACAGCAAGTGCAGAGATACAGTACGACGAAAGTGCAGCTGGCATGCGACCTAC 395
DB 236 GCGTACAGCAAGTGCAGAGATACAGTACGACGAAAGTGCAGCTGGCATGCGACCTAC 295
QY 396 GAGATGCTGATTAACACATCTGGAAGGCTTGGATGACAGCTGGCGCTTTGAAGACAT 455
DB 296 GAGATGCTGATTAACACATCTGGAAGGCTTGGATGACAGCTGGCGCTTTGAAGACAT 355
QY 456 CTGAAGGACAAAGTGAAGGAGGAGTATTTGAAAGCTCCGAGAGGCGAGGTTAAAAA 515
DB 356 CTGAAGGACAAAGTGAAGGAGGAGTATTTGAAAGCTCCGAGAGGCGAGGTTAAAAA 415
QY 516 GCGCGGGGTGAGAAAGAAAAAGAGGTCGCCGGGCGGAGGCGAGAGACATCAGAGAA 575
DB 416 GCGCGGGGTGAGAAAGAAAAAGAGGTCGCCGGGCGGAGGCGAGAGACATCAGAGAA 475
QY 576 GACACACCAAGAAAGAAAGCAAGAGAGGCTGAGTCTGATCTACACATCTGCTG 635
DB 476 GACACACCAAGAAAGAAAGCAAGAGAGGCTGAGTCTGATCTACACATCTGCTG 535
QY 636 GTGCACCCCTGATGCTGTCGACATGCCGTCGACCCCAAGACCCACGTCCTG 695
DB 536 GTGCACCCCTGATGCTGTCGACATGCCGTCGACCCCAAGACCCACGTCCTG 595
QY 696 TGCACACAGGTCCTATGAGGAGATGATGCTGTGACATCCAGACTGTCATTTGAG 755
DB 596 TGCACACAGGTCCTATGAGGAGATGATGCTGTGACATCCAGACTGTCATTTGAG 655
QY 756 TGGTTCACTTGGCCGCGGAGACCTTACACGAAACCCAAAGGAAATGTTCTGTCCA 815
DB 656 TGGTTCACTTGGCCGCGGAGACCTTACACGAAACCCAAAGGAAATGTTCTGTCCA 715
QY 816 CGGTGTGTCAGGAAAGAGAGAGATGAGAGAGCTGTGCCGATCCGAGCA 875
DB 716 CGGTGTGTCAGGAAAGAGAGAGATGAGAGAGCTGTGCCGATCCGAGCA 775
QY 876 GCAAGTTAATCTGTCCTTCATTCGTGCGCAATATTTCCCTTCCTTTAAAACTACTT 935
DB 776 GCAAGTTAATCTGTCCTTCATTCGTGCGCAATATTTCCCTTCCTTTAAAACTACTT 835
QY 936 GTTCGGTGTGATCTAGTAAC 956
DB 836 GTTCGGTGTGATCTAGTAAC 856

RESULT 8

US-09-442-013-3

; Sequence 3, Application US/09442013
; GENERAL INFORMATION:
; APPLICANT: Lou, Yang
; APPLICANT: Xu, Xiang
; APPLICANT: Leo, Cindy
; APPLICANT: Huang, Betty
; APPLICANT: Shen, Mary
; TITLE OF INVENTION: NOVEL IAPS ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS

; TITLE OF INVENTION: AND METHODS OF USE
; FILE REFERENCE: A-68289/DJB/RMS/DAV
; CURRENT APPLICATION NUMBER: US/09/442,013
; CURRENT FILING DATE: 1999-11-17
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 807
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-442-013-3

Query Match 82.2%; Score 787.4; DB 18; Length 807;
Best Local Similarity 98.6%; Pred. No. 3.2e-201;
Matches 794; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 TGTGACCTCAGCCCTGCTGGCGCTATGAGAGGTGCTGGCTGAGCATCCAGTCTCC 62
DB 1 TGTGACCTCAGCCCTGCTGGCGCTATGAGAGGTGCTGGCTGAGCATCCAGTCTCC 60
QY 63 TTGCTACTGCACTGACAGCTCAGGCTGATTTCCAGCACTGTCTGCAGAGCAATG 122
DB 61 TTGCTACTGCACTGACAGCTCAGGCTGATTTCCAGCACTGTCTGTCCAGAGCAATG 120
QY 123 GGAGCAAGAGTCACTCCACAGACTCTGAGAGGCTGATGATGATGAGAACTTCCCTGC 182
DB 121 GGAGCAAGAGTCACTCCACAGACTCTGAGAGGCTGATGATGATGAGAACTTCCCTGC 180
QY 183 GAACCTCAAGAGAACTTCCAGCTGATGCGAGAGCTTGACCAAGAGCGGAACATTAAGAA 242
DB 181 GAACCTCAAGAGAACTTCCAGCTGATGCGAGAGCTTGACCAAGAGCGGAATTAAGAA 240
QY 243 GCAGATTTGACATCTGCTGCTGAGAGTACATCTCCAGGCTGAGAGAGCTGTCTCCAGAC 302
DB 241 GCAGATTTGACATCTGCTGCTGAGAGTACATCTCCAGGCTGAGAGAGCTGTCTCCAGAC 300
QY 303 CAGCGGTGAGGCGCTGCAAGAGATCCAGAACGCTTACAGCAAGTGCAGAGATACACT 362
DB 301 CAGCGGTGAGGCGCTGCAAGAGATCCAGAACGCTTACAGCAAGTGCAGAGATACACT 360
QY 363 GACGAAAGTGTAGTGGCCATGCGACGCTGAGAGATGATGATGATGATGATGATGATG 422
DB 361 GACGAAAGTGTAGTGGCCATGCGACGCTGAGAGATGATGATGATGATGATGATGATG 420
QY 423 CTGTGATGACAGACTGCGGCGCTTTGAAGCAGATCTGAAGACAAATGAGAGGCACTGAT 482
DB 421 CTGTGATGACAGACTGCGGCGCTTTGAAGCAGATCTGAAGACAAATGAGAGGCACTGAT 480
QY 483 TTTGAAAGCTCGGAGGCGAGGCTTTAAAAAAGCCCGGGGTTCAGAAAGAAAAAGAGGG 542
DB 481 TTTGAAAGCTCGGAGGCGAGGCTTTAAAAAAGCCCGGGGTTCAGAAAGAAAAAGAGGG 540
QY 543 TCCCGGGGCGGAGGCGAGAGATCAGAGGAAACACACCAAGAAAAAGAAAGCAAA 602
DB 541 TCCCGGGGCGGAGGCGAGAGATCAGAGGAAACACACCAAGAAAAAGAAAGCAAA 600
QY 603 GGAAGGCTGAGTTCACCTGACACACATCTGTCGTCGACCCCTGATGCTGTCGACATG 662
DB 601 GGAAGGCTGAGTTCACCTGACACACATCTGTCGTCGACCCCTGATGCTGTCGACATG 660
QY 663 CCCGTGAGCCCAAGAACCAACGATCTGCTGTCGACACAGGCTCTATGAGGAGATG 722
DB 661 CCCGTGAGCCCAAGAACCAACGATCTGCTGTCGACACAGGCTCTATGAGGAGATG 720
QY 723 ATTTGGCTGTGACATATCAGACATCTGCAATTTGAGTGTTCACCTTCCCTGCGTGGACCTT 782
DB 721 ATTTGGCTGTGACATATCAGACATCTGCAATTTGAGTGTTCACCTTCCCTGCGTGGACCTT 780
QY 783 ACCAGAAACCCCAAGAAATGCT 807
DB 781 ACCAGAAACCCCAAGAAATGCT 805

```
RESULT 9
US-09-442-013-5
; Sequence 5, Application US/09442013
; GENERAL INFORMATION:
; APPLICANT: Lou, Ying
; APPLICANT: Xu, Xiang
; APPLICANT: Leo, Cindy
; APPLICANT: Huang, Betty
; APPLICANT: Shen, Mary
; TITLE OF INVENTION: NOVEL IAPS ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS
; TITLE OF INVENTION: AND METHODS OF USE
; FILE REFERENCE: A-68289/DJB/RMS/DAV
; CURRENT APPLICATION NUMBER: US/09/442.013
; CURRENT FILING DATE: 1999-11-17
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 807
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-442-013-5

Query Match      82.2%; Score 787.4; DB 18; Length 807;
Best Local Similarity 98.6%; Pred. No. 3.2e-201;
Matches 794; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 3 TGCAGACTCAGCCCTGCGTGGCGTATTGAGGCTCTGCGTGGCTGAGCATCTCCAGTCC 62
    |||||||
DB 1 TGCAGACTCAGCCCTGCGTGGCGTATTGAGGCTCTGCGTGGCTGAGCATCTCCAGTCC 60
    |||||||

QY 63 TTCTACTGCGCAGTACAGCCTCAAGCCTGATTTCCAGCAGTCTGTCAGAGCAATG 122
    |||||||
DB 61 TTCTACTGCGCAGTACAGCCTCAAGCCTGATTTCCAGCAGTCTGTCAGAGCAATG 120
    |||||||

QY 123 GGAGCAAGAGTACTCAGAGACTCTGAGAGCCTGATAGGTATCGAAGACCTTCCCTGC 182
    |||||||
DB 121 GGAGCAAGAGTACTCAGAGACTCTGAGAGCCTGATAGGTATCGAAGACCTTCCCTGC 180
    |||||||

QY 183 GAAGTTGAGAGAACTTCCAGCTGTGAGAGCTGGAGAGCTGGACAGAGAGCAAGATTAAGAA 242
    |||||||
DB 181 GAAGTTGAGAGAACTTCCAGCTGTGAGAGCTGGAGAGCTGGACAGAGAGCAAGATTAAGAA 240
    |||||||

QY 243 GCAGAGATTGACATCTGCGTGGCTGAGAGTACATCTCCAGGAGCCTGCTCCAGAC 302
    |||||||
DB 241 GCAGAGATTGACATCTGCGTGGCTGAGAGTACATCTCCAGGAGCCTGCTCCAGAC 300
    |||||||

QY 303 CAGCGCGTGAAGCGCTGCGAGAAATCCAGAACGCTTACAGCAAGTGCAGGAATACAGT 362
    |||||||
DB 301 CAGCGCGTGAAGCGCTGCGAGAAATCCAGAACGCTTACAGCAAGTGCAGGAATACAGT 360
    |||||||

QY 363 GAGCAAGAGTGAAGCTGCGAGCTGAGAGTACAGAGATGGTGGATTAACACATTCGAAGG 422
    |||||||
DB 361 GAGCAAGAGTGAAGCTGCGAGCTGAGAGTACAGAGATGGTGGATTAACACATTCGAAGG 420
    |||||||

QY 423 CTGATGAGAGCTGCGCGCTTTGAAGCAATCTGAAGGACAGAGTGGAGGCGAGTAT 482
    |||||||
DB 421 CTGATGAGAGCTGCGCGCTTTGAAGCAATCTGAAGGACAGAGTGGAGGCGAGTAT 480
    |||||||

QY 483 TTTGAAAGCTCCGAGAGGCGGTTAAAAAAGCGCGGGTTCAGAAAAGAAAAAGAGGG 542
    |||||||
DB 481 TTTGAAAGCTCCGAGAGGCGGTTAAAAAAGCGCGGGTTCAGAAAAGAAAAAGAGGG 540
    |||||||

QY 543 TCCGGGGGCGAGGAGGAGGAGCATGAGAGAGACACCAAGAAAAAGAAAGACAAA 602
    |||||||
DB 541 TCCGGGGGCGAGGAGGAGGAGCATGAGAGAGACACCAAGAAAAAGAAAGACAAA 600
    |||||||

QY 603 GGAGGGTCTGAGTCTACATGACACCATCTGTCGTCACCCCTCGATGCTGTGAGATG 662
    |||||||
DB 601 GGAGGGTCTGAGTCTACATGACACCATCTGTCGTCGTCACCCCTCGATGCTGTGAGATG 660
    |||||||

QY 663 CCCGTGACCCAAAGAAAGCAAGTACTGCTGTGACCAAGAGTCTCTATGGGAGATG 722
    |||||||
DB 661 CCCGTGACCCAAAGAAAGCAAGTACTGCTGTGACCAAGAGTCTCTATGGGAGATG 720
    |||||||
```

```
QY 723 ATTGCGTGAACAATCCAGACTGTCCAAATGAGTGGTTTCACTTGCCCTGGCGGAGCCTT 782
    |||||||
DB 721 ATTGCGTGTGACAATCCAGACTGTCCAAATGAGTGGTTTCACTTGCCCTGGCGGAGCCTT 780
    |||||||

QY 783 ACCACGAACCCAAAGAAATGCT 807
    |||||||
DB 781 ACCACGAACCCAAAGAAATGCT 805
    |||||||

RESULT 10
PCT-US02-25465-43
; Sequence 43, Application PC/TUS0225465
; GENERAL INFORMATION:
; APPLICANT: INCYTE GENOMICS, INC.
; APPLICANT: AZIMZAI, Yaida
; APPLICANT: BARROSO, Ines
; APPLICANT: BAUGHN, Mariah R.
; APPLICANT: BECHA, Shanya D.
; APPLICANT: BOROWSKY, Mark L.
; APPLICANT: DUGGAN, Brendan M.
; APPLICANT: ELLIOTT, Vicki S.
; APPLICANT: EMERLING, Brooke M.
; APPLICANT: FORSYTHE, Ian J.
; APPLICANT: GIEZEN, Kimberly J.
; APPLICANT: GORVAD, Ann E.
; APPLICANT: GRAUL, Richard C.
; APPLICANT: GRIFFIN, Jennifer A.
; APPLICANT: GURURAJAN, Rajagopal
; APPLICANT: HAPALIA, April J.A.
; APPLICANT: ISON, Craig H.
; APPLICANT: KABLE, Amy E.
; APPLICANT: KHAN, Farrah A.
; APPLICANT: LEE, Sally
; APPLICANT: LEE, Soo Yeun
; APPLICANT: LI, Joana X.
; APPLICANT: REDDY, Roopa
; APPLICANT: SPRAGUE, William W.
; APPLICANT: SWARNAKAR, Anita
; APPLICANT: TANG, Y. Tom
; APPLICANT: WARREN, Bridget A.
; APPLICANT: XU, Yuming
; APPLICANT: YAO, Monique G.
; APPLICANT: YUE, Henry
; APPLICANT: YUE, Huibin
; TITLE OF INVENTION: PROTEINS ASSOCIATED WITH CELL GROWTH, DIFFERENTIATION, AND DEATH
; FILE REFERENCE: PF-1126 PCT
; CURRENT APPLICATION NUMBER: PCT/US02/25465
; CURRENT FILING DATE: 2002-08-08
; PRIOR APPLICATION NUMBER: US 60/311,017
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: US 60/313,070
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: US 60/313,071
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: US 60/314,678
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: US 60/316,692
; PRIOR FILING DATE: 2001-08-31
; PRIOR APPLICATION NUMBER: US 60/317,913
; PRIOR FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: US 60/322,182
; PRIOR FILING DATE: 2001-09-14
; PRIOR APPLICATION NUMBER: US 60/340,747
; PRIOR FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: US 60/342,761
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: US 60/369,129
; PRIOR FILING DATE: 2002-03-29
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: PERL Program
; SEQ ID NO 43
```

LENGTH: 1082
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
OTHER INFORMATION: Incyte ID No: 72332548CB1
PCT-US02-25465-43

Query Match 80.5%; Score 771; DB 1; Length 1082;
Best Local Similarity 99.1%; Pred. No. 9.3e-197;
Matches 796; Conservative 0; Mismatches 5; Indels 2; Gaps 2;

Oy 156 CTGATAGTATCGAGAACCTCCCTGCGAAGCTTCAGAGGAACTCCAGTGTGCGAGAG 215
||| |||||
Db 43 CTGACAGTATGAGAACTCCCTCGCAAGCTTCAGAGGAACTCCAGTGTGCGAGAG 102
||| |||||
Oy 216 CTGGACAGAGAGCGGAATTAAGAAAGCAGAGATTGACATCTGGCTGCAGAGTACATC 275
||| |||||
Db 103 CTGGACAGAGAGCGGAATTAAGAAAGCAGAGATTGACATCTGGCTGCAGAGTACATC 162
||| |||||
Oy 276 TCCAGGTGAAGACGCTGCTCCAGACGAGCGGTGAGCGCTGCGAAGATCCAGAAC 335
||| |||||
Db 163 TCCAGGTGAAGACGCTGCTCCAGACGAGCGGTGAGCGCTGCGAAGATCCAGAAC 222
||| |||||
Oy 336 GCGTACAGCAAGTGCAGAGGAATACAGTGAACAAAGTCAAGTGCAGTGCAGACCTAC 395
||| |||||
Db 223 GCGTACAGCAAGTGCAGAGGAATACAGTGAACAAAGTCAAGTGCAGTGCAGACCTAC 282
||| |||||
Oy 396 GAGATGCTGATTAACACATTTGGAAGGCTTGTGATGCAGACTGGCGGCTTTGAAGCAGAT 455
||| |||||
Db 283 GAGATGCTGATTAACACATTTGGAAGGCTTGTGATGCAGACTGGCGGCTTTGAAGCAGAT 342
||| |||||
Oy 456 CTGAAGAGCAAGATGAGAGGAGCATGATTTTGAAGCTCCGAGAGGCGAGGTTAAAAAAA 515
||| |||||
Db 343 CTGAAGAGCAAGATGAGAGGAGCATGATTTTGAAGCTCCGAGAGGCGAGGTTAAAAAAA 402
||| |||||
Oy 516 GCGCGGGGTGCAGAAAAAGAGGGTCCCGGGGCGGAGGAGAGAGCATCAGAGAA 575
||| |||||
Db 403 GCGCGGGGTGCAGAAAAAGAGGGTCCCGGGGCGGAGGAGAGCATCAGAGAA 462
||| |||||
Oy 576 GACACACCAAAAAAGAGAGAGAGGCTTGAATTCATCTACACATCTCTGTC 635
||| |||||
Db 463 GACACACCAAAAAAGAGAGAGAGGCTTGAATTCATCTACACATCTCTGTC 522
||| |||||
Oy 636 GTGACACCCCTGATGCTGCTGGACATGCCGTGGACCCCAAGAACCCACGACTGCTG 695
||| |||||
Db 523 GTGACACCCCTGATGCTGCTGGACATGCCGTGGACCCCAAGAACCCACGACTGCTG 582
||| |||||
Oy 696 TGCACACAGGCTCTCTATGGGAGATGATGGCTGTGACAAATCCAGACTGCTCAATTGAG 755
||| |||||
Db 583 TGCACACAGGCTCTCTATGGGAGATGATGGCTGTGACAAATCCAGACTGCTCAATTGAG 642
||| |||||
Oy 756 TGGTTCACTTTGCTGCTGCTGGACCTTACCAGGAAACCCAAAGGAAATGCTTCTCCA 815
||| |||||
Db 643 TGGTTCACTTTGCTGCTGCTGGACCTTACCAGGAAACCCAAAGGAAATGCTTCTCCA 702
||| |||||
Oy 816 CGGTGCTCCAGAAAAAGAGAAAGAGTGAAGAGAGC-TGTGAGCCC-GGATCCGAG 873
||| |||||
Db 703 CGGTGCTCCAGAAAAAGAGAAAGAGTGAAGAGAGCAGATGTGTGCCAGAGATCCGAG 762
||| |||||
Oy 874 GAGCAAGTTAATCTGCTCCCTTCAATTCGTCGAATATTTCCCTTTTAAACTACC 933
||| |||||
Db 763 GAGCAAGTTAATCTGCTCCCTTCAATTCGTCGAATATTTCCCTTTTAAACTACC 822
||| |||||
Oy 934 TTGTTGCTGTTGATCTTAAAC 956
||| |||||
Db 823 TTGTTGCTGTTGATCTTAAAC 845
||| |||||

RESULT 11
US-09-442-013-9
Sequence 9, Application US/09442013
GENERAL INFORMATION:

APPLICANT: Lou, Ying
APPLICANT: Xu, Xiang
APPLICANT: Leo, Cindy
APPLICANT: Huang, Betty
APPLICANT: Shen, Mary
TITLE OF INVENTION: NOVEL IAPs ASSOCIATED CELL CYCLE PROTEINS, COMPOSITIONS
FILE REFERENCE: A-68289/DJB/RMS/DAY
CURRENT APPLICATION NUMBER: US/09/442,013
CURRENT FILING DATE: 1999-11-17
NUMBER OF SEQ ID NOS: 20
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 9
LENGTH: 958
TYPE: DNA
ORGANISM: Homo sapiens
US-09-442-013-9

Query Match 67.6%; Score 647.4; DB 18; Length 958;
Best Local Similarity 99.1%; Pred. No. 1.9e-163;
Matches 651; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Oy 149 TGGAGGCTGATGATGATGATGAGACCTTCCCTGCGAAGCTTCAGAGGAACTCCAGCTGAT 208
||| |||
Db 301 TGGTGGATTAAGATGATGATGAGACCTTCCCTGCGAAGCTTCAGAGGAACTCCAGCTGAT 360
||| |||
Oy 209 GCGAGAGCTGAGACCGAGAGAGCGGAAGATTAAGAAAGAGAGATTGACATCTGCTGAGAG 268
||| |||
Db 361 GCGAGAGCTGAGACCGAGAGAGCGGAAGATTAAGAAAGAGAGATTGACATCTGCTGAGAG 420
||| |||
Oy 269 GTACATCTCCAGGTTGAAGACGCTGCTCCAGACGAGCGCTGAGAGCGCTTGCAGAAAT 328
||| |||
Db 421 GTACATCTCCAGGTTGAAGACGCTGCTCCAGACGAGCGCTGAGAGCGCTTGCAGAAAT 480
||| |||
Oy 329 CCAGAGCGCTTACAGCAAGTGAAGATTAAGATTAAGATTAAGATTAAGATTAAGATTAAG 388
||| |||
Db 481 CCAGAGCGCTTACAGCAAGTGAAGATTAAGATTAAGATTAAGATTAAGATTAAGATTAAG 540
||| |||
Oy 389 GACCTGAGATGATGATGATTAAGACATTTGGAAGGCTTGAATGCAGACTGCGGCTTTGA 448
||| |||
Db 541 GACCTGAGATGATGATGATTAAGACATTTGGAAGGCTTGAATGCAGACTGCGGCTTTGA 600
||| |||
Oy 449 AGCAGATCTGAAGGACAGATGAGAGGAGTATTTGGAAGCTCCGAGGCGAGGCTT 508
||| |||
Db 601 AGCAGATCTGAAGGACAGATGAGAGGAGTATTTGGAAGCTCCGAGGCGAGGCTT 660
||| |||
Oy 509 AAAAAAGGCGGGGTGCAGAAAAAGAGGCTCCCGGGGCGGAGGAGAGGAGCATC 568
||| |||
Db 661 AAAAAAGGCGGGGTGCAGAAAAAGAGGCTCCCGGGGCGGAGGAGGAGGAGCATC 720
||| |||
Oy 569 AGAGGAAGACACCAAGAAAAAGAGAGCAAAAGAGGAGGCTGATTCAGTACACCAT 628
||| |||
Db 721 AGAGGAAGACACCAAGAAAAAGAGAGCAAAAGAGGAGGCTGATTCAGTACACCAT 780
||| |||
Oy 629 CCGTCCGAGACCCCTGATGCTGCTGACATGCCGCTGGAGCCCAAGAACCCACGTA 688
||| |||
Db 781 CCGTCCGAGACCCCTGATGCTGCTGACATGCCGCTGGAGCCCAAGAACCCACGTA 840
||| |||
Oy 689 CTGCTGTGCGACACAGTCTCTATGGGAGATGATTTGGCTGTGACAAATCCAGAGTCTGC 748
||| |||
Db 841 CTGCTGTGCGACACAGTCTCTATGGGAGATGATTTGGCTGTGACAAATCCAGAGTCTGC 900
||| |||
Oy 749 AATGAGTGGTTCACTTGGCTGCTGAGACCTTACCAGAGAAACCCAAAGAGAAATG 805
||| |||
Db 901 AATGAGTGGTTCACTTGGCTGCTGAGACCTTACCAGAGAAACCCAAAGAGAAATG 957
||| |||

RESULT 12
US-60-184-797-652
Sequence 652, Application US/60184797
GENERAL INFORMATION:
APPLICANT: Hodgson, David M.
APPLICANT: Lincoln, Stephen E.
Jones, Anissa L.
Yu, Jimmy Y.

APPLICANT:	Russo, Frank D.	Greenewalt, Lila B.
APPLICANT:	Spitz, Peter A.	Panzer, Scott R.
APPLICANT:	Banville, Steve A.	Roseberry, Ann M.
APPLICANT:	Bratcher, Shawn R.	Wright, Rachel J.
APPLICANT:	Dufour, Gerard E.	Chen, Wensheng
APPLICANT:	Cohen, Howard J.	Li, Tommy
APPLICANT:	Rosen, Bruce	Yap, Pierre E.
APPLICANT:	Shah, Purvi	Stockbreher, Theresa K.
APPLICANT:	Chalup, Michael S.	Amshey, Stefan
APPLICANT:	Hillman, Jennifer L.	Fong, Willy Tuen
FILE OF INVENTION:	MOLECULES ASSOCIATED WITH GROWTH AND DEVELOPMENT	
FILE REFERENCE:	PT-0114 P	
CURRENT APPLICATION NUMBER:	US/60/184,797	
CURRENT FILING DATE:	2000-02-24	
NUMBER OF SEQ ID NOS:	1667	
SOFTWARE:	PERL Program	
SEQ ID NO	652	
LENGTH:	1275	
TYPE:	DNA	
ORGANISM:	Homo sapiens	
FEATURE:		
NAME/KEY:	misc_feature	
OTHER INFORMATION:	Incyte ID No: 121128.14	
US-60-184-797-652		

```

RESULT 13
US-60-278-258-16936
: Sequence 16936, Application US/60278258
: GENERAL INFORMATION:
: APPLICANT: Morris, MacDonald
: APPLICANT: Lal, Preethi
: TITLE OF INVENTION: Method for the Identification of Sequence Polymorphisms Using
: TITLE OF INVENTION: Polynucleotide Sequence Databases, and Single Nucleotide
: TITLE OF INVENTION: Polymorphisms Identified Thereby
: FILE REFERENCE: GX-0010-1 P
: CURRENT APPLICATION NUMBER: US/60/278, 258
: CURRENT FILING DATE: 2001-03-23
: NUMBER OF SEQ ID NOS: 17730
: SOFTWARE: PERL Program
: SEQ ID NO 16936
: LENGTH: 1275
: TYPE: DNA
: ORGANISM: Homo sapiens
: FEATURE:
: NAME/KEY: misc-feature
: OTHER INFORMATION: Incyte ID No: 121128.14
US-60-278-258-16936

```

Query Match	67.4%	Score 645.6	DB 62	Length 1275	
Best Local Similarity	99.4%	Pred. No. 6.4e-163			
Matches 648	Conservative 0	Mismatches 4	Indels 0	Gaps 0	
QY	156	CTGATAGGTATCGAGAACCTTCCCTGCGAAGCTTCAGAGSAACTTCACAGCTGATGCGAGAG	215		
Db	56	CTGCACTATTCCTCGAAGAACCTTCCCTGCGAAGCTTCAGAGSAACTTCACAGCTGATGCGAGAG	115		
QY	216	CTGGACCGAGAGCGSAGGATATAGAAACAGAGATTGACATCCTGGCTCCGACAGTATAC	275		
Db	116	CTGGACCGAGAGCGSAGGATATAGAAACAGAGATTGACATCCTGGCTCCGACAGTATAC	175		
QY	276	TCCACGGTGAAGACGCTGTCTCCACACGACGCGCTGGAGCGCCTCGAGAAATCCAGAAC	335		
Db	176	TCCACGGTGAAGACGCTGTCTCCACACGACGCGCTGGAGCGCCTCGAGAAATCCAGAAC	235		
QY	336	GCCCTACACCAAGTCGAAGAATACAGTACACACAAAGTGCAGCTGCGCTGCACAGACTAC	395		
Db	236	GCCCTACACCAAGTCGAAGAATACAGTACACACAAAGTGCAGCTGCGCTGCACAGACTAC	295		
QY	396	GAGATGTGTGATTAACACATTCGGAAGGCTGTATGTCAGACCTGGCGGCGCTTTGAAGCAGAT	455		
Db	296	GAGATGTGTGATTAACACATTCGGAAGGCTGTATGTCAGACCTGGCGGCGCTTTGAAGCAGAT	355		
QY	456	CTGAAAGCAAGAGTGGAGGGCAGTGAATTTGAAAGCTCCGGAAGGGCGAGGGTTAAAAA	515		
Db	356	CTGAAAGCAAGAGTGGAGGGCAGTGAATTTGAAAGCTCCGGAAGGGCGAGGGTTAAAAA	415		
QY	516	GGCCGGGGTTCAGAAAGAAAAAGAGGGTCCCGGGGCCGAGGACGAGAGGACATCAGAGSAA	575		
Db	416	GGCCGGGGTTCAGAAAGAAAAAGAGGGTCCCGGGGCCGAGGACGAGAGGACATCAGAGSAA	475		
QY	576	GACACACCAAAAGAAAAAGAACGACAAAGAGGGTCTGAGTTCACTACACATCTCGTCC	635		
Db	476	GACACACCAAAAGAAAAAGAACGACAAAGAGGGTCTGAGTTCACTACACATCTCGTCC	535		
QY	636	GTGCAACCCCTCTGATGTGCTGGACATGCCCGGTGACCCAAACGAACCCACGTACTGCTG	695		
Db	536	GTGCAACCCCTCTGATGTGCTGGACATGCCCGGTGACCCAAACGAACCCACGTACTGCTG	595		
QY	696	TGCCACACAGGTCCTCTATAGGGAGATGATGTGCTGTGACATTCAGACTGTCCAAATTGAG	755		
Db	596	TGCCACACAGGTCCTCTATAGGGAGATGATGTGCTGTGACATTCAGACTGTCCAAATTGAG	655		
QY	756	TGGTTTCACTTTGCTGCGGTGGACCTTACACGAAGCCCAAGAGAAATGTT	807		
Db	656	TGGTTTCACTTTGCTGCGGTGGACCTTACACGAAGCCCAAGAGAAATGTT	707		

Query Match	Similarity	99.4%	Pred.	No. 6.4e-163	Length 1275
Matches	648: Conservative	0	Mismatches	4	Indels
		0			Gaps
					0
QY	156	CTGATAGGTATCGAGAACCTTCCCTGCGAAGCTTCAGAGAACTTCACGCTGATGCGAGAG	215		
Db	56	CTGGACAGTATCGAGAACCTTCCCTGCGAAGCTTCAGAGAACTTCACGCTGATGCGAGAG	115		
QY	216	CTGGACACAGAGACCGGAAGATTAAGAAAGCAGAGATTGACATCTCGCTTCAGAGTACATC	275		
Db	116	CTGGACACAGAGACCGGAAGATTAAGAAAGCAGAGATTGACATCTCGCTTCAGAGTACATC	175		
QY	276	TCCACGGTGAAACGCTGTCTCCAGACCGCCGTTGGAGACGGCTGCGAGAAGATCCAGAAC	335		
Db	176	TCCACGGTGAAACGCTGTCTCCAGACCGCCGTTGGAGACGGCTGCGAGAAGATCCAGAAC	235		
QY	336	GCCCTACAGCAAGTGCAGAGAAATACAGTACGACACAAAGTGCAGCTGCGCATTCACAGACTTAC	395		
Db	236	GCCCTACAGCAAGTGCAGAGAAATACAGTACGACACAAAGTGCAGCTGCGCATTCACAGACTTAC	295		
QY	396	GAGATGGTGATTAACACATCTCGAAGGCTTGATTCGACACTGTCGCGCGCTTTGAAGCAGAT	455		
Db	296	GAGATGGTGATTAACACATCTCGAAGGCTTGATTCGACACTGTCGCGCGCTTTGAAGCAGAT	355		
QY	456	CTGAAAGACAGATGGAGGGCGAGTATTTGAAAGCTCCGGAAGGGCGAGGGTTAAAAAAA	515		
Db	356	CTGAAAGACAGATGGAGGGCGAGTATTTGAAAGCTCCGGAAGGGCGAGGGTTAAAAAAA	415		
QY	516	GGCCGGGGGTCAGAAAGAAAAAGAGGGTCCCGGGCGCGAGGACGAGAGACATCAGAGGAA	575		
Db	416	GGCCGGGGGTCAGAAAGAAAAAGAGGGTCCCGGGCGCGAGGACGAGAGACATCAGAGGAA	475		
QY	576	GACACACCAAGAAAAAGAGAGCACAAGAGAGGGTCTGAATTCTACTGACACATCTCTGTCC	635		
Db	476	GACACACCAAGAAAAAGAGAGCACAAGAGAGGGTCTGAATTCTACTGACACATCTCTGTCC	535		
QY	636	GTCACACCTCTGATGTGCTGGACATGCCCGTGGACCCAAACGAAACCCACATCTGCTTG	695		
Db	536	GTCACACCTCTGATGTGCTGGACATGCCCGTGGACCCAAACGAAACCCACATCTGCTTG	595		
QY	696	TGCCACACAGGTTCCTATGCGGAGATGATTGGCTGTGAACATTCACAGCTGTCCAATTGAG	755		
Db	596	TGCCACACAGGTTCCTATGCGGAGATGATTGGCTGTGAACATTCACAGCTGTCCAATTGAG	655		
QY	756	TGGTTTCACTTTGCCCTGCGTGACCTTACACAGAAACCCAAAGAAATAGT	807		
Db	656	TGGTTTCACTTTGCCCTGCGTGACCTTACACAGAAACCCAAAGAAATAGT	707		

Db 461 GCCCTACAGCAAGTGCAGGAATACAGTACGACAAAGTGCAGCTGGCCATGCAGACTTAC 520
QY 396 GAGATGTTGGATTAACACATTGGAAGGCTTGATGACAGACTGGCCGCTTTGAAGCAGAT 455
Db 521 GAGATGGTGGATTAACACATTGGAAGGCTTGATGACAGACTGGCCGCTTTGAAGCAGAT 580
QY 456 CTGAAGGACAGATGAGGGGACAGTATTTTGAAGCTCCGAGGGGAGGGTTAAAAANA 515
Db 581 CTGAAGGACAGATGAGGGGACAGTATTTTGAAGCTCCGAGGGGAGGGTTAAAAANA 640
QY 516 GGGCGGGGTACAGAAAAAGAGGGTCCGGGGCCGAGGAGGAGATCAGAGGAA 575
Db 641 GGGCTGGCTCAGAAAAAGAGGGTCCGGGGCCGAGGAGGAGATCAGAGGAA 700
QY 576 GACAGACCAAGAAAAAGACACAAAGAGGGTCTGAGTTCACTGACACCATCCTGTCC 635
Db 701 GACAGACCAAGAAAAAGACACAAAGAGGGTCTGAGTTCACTGACACCATCCTGTCC 760
QY 636 GTGCACCCCTCTGATGCTGGACATGCCGTTGACCCCAACGAAACCACGTAATGCTG 695
Db 761 GTGCACCCCTCTGATGCTGGACATGCCGTTGACCCCAACGAAACCACGTAATGCTG 820
QY 696 TGCCACCAAGTCTCTATGGGAGATGATGGCTGTGACATCCAGACTGTCCAAATTGAG 755
Db 821 TGCCACCAAGTCTCTATGGGAGATGATGGCTGTGACATCCAGACTGTCCAAATTGAG 880
QY 756 TGGTTTCACTTGGCTGGCTGACCTTACACGAAACCAAGGAAATGTT 808
Db 881 TGGTTTCACTTGGCTGGCTGACCTTACACGAAACCAAGGAAATGATT 933

Search completed: February 22, 2003, 22:02:55
Job time : 4166 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 22, 2003, 20:16:33 : Search time 90 Seconds
(without alignments)
5978.339 Million cell updates/sec

Title: US-09-442-013-7

Perfect score: 958

Sequence: 1 ttgttgaccctcagcctgc.....cgtgtactactagtaacaa 958

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 442118 seqs, 280819700 residues

Total number of hits satisfying chosen parameters: 884236

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published_Applications_NA:*

- 1: /cgn2_6/ptodata/2/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/2/pubpna/PCr_NEM_PUB.seq:*
- 3: /cgn2_6/ptodata/2/pubpna/US06_NEM_PUB.seq:*
- 4: /cgn2_6/ptodata/2/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/2/pubpna/US07_NEM_PUB.seq:*
- 6: /cgn2_6/ptodata/2/pubpna/PCrUS_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/2/pubpna/US08_NEM_PUB.seq:*
- 8: /cgn2_6/ptodata/2/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/2/pubpna/US09_NEM_PUB.seq:*
- 10: /cgn2_6/ptodata/2/pubpna/US09_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/2/pubpna/US10_NEM_PUB.seq:*
- 12: /cgn2_6/ptodata/2/pubpna/US10_PUBCOMB.seq:*
- 13: /cgn2_6/ptodata/2/pubpna/US60_NEM_PUB.seq:*
- 14: /cgn2_6/ptodata/2/pubpna/US60_PUBCOMB.seq:*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	113	8487	10	US-09-764-877-3454	Sequence 3454, Ap
2	97	10.1	840	US-10-115-899-6	Sequence 6, Appli
3	97	10.1	1078	US-10-115-899-7	Sequence 7, Appli
4	75.8	7.9	754	US-09-731-872-187	Sequence 187, Ap
5	65.2	6.8	813	US-09-938-842A-1178	Sequence 1178, Ap
6	59.8	6.2	352	US-09-867-701-2399	Sequence 2399, Ap
7	52	5.4	993	US-09-801-368-257	Sequence 257, App
8	41.6	4.3	450	US-09-867-550-223	Sequence 223, App
9	41	4.3	846	US-09-867-550-1931	Sequence 1931, Ap
10	40	4.2	454	US-09-864-761-19549	Sequence 19549, A
11	39	4.1	451	US-09-854-133-146	Sequence 146, App
12	39	4.1	451	US-09-738-973-146	Sequence 146, App
13	37.8	3.9	398	US-09-960-352-8059	Sequence 8059, Ap
14	37.6	3.9	659158	US-09-771-208-20	Sequence 20, Appl
15	36.8	3.8	368	US-09-878-574-1665	Sequence 1665, Ap
16	36.8	3.8	387	US-09-878-574-1404	Sequence 1404, Ap
17	36.8	3.8	448	US-09-960-352-5218	Sequence 5218, Ap
18	36.8	3.8	643	US-09-764-869-577	Sequence 577, App
19	36.8	3.8	1329	US-09-815-242-4023	Sequence 4023, Ap

20	36.2	3.8	421	10	US-09-960-352-14430	Sequence 14430, A
21	36	3.8	415	10	US-09-960-352-2580	Sequence 2580, Ap
22	35.8	3.7	2153	10	US-09-822-849A-286	Sequence 286, App
23	35.8	3.7	3416	8	US-08-987-689A-1	Sequence 1, Appli
24	35.4	3.7	475	10	US-09-864-761-6203	Sequence 6203, Ap
25	35.4	3.7	511	10	US-09-864-761-22817	Sequence 22817, A
26	35.4	3.7	1209	10	US-09-815-242-9956	Sequence 9956, Ap
27	35	3.7	343	10	US-09-960-352-4500	Sequence 4500, Ap
28	34.4	3.6	420	10	US-09-960-352-9532	Sequence 9532, Ap
29	34.2	3.6	209	10	US-09-867-701-8665	Sequence 8665, Ap
30	34.2	3.6	266	9	US-10-040-739-902	Sequence 902, App
31	34	3.5	2105	10	US-09-999-678-1	Sequence 1, Appli
32	34	3.5	4796	10	US-09-764-847-1627	Sequence 1627, Ap
33	34	3.5	5835	9	US-09-927-597-1	Sequence 1, Appli
34	34	3.5	5937	9	US-09-927-597-3	Sequence 3, Appli
35	34	3.5	13337	10	US-09-764-846-312	Sequence 312, App
36	34	3.5	13337	10	US-09-764-847-1629	Sequence 1629, Ap
37	34	3.5	88421	9	US-09-976-059-1	Sequence 1, Appli
38	33.8	3.5	394	10	US-09-864-761-18958	Sequence 18958, A
39	33.6	3.5	215	10	US-09-867-701-9278	Sequence 9278, Ap
40	33	3.4	417	10	US-09-960-352-13113	Sequence 13113, A
41	33	3.4	462	10	US-09-149-721-2	Sequence 2, Appli
42	33	3.4	493	10	US-09-864-761-29936	Sequence 29936, A
43	33	3.4	599	10	US-09-864-761-13376	Sequence 13376, A
44	33	3.4	2489	10	US-09-764-864-552	Sequence 552, App
45	33	3.4	2504	10	US-09-764-864-103	Sequence 103, App

ALIGNMENTS

RESULT 1
US-09-764-877-3454
; Sequence 3454, Application US/09764877
; Patent No. US20020147140A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC005
; CURRENT APPLICATION NUMBER: US/09/764,877
; PRIOR FILING DATE: 2001-01-17
; PRIOR APPLICATION data removed - refer to PALM or file wrapper
; NUMBER OF SEQ ID NOS: 4031
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO: 3454
; LENGTH: 8487
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-764-877-3454

Query Match 11.8%; Score 113; DB 10; Length 8487;
Best Local Similarity 72.6%; Pred. No. 5.9e-23;
Matches 146; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY	657	GACATGCCGTGGACCAACGACCCAGCTGCTGCTGCACAGGTCCTATGAGG	716
DB	6700	GACCTCCCATGACGACCCACGACCCAGCTGCTGCTGCACAGGTCCTATGAGG	6759
QY	717	GAGATGATTTGCTGTGACATCCAGCTGCTGCTGCTGCTGCTGCTGCTGCTG	776
DB	6760	GAGATGATGCTGTGACGACGACGACGACGACGACGACGACGACGACGACG	6819
QY	777	GACCTTACGACGACGACGACGACGACGACGACGACGACGACGACGACGACG	836
DB	6820	GAGCTTACGACGACGACGACGACGACGACGACGACGACGACGACGACGACG	6879
QY	837	AAG	857
DB	6880	AAG	6900

RESULT 2
US-10-115-899-6

```
; Sequence 6, Application US/10115899
; Patent No. US20020151025A1
; GENERAL INFORMATION:
; APPLICANT: Oetuka Pharmaceutical Co., Ltd.
; TITLE OF INVENTION: Human TSC403 gene and human ING1L gene
; FILE REFERENCE: 060193
; CURRENT APPLICATION NUMBER: US/10/115,899
; CURRENT FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: 09/601,478
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: JP H10-134679
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: JP H10-73234
; PRIOR FILING DATE: 1998-03-05
; PRIOR APPLICATION NUMBER: JP H10-38133
; PRIOR FILING DATE: 1998-02-03
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 6
; LENGTH: 840
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: human embryonic brain cDNA library
US-10-115-899-6
```

```
Query Match          10.1%; Score 97; DB 12; Length 840;
Best Local Similarity 68.9%; Pred. No. 9.5e-19;
Matches 133; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
```

```
QY 655 TGCACATGCCGTGACCCCAACCAACCCAGTACTGCTGTGCCACAGTCTCTATG 714
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 608 TTGAGTTTGCATATGATCCATGAACCTACATGCTTATGCAACCAAGTCTTATG 667
QY 715 GGGAGATGATGGCTGGAATCCAGACGTGCTCAATGTAGTGTTCATTTGCCCTGCG 774
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 668 GGGAGATGATGAGATGACAAATGAACAGTGTCCAAATGATGTTCACCTTTTCATGTG 727
QY 775 TGGACCTTACCAAGAACCAAGAAATGTTCTGTCCAGCGTGTCCAGAAAGA 834
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 728 TTTCACCTTACCTTAAACCAAGGGAATGATTTGCCCAAGTGCAGGAGATATATG 767
QY 835 GGAAGAAGAAGTA 847
    ||| ||| |||
DB 788 AGAAACAATGGA 800
```

RESULT 3

```
US-10-115-899-7
; Sequence 7, Application US/10115899
; Patent No. US20020151025A1
; GENERAL INFORMATION:
; APPLICANT: Oetuka Pharmaceutical Co., Ltd.
; TITLE OF INVENTION: Human TSC403 gene and human ING1L gene
; FILE REFERENCE: 060193
; CURRENT APPLICATION NUMBER: US/10/115,899
; CURRENT FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: 09/601,478
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: JP H10-134679
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: JP H10-73234
; PRIOR FILING DATE: 1998-03-05
; PRIOR APPLICATION NUMBER: JP H10-38133
; PRIOR FILING DATE: 1998-02-03
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 7
; LENGTH: 1078
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: human embryonic brain cDNA library
```

```
; NAME/KEY: CDS
; LOCATION: (92)..(931)
; US-10-115-899-7
```

```
Query Match          10.1%; Score 97; DB 12; Length 1078;
Best Local Similarity 68.9%; Pred. No. 1.1e-18;
Matches 133; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
```

```
QY 655 TGCACATGCCGTGACCCCAACCAACCCAGTACTGCTGTGCCACAGTCTCTATG 714
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 699 TTGAGTTTGCATATGATCCATGAACCTACATGCTTATGCAACCAAGTCTTATG 758
QY 715 GGGAGATGATGGCTGTGACATCCAGACTGTCCAAATGAGTGTTCACCTTTGCCG 774
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 759 GGGAGATGATGAGATGTGACAAATGAACAGTGTCCAAATGATGTTTCATTTGATG 818
QY 775 TGGACCTTACCAAGAACCAAGAAATGTTCTGTCCAGCGTGTTCAGAAAGA 834
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 819 TTTCACCTTACCTTAAACCAAGGGAATGATTTGCCCAAGTGCAGGAGATATATG 878
QY 835 GGAAGAAGAAGTA 847
    ||| ||| |||
DB 879 AGAAACAATGGA 891
```

RESULT 4

```
US-09-731-872-187/c
; Sequence 187, Application US/09731872
; Patent No. US20020102604A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, Jean Baptiste
; APPLICANT: Bouguerelet, Lydie
; APPLICANT: Jobert, Severin
; TITLE OF INVENTION: FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
```

```
; FILE REFERENCE: 78.US. REG
; CURRENT APPLICATION NUMBER: US/09/731,872
; CURRENT FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: US 60/169,629
; PRIOR FILING DATE: 1999-12-08
; PRIOR APPLICATION NUMBER: US 60/187,470
; PRIOR FILING DATE: 2000-03-06
; NUMBER OF SEQ ID NOS: 482
; SOFTWARE: Patent.pm
```

```
; SEQ ID NO 187
; LENGTH: 754
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
; FEATURE:
```

```
; NAME/KEY: CDS
; LOCATION: 181..462
US-09-731-872-187
```

```
Query Match          7.9%; Score 75.8; DB 10; Length 754;
Best Local Similarity 75.7%; Pred. No. 1.6e-12;
Matches 137; Conservative 0; Mismatches 32; Indels 12; Gaps 3;
```

```
QY 776 GACCTTACCAACCAACCAAGAAATGTTCTGTCCACGCTGTCCAGGAAAGAG 835
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 294 GACCTTACCATG-AATCCAGAGGAAATGCTGTCTCCAGGCTGTCCAGGAAAGAG 236
QY 836 GAAGAAGAAGTAGAGAGCTGTGTGCCGATCCAGAGCAAGTTAATCTGCTCCCTTC 895
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 235 GAAGAAG--GAAGGAAGAGCTGTATGCCAGATCAAG-----AGCTATCTCTTT 187
QY 896 ATTCGTGTCCCAATATTTCCTCTTAAACTACTGTTGCGTGTATAGTAA 955
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 186 ATTCATGTTGCAAGATTTCCTTCATTTAAACTACTGTTCAATGATATGATATAA 127
QY 956 C 956
    |
DB 126 C 126
```

```
RESULT 5
US-09-938-842A-1178
; Sequence 1178, Application US/09938842A
; Patent No. US20020160378A1
; GENERAL INFORMATION:
; APPLICANT: Harper, Jeff
; APPLICANT: Kreps, Joel
; APPLICANT: Wang, Xun
; APPLICANT: Zhu, Tong
; TITLE OF INVENTION: STRESS-REGULATED GENES OF PLANTS, TRANSGENIC PLANTS CONTAINING
; FILE REFERENCE: SAME, AND METHODS OF USE
; CURRENT APPLICATION NUMBER: US/09/938, 842A
; CURRENT FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: US 60/227, 866
; PRIOR FILING DATE: 2000-08-24
; PRIOR APPLICATION NUMBER: US 60/264, 647
; PRIOR FILING DATE: 2001-01-16
; PRIOR APPLICATION NUMBER: US 60/300, 111
; PRIOR FILING DATE: 2001-06-22
; NUMBER OF SEQ ID NOS: 5379
; SEQ ID NO 1178
; LENGTH: 813
; TYPE: DNA
; ORGANISM: Arabidopsis thaliana
US-09-938-842A-1178

Query Match          6.8%; Score 65.2; DB 9; Length 813;
Best Local Similarity 67.7%; Pred. No. 2.3e-09;
Matches 107; Conservative 0; Mismatches 48; Indels 3; Gaps 1;

Oy 657 GACATGCCCGTGACCAAGCAAGCCACGTCGCTGTCACACAGTCTCCATGGG 716
    || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 550 GAGCAGCCAAATGATGACCAAGCAAGCAACTTACTGTCTGTCACAGGTGCTTTGGA 609
Oy 717 GAGATGATTGGCTGTGACATCCAGACTGTC--CAATTGAGTGGTTTCACTTGCCTGC 773
    || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 610 GACATGATTGGCTGTGACATGAGAATTGCCAAGAGGATGTTTCATATACATGC 669
Oy 774 GTGACCTTACCAAGCAAGCCCAAGGAAGGTTGCTG 811
    || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 670 GTTGGCTTCACACTGAGACGAGATTCAAGGGAATG 707

RESULT 6
US-09-867-701-2399
; Sequence 2399, Application US/09867701
; Patent No. US2002013237A1
; GENERAL INFORMATION:
; APPLICANT: Aglate, Paul A.
; APPLICANT: Jones, Robert
; APPLICANT: Harlocker, Susan L.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
; FILE REFERENCE: 210121.497
; CURRENT APPLICATION NUMBER: US/09/867, 701
; CURRENT FILING DATE: 2001-05-29
; NUMBER OF SEQ ID NOS: 10912
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2399
; LENGTH: 352
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; NAME/KEY: misc-feature
; LOCATION: (1)...(352)
; OTHER INFORMATION: n = A,T,C or G
US-09-867-701-2399

Query Match          6.2%; Score 59.8; DB 10; Length 352;
Best Local Similarity 50.9%; Pred. No. 5.8e-08;
Matches 139; Conservative 0; Mismatches 134; Indels 0; Gaps 0;
```

```
Oy 156 CTGATAGCTATCGAGAACCTTCCCTGCGMACTTCAGAGAACTTCACATGCGAGAG 215
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 80 CTGAAATGATTTGACACCTTCCTATGATCTGCGGACACNTTTCAGGAAATGGCGAG 139
Oy 216 CTGACACAGAGACGGAAGATTAAGAAAGCAGAGATTGATCTCTGTCGACAGTACATC 275
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 140 ATGACACTGACAGTGCAGAAATTAATTGGATCACTAGAAACAAAGAGTCAATTTCTTT 199
Oy 276 TCACAGGTGAAGACGCTGTCTCCAGACACGCGCTGAGAGCCCTGCAGAAATCCAGAAC 335
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 200 ATGAATGGAAGAAATAATTAACCTGAGTGGAGGGAAGACAAATGGATCCATCAAAAAA 259
Oy 336 GCCTACAGCAAGTGCAGGAATATACAGTGCAGCAAGATGCAAGTGCATGACAGACTAC 395
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 260 GACTACTATTAAGCTTTTGGAGATGACATGAGAAAGTTTCACTTGGCAACCAAGATATAT 319
Oy 396 GAGATGTGTGATTAACACATTCGAAGGCTTGAT 428
    || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 320 GACTTGTATGATGACACTTGAGAAAGCTGGAT 352
```

```
RESULT 7
US-09-801-368-257
; Sequence 257, Application US/09801368
; Patent No. US20020128250A1
; GENERAL INFORMATION:
; APPLICANT: Busby, Robert
; APPLICANT: Call, Brian
; APPLICANT: Hecht, Peter
; APPLICANT: Holtzman, Doug
; APPLICANT: Madden, Kevin
; APPLICANT: Maxon, Mary
; APPLICANT: Milne, Todd
; APPLICANT: No. US20020128250A1man, Thea
; APPLICANT: Royer, John
; APPLICANT: Salama, Sofie
; APPLICANT: Sherman, Amir
; APPLICANT: Silva, Jeff
; APPLICANT: Summers, Eric
; TITLE OF INVENTION: Methods for Improving Secondary Metabolite Production in Fungi
; FILE REFERENCE: 109272.147
; CURRENT APPLICATION NUMBER: US/09/801, 368
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 09/487, 558
; PRIOR FILING DATE: 2000-01-19
; PRIOR APPLICATION NUMBER: US 60/160, 587
; PRIOR FILING DATE: 1999-10-20
; NUMBER OF SEQ ID NOS: 440
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 257
; LENGTH: 993
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-801-368-257
```

```
Query Match          5.4%; Score 52; DB 10; Length 993;
Best Local Similarity 59.5%; Pred. No. 2e-05;
Matches 88; Conservative 0; Mismatches 60; Indels 0; Gaps 0;

Oy 664 CCGTGAGCCCAAGCAAGCCACGTAAGTGTGCGCCAGGCTTCCTATGGGAGATGA 723
    || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 821 CCAAGACTAGCGGCGACCGCTCTACTGTACTGTACCAAGATGGCATAAGGGAATGG 880
Oy 724 TTGGCTGTGACATCAAGACTGTCCAAATGAGTGTTCCTTTCCTGCGTGAACCTTA 783
    || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 881 TGGGCTGTGATGGCGCAGACTGTGAGCTAAGATGCTTCATTTGCCATGTATTGACTCG 940
Oy 784 CCACGAAGCCCAAGGAATATGTTCTG 811
    || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 941 AACTCTACTTAAGGCAAGTGTATTG 968
```

RESULT 8

```
US-09-867-550-223
; Sequence 223, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Mehraban, Foad.
; APPLICANT: Conley, Pamela
; APPLICANT: Law, Debbie
; APPLICANT: Topper, James
; TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and
; TITLE OF INVENTION: Thereby
; FILE REFERENCE: 21402-013 (Cura-313)
; CURRENT APPLICATION NUMBER: US/09/867,550
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: USSN 60/208,427
; PRIOR FILING DATE: 2000-05-30
; NUMBER OF SEQ ID NOS: 2125
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 223
; LENGTH: 450
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(31)
; OTHER INFORMATION: wherein any n is one of a or t or g or c
US-09-867-550-223
```

```
Query Match 4.3%; Score 41.6; DB 10; Length 450;
Best Local Similarity 50.2%; Pred. No. 0.016;
Matches 101; Conservative 0; Mismatches 100; Indels 0; Gaps 0;
```

```
OY 201 CAGCTGATGGAGAGCTGGACGAGAGGAGATGAAGAACGACGATTGACATCTG 260
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 25 CAGGTGATCCACCATGAGTGGAAATCGCGTCATGACGTGGAGAGCCCATCCG 84
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
OY 261 GCTGACAGTACATCTCCACGGGTGAAGACGCTGTCTCCAGACCGCGCTGAGCCCTG 320
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
Db 85 AACCGGTGAAGCGGAGATGAGAGACGACGCGGAATCTCAACGAGAGATG 144
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
OY 321 CAGAAATCCAGAACCCCTTACAGCAAGTACAGGAAATACAGTACAGCAAAATGCAAGCTG 360
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
Db 145 AAGCGCATCCAGAAAGCTCGCGGAGGCGAGAGAGCGCGGACGAGACGCCGAGATC 204
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
OY 381 GCCATGACAGCTACGAGATG 401
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
Db 205 GAGGAGAAATCAAGAAGACG 225
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
```

```
RESULT 9
US-09-867-550-1931
; Sequence 1931, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
; APPLICANT: Leach, Martin D.
; APPLICANT: Mehraban, Foad.
; APPLICANT: Conley, Pamela
; APPLICANT: Law, Debbie
; APPLICANT: Topper, James
; TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and
; TITLE OF INVENTION: Thereby
; FILE REFERENCE: 21402-013 (Cura-313)
; CURRENT APPLICATION NUMBER: US/09/867,550
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: USSN 60/208,427
; PRIOR FILING DATE: 2000-05-30
; NUMBER OF SEQ ID NOS: 2125
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1931
; LENGTH: 846
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-867-550-1931
```

```
Query Match 4.3%; Score 41; DB 10; Length 846;
Best Local Similarity 50.8%; Pred. No. 0.033;
Matches 98; Conservative 0; Mismatches 95; Indels 0; Gaps 0;

OY 468 ATGAGGCGAGTATTTTGAAGCTCCGAGGCGGAGGTTAAAAAGCCGGGCTCAG 527
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
Db 436 AGCTGTGTAATATCATCGAAGCTCTTGAAGCGCTTAATTAAGGACATGTGA 495
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
OY 528 AAGAAAAAGAGAGGTCGCCGGCGGAGAGGACATCAGAGAACACACCAAG 587
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
Db 496 GAGAAAGTTCTTGCTACATGAGGCGAGACCTGAGAACCGAAGGTAAAGACATGAGT 555
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
OY 588 AAAAAGACACAAAGAGGCTGTGATTCACCTGACATCCTGTCACCCCTCT 647
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
Db 556 GCAGTACAGCCACAAACAGAGTAGTAGCATTCATCCACGCTTTTGGGGCCACTCT 615
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
OY 648 GATGTCTGACA 660
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
Db 616 TATCTATGAGACA 628
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||
```

```
RESULT 10
US-09-864-761-19549/c
; Sequence 19549, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FO
; TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
; FILE REFERENCE: Aecmics-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
```

```
SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 19549
; LENGTH: 454
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC006371.2
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 3.6
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 4.5
; OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 3.4
; OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 2.3
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2.5
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 3
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 3.3
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 3.4
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 3.9
; OTHER INFORMATION: EST_HUMAN HIT: AW900281.1, EVALUE 7.30e+02
; OTHER INFORMATION: NT HIT: Y12488.1, EVALUE 4.50e+00
; OTHER INFORMATION: SWISSPROT HIT: O68827, EVALUE 7.80e+00
US-09-864-761-19549

Query Match 4.2%; Score 40; DB 10; Length 454;
Best Local Similarity 48.7%; Pred. No. 0.047;
Matches 109; Conservative 0; Mismatches 115; Indels 0; Gaps 0;

QY 384 ATGCAGACCTAGCAGATGGTGATTAACCATTCGAGGCTTGATGCACACCTGGCGCC 443
DB 451 AGGAAGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 392
QY 444 TTGGAAGCAGATCTGAGAGCAAGATGAGGCGCAGTATTGAAAGCTCCGAGGCGA 503
DB 391 AAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 332
QY 504 GGGTAAAAAAGCCGGGCTCAGAAAGAAAAGAGGCTCCGGGCGGCGAGAGAGG 563
DB 331 GGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 272
QY 564 ACATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 607
DB 271 AGAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 228

RESULT 11
US-09-854-133-146
; Sequence 146, Application US/09854133
; Publication No. US20020183499A1
; GENERAL INFORMATION:
; APPLICANT: Lodes, Michael J.
; APPLICANT: Mohamath, Raedoh
; APPLICANT: Henderson, Robert A.
; APPLICANT: Benson, Darin R.
; APPLICANT: Secrist, Heather
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; FILE REFERENCE: 210121.475C10
; CURRENT APPLICATION NUMBER: US/09/854.133
; NUMBER OF SEQ ID NOS: 735
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 146
; LENGTH: 451
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-854-133-146

Query Match 4.1%; Score 39; DB 9; Length 451;
Best Local Similarity 48.5%; Pred. No. 0.092;
Matches 146; Conservative 0; Mismatches 145; Indels 10; Gaps 1;
```

```
QY 221 CCAGAGAGAGAGAGATTAAGAAAGCAGAGATGCATCTGGCTGAGAGATACATCCAC 280
DB 73 CGCGAATATACCAAGAGATCTTCAAGAGAGCTTAACGAGTCTTACGAGCGCTTACGCGA 132
QY 281 GGTGAAGAGCGTGTCTCCAGACCGCGTGGAGCGCTTCAGAAAGATCCAGAAAGCGCTA 340
DB 133 GACAGACGGGGGCGAAGACGGCGGATGCTGCATGTGTGACAGCGCGGCTGATCCGCAC 192
QY 341 CAGCAAGTCAAGGAATACAGTGCAGCAAAAGTGCAGCTGGCCATGCAGACCTACAGAT 400
DB 193 CAGGAGCTG-----GGCGAGAGAAAGATCCAGATCTGCAGCCAGATGTGGAGCT 242
QY 401 GGTGATTAACACATTTCGAAGGCTTGATGCACAGCTGGCGGCTTTGAAGCAGATCTGAA 460
DB 243 GGTGAGAAACCCGACGGCGAGGTGACAGCCACTGGAGCTTTTCGAGGCGCAGCAGGA 302
QY 461 G 461
DB 303 G 303

RESULT 12
US-09-738-973-146
; Sequence 146, Application US/09738973
; Patent No. US20020110563A1
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Henderson, Robert A.
; APPLICANT: Lodes, Michael J.
; APPLICANT: Fling, Steven P.
; APPLICANT: Mohamath, Raedoh
; APPLICANT: Algate, Paul A.
; APPLICANT: Secrist, Heather
; APPLICANT: Indrias, Carol Yoseph
; APPLICANT: Benson, Darin R.
; APPLICANT: Elliot, Mark
; APPLICANT: Mannion, Jane
; APPLICANT: Kalos, Michael D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; FILE REFERENCE: 210121.475C9
; CURRENT APPLICATION NUMBER: US/09/738.973
; NUMBER OF SEQ ID NOS: 587
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 146
; LENGTH: 451
; TYPE: DNA
; ORGANISM: Homo sapien
US-09-738-973-146

Query Match 4.1%; Score 39; DB 10; Length 451;
Best Local Similarity 48.5%; Pred. No. 0.092;
Matches 146; Conservative 0; Mismatches 145; Indels 10; Gaps 1;
```

```
DB 243 GGTGGAGAACCGACCGCGGAGGTGGACACCGCTGGAGCTGTTCGAGCGCGACGACGGA 302
OY 461 G 461
DB 303 G 303

RESULT 13
US-09-960-352-8059
: Sequence 8059, Application US/09960352
: Patent No. US20020137139A1
: GENERAL INFORMATION:
: APPLICANT: Warren, Wesley C.
: APPLICANT: Tao, Nengbing
: APPLICANT: Byatt, John C.
: APPLICANT: Mathalagan, Nagappan
: TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND
: FILE REFERENCE: 16511.006/37-21(10298)C
: CURRENT APPLICATION NUMBER: US/09/960,352
: CURRENT FILING DATE: 2001-09-24
: NUMBER OF SEQ ID NOS: 15112
: SEQ ID NO 8059
: LENGTH: 398
: TYPE: DNA
: ORGANISM: Bos taurus
: OTHER INFORMATION: Clone ID: 35-BOVMS1-019-Q1-E1-A4
US-09-960-352-8059

Query Match
Best Local Similarity 46.4%; Score 37.8; DB 10; Length 398;
Matches 123; Conservative 0; Mismatches 142; Indels 0; Gaps 0;

OY 216 CTGGACCAAGAGGAGATAGAAAGACGAGATGACATCTCGTGGTGGAGATGATC 275
DB 48 CAGGAAGCTGCAACGAGAGAAAGCCAGAAAGCCATCTGATGCGAGCATGATG 107
OY 276 TCCAGCGTGAAGAGCTGTCTCCAGACACGCGTGGAGCGCTGCGAGAGATCCAGAAC 335
DB 108 GCTGAGGAGCTGAAGAAAGAGACACGAGCGCCACTGAGCGGATGAGAGAAAGAAC 167
OY 336 GCCTACAGCAAGTGAAGAAATACAGTACAGACAAAGTGCAGTGGCCATGACAGACCTAC 395
DB 168 ATGAGAGAGCGGTGAAGACCTGACAGAACCTGTGGATGAGGCTGAGAGCTGGCCCTG 227
OY 396 GAGATGGTGAATAACACATTGAGAGCGTGTGATGAGACACTGGCGGCTTTGAAGAGAT 455
DB 228 AAGGCGGGAAGAGACGATCCAGAACTGGAGGCCAAGGTGCTGAGCTGGAAGGAGAG 287
OY 456 CTGAAGGACAAAGATGAGGCGCAGTG 480
DB 288 GTATAGAGTACGACGAAGCGCAATG 312

RESULT 14
US-09-771-208-20/C
: Sequence 20, Application US/09771208
: Patent No. US2002015554A1
: GENERAL INFORMATION:
: APPLICANT: MEDRANO, JUAN
: APPLICANT: BRADFORD, ERIC
: APPLICANT: HORVAT, SIMON
: TITLE OF INVENTION: CLONING OF A HIGH-GROWTH GENE
: FILE REFERENCE: 407T-923710US
: CURRENT APPLICATION NUMBER: US/09/771,208
: CURRENT FILING DATE: 2001-01-26
: PRIOR APPLICATION NUMBER: US 08/999,477
: PRIOR FILING DATE: 1997-12-29
: NUMBER OF SEQ ID NOS: 20
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 20
: LENGTH: 659158
```

```
: TYPE: DNA
: ORGANISM: Mus musculus
: FEATURE:
: NAME/KEY: misc.feature
: LOCATION: (123459)..(123478)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (602466)..(602485)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (546998)..(547017)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (494715)..(494814)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (390986)..(391005)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (346860)..(346823)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (317174)..(317193)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (280353)..(280373)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (271829)..(271848)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (183872)..(183891)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (170625)..(170645)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: LOCATION: (132680)..(132700)
: OTHER INFORMATION: n is unidentified a, c, g, or t
: NAME/KEY: misc.feature
: OTHER INFORMATION: n is a, c, g, or t
US-09-771-208-20

Query Match
Best Local Similarity 45.1%; Score 37.6; DB 9; Length 659158;
Matches 139; Conservative 0; Mismatches 169; Indels 0; Gaps 0;

OY 167 CGGAACCTTCCCTGCGAATTCAGAGAACTTCCAGCTGATCGAGAGCTGGACGAGAA 226
DB 251205 CGTGAACCTTCCCTCCATTCCTAAGTAAATGAAGCTGAGAGCTGTGATGGCGATG 251146
OY 227 GACGGAAGATGAAGAGACAGATGACATCTGCTGACAGATACATCTCCACGCTGAA 286
DB 251145 GAAGGCAAGGTGAGATGGAGGCTCTTAGAGAGAAAGAGAGAGAGAGAGAGAGAA 251086
OY 287 GACGCTGTCTCCAGACCGCGCTGAGCGCCTGAGAAAGATCCAGAACGCCCTACAGCAA 346
DB 251085 GGAGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAA 251026
OY 347 GTCAAGGAATACAGTGAAGACAAAGTGCAGCTGGCCATGACAGACTTACGAGATGATGGA 406
DB 251025 GGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAA 250966
OY 407 TAAACACATTGCAAGGCTTTCAGACCTTGGCGCCCTTTGAAGCATCTGAAGAGACAA 466
DB 250965 GGAGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAA 250906
OY 467 GATGAGAG 474
DB 250905 GGAGGAGG 250898

RESULT 15
```



```

PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 08/569721
: FILING DATE: 08-DEC-1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Mooi, Leslie A.
: REGISTRATION NUMBER: 37,047
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 415-854-7400
: TELEFAX: 415-854-8275
: INFORMATION FOR SEQ ID NO: 9:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 2061 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
: FEATURE:
: NAME/KEY: CDS
: LOCATION: 16..900
: US-08-751-230-9

```

```

Query Match          11.8%; Score 113; DB 3; Length 2061;
Best Local Similarity 72.6%; Pred. No. 2.1e-24;
Matches 146; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

```

```

QY 657 GACATGCCCGTGAGCCCAAGACGACGATGCTGCTGCGCCAGGCTCTCTATGGG 716
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 664 GACCTCCCATCGACCCCAAGACGACGATGCTGCTGCGCCAGGCTCTCTATGGG 723
QY 717 GAGATGATGGCTGTGACATTCAGACATGTCCTCAATTGAGTGGTTTCATTGCGCTG 776
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 724 GAGATGATGGCTGTGACATTCAGACGAGATGTCCTCAATTGAGTGGTTTCATTGCGCTG 783
QY 777 GACCTTACACAGAAACCAAGAAATGTTCTGTCACGCGTGTGTCCAGAAAGAGG 836
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 784 GGGCTCATCATTAACCCCAAGGGCAAGTGTACTGTCCCAAGTGGCGGGGAGAACGAG 843
QY 837 AAGAAGAGTAGAGAGAGCTG 857
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 844 AAGACCATGACAAAGCCCTG 864

```

```

RESULT 13
US-09-499-082-9
: Sequence 9, Application US/09499082
: Patent No. 6143522
: GENERAL INFORMATION:
: APPLICANT: Helding, Caren C.
: APPLICANT: Riadowol, Karl
: APPLICANT: Johnston, Randall N.
: APPLICANT: Garkavtsev, Igor
: TITLE OF INVENTION: METHODS OF MODULATING APOPTOSIS
: NUMBER OF SEQUENCES: 23
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Burns, Doane, Swecker & Mathis
: STREET: 699 Prince Street
: CITY: Alexandria
: STATE: VA
: COUNTRY: USA
: ZIP: 22313-1404
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/499,082
: FILING DATE:
: CLASSIFICATION:
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US/08/828,158
: FILING DATE: 27-MAR-1997

```

```

: APPLICATION NUMBER: US 08/751230
: FILING DATE: 15-NOV-1996
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: US 08/569721
: FILING DATE: 08-DEC-1995
: ATTORNEY/AGENT INFORMATION:
: NAME: Mooi, Leslie A.
: REGISTRATION NUMBER: 37,047
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 415-854-7400
: TELEFAX: 415-854-8275
: INFORMATION FOR SEQ ID NO: 9:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 2061 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: linear
: MOLECULE TYPE: cDNA
: FEATURE:
: NAME/KEY: CDS
: LOCATION: 16..900
: US-09-499-082-9

```

```

Query Match          11.8%; Score 113; DB 3; Length 2061;
Best Local Similarity 72.6%; Pred. No. 2.1e-24;
Matches 146; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

```

```

QY 657 GACATGCCCGTGAGCCCAAGACGACGATGCTGCTGCGCCAGGCTCTCTATGGG 716
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 664 GACCTCCCATCGACCCCAAGACGACGATGCTGCTGCGCCAGGCTCTCTATGGG 723
QY 717 GAGATGATGGCTGTGACATTCAGACATGTCCTCAATTGAGTGGTTTCATTGCGCTG 776
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 724 GAGATGATGGCTGTGACATTCAGACGAGATGTCCTCAATTGAGTGGTTTCATTGCGCTG 783
QY 777 GACCTTACACAGAAACCAAGAAATGTTCTGTCACGCGTGTGTCCAGAAAGAGG 836
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 784 GGGCTCATCATTAACCCCAAGGGCAAGTGTACTGTCCCAAGTGGCGGGGAGAACGAG 843
QY 837 AAGAAGAGTAGAGAGAGCTG 857
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 844 AAGACCATGACAAAGCCCTG 864

```

```

RESULT 14
US-09-258-372-9
: Sequence 9, Application US/09258372
: Patent No. 6238918
: GENERAL INFORMATION:
: APPLICANT: Garkavtsev, Igor
: APPLICANT: Riadowol, Karl
: TITLE OF INVENTION: DNA SEQUENCE ENCODING THE TUMOR
: NUMBER OF SEQUENCES: 23
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Burns, Doane, Swecker & Mathis
: STREET: 699 Prince Street
: CITY: Alexandria
: STATE: VA
: COUNTRY: USA
: ZIP: 22313-1404
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: IBM PC compatible
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/09/258,372
: FILING DATE:
: CLASSIFICATION:
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 08/751,230

```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA: US/09/258,372
APPLICATION NUMBER: 08/751,230
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/751,230
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: MOOI, Leslie A.
REGISTRATION NUMBER: 37,047
REFERENCE/DOCKET NUMBER: 028722-144
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-854-7400
TELEFAX: 415-854-8275
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1902 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 109..741
US-09-258-372-1

Query Match 11.8%; Score 113; DB 4; Length 1902;
Best Local Similarity 72.6%; Pred. No. 2e-24;
Matches 146; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 657 GACATCCCCGTGAGCCCAAGCAACCCAGTACTGCTGTGCACAGGTCTCTATGGG 716
DB 505 GACCTCCCATGACCCCAAGCAACCCAGTACTGCTGTGCACAGGTCTCTATGGG 564
QY 717 GAGATGATGGCTGTGACATCAATCCAGACTGTCCAAATTGAGTGGTTTCACTTGGCTGCGTG 776
DB 565 GAGATGATGGCTGTGACATCAATCCAGACTGTCCAAATTGAGTGGTTTCACTTGGCTGCGTG 624
QY 777 GACCTTACCAAGCAACCAAGAAATGTTCTGTCCAGGTGTGCCAGAAAGAGG 836
DB 625 GGGCTCAATCATTAACCAAGGCAAGTGTACTGTCCCAAGTGGCGGGGAGAAAGAGG 684
QY 837 AAGAAGATAGAGAGAGCTG 857
DB 685 AAGACCATGACAAAGCCCTG 705

RESULT 11

US-09-258-371-9
Sequence 9, Application US/09258371
Patent No. 5986078
GENERAL INFORMATION:
APPLICANT: Garkavtsev, Igor
APPLICANT: Riabowol, Karl
TITLE OF INVENTION: DNA SEQUENCE ENCODING THE TUMOR
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Burns, Doane, Swecker & Mathis
STREET: 699 Prince Street
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/258,371
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/751,230
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: MOOI, Leslie A.
REGISTRATION NUMBER: 37,047
REFERENCE/DOCKET NUMBER: 028722-144
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-854-7400
TELEFAX: 415-854-8275
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 2061 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 16..900
US-09-258-371-9

Query Match 11.8%; Score 113; DB 2; Length 2061;
Best Local Similarity 72.6%; Pred. No. 2.1e-24;
Matches 146; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 657 GACATCCCCGTGAGCCCAAGCAACCCAGTACTGCTGTGCACAGGTCTCTATGGG 716
DB 664 GACCTCCCATGACCCCAAGCAACCCAGTACTGCTGTGCACAGGTCTCTATGGG 723
QY 717 GAGATGATGGCTGTGACATCAATCCAGACTGTCCAAATTGAGTGGTTTCACTTGGCTGCGTG 776
DB 724 GAGATGATGGCTGTGACATCAATCCAGACTGTCCCAATGAGTGGTTTCACTTGGCTGCGTG 783
QY 777 GACCTTACCAAGCAACCAAGAAATGTTCTGTCCAGGTGTGCCAGGAAAGAGG 836
DB 784 GGGCTCAATCATTAACCAAGGCAAGTGTACTGTCCCAAGTGGCGGGGAGAAAGAGG 843
QY 837 AAGAAGATAGAGAGAGCTG 857
DB 844 AAGACCATGACAAAGCCCTG 864

RESULT 12

US-08-751-230-9
Sequence 9, Application US/08751230
Patent No. 6117633
GENERAL INFORMATION:
APPLICANT: Garkavtsev, Igor
APPLICANT: Riabowol, Karl
TITLE OF INVENTION: DNA SEQUENCE ENCODING THE TUMOR
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Burns, Doane, Swecker & Mathis
STREET: 699 Prince Street
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22313-1404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/751,230
FILING DATE: 15-NOV-1996
CLASSIFICATION: 514

QY	576	GACACACCAAGAAAAGAACAGACAAAGAGAGGGGTGCTAGTTCACTGACACATCTGTC	635
Db	451	GACACACCAAGAAAAGAACAGACAAAGAGAGGGGTGCTAGTTCACTGACACATCTGTC	510
QY	636	GTGCACCCCTCTGATGTGCTGGACATGCCCGTGGACCCCAACGACCCAGTACTGCTG	695
Db	511	GTGCACCCCTCTGATGTGCTGGACATGCCCGTGGACCCCAACGACCCAGTACTGCTG	570
QY	696	TGCCACCAAGCTCTCTATTGGGAGATATTGGCTGTGACATCCAGACTGTCCAATTGAG	755
Db	571	TGCCACCAAGCTCTCTATTGGGAGATATTGGCTGTGACATCCAGACTGTCCAATTGAG	630
QY	756	TGGTTCACTTGGCTGCGTGGACCTTACACAGAAACCCAAAGGAAA	803
Db	631	TGGTTCACTTGGCTGCGTGGACCTTACACAGAAACCCAAAGGAAA	678
RESULT 2			
US-09-195-286-2			
: Sequence 2, Application US/09195286			
: Patent No. 6066474			
: GENERAL INFORMATION:			
: APPLICANT: Marcou, Kenneth B.			
: TITLE OF INVENTION: Y2H56 A STRONG IKK BINDING PROTEIN			
: FILE REFERENCE: Docket No. 6066474 178-258			
: CURRENT APPLICATION NUMBER: US/09/195,286			
: CURRENT FILING DATE: 1998-11-18			
: NUMBER OF SEQ ID NOS: 3			
: SOFTWARE: PatentIn Ver. 2.0			
: SEQ ID NO 2			
: LENGTH: 699			
: TYPE: DNA			
: ORGANISM: Homo sapiens			
: US-09-195-286-2			

Query Match	66.5%	Score 636.8;	DB 3;	Length 699;
Best Local Similarity	98.9%	Pred. No. 1.5e-183;		
Matches 641;	Conservative	0;	Mismatches 7;	Indels 0;
				Gaps 0

QY	156	CTGTAGAGTATCGAAGACCTTCCCTGGAACTTCAGAGAAACTTCAGCTGATGCGAG	215
Db	52	CTGAGACGTATCGACACCATCTCCCTGGAACTTCAGAGAACTTCCAGCTGATGCGAG	111
QY	216	CTGAGCCAGAGAGCGAAGATTAAGAAAGCAGAGATTACATCTCGCTGCAGAGTACATC	275
Db	112	CTGGACCGAGAGAGCGAAAGATTAAGAAAGCAGAGATTACATCTCGCTGCAGAGTACATC	171
QY	276	TTCCACGGTGAAGACGCTGTCTCCAGACCAGCGCGTGGAGCGCCTGCAGAAAGATCCAGAAC	335
Db	172	TTCCACGGTGAAGACGCTGTCTCCAGACCAGCGCGTGGAGCGCCTGCAGAAAGATCCAGAAC	231
QY	336	GCCATACAGCAAGTCACCAAGGAATACAGTACAGACAAACTGAGCTGGCGATACGACCTTAC	395
Db	232	GCCATACAGCAAGTCACCAAGGAATACAGTACAGACAAACTGAGCTGGCGATACGACCTTAC	291
QY	396	GAGATGTGTGATTAACACCATTCGAAAGGCTTGATGACAGCACTGGCGCGCTTTGAAGCAGAT	455
Db	292	GAGATGTGTGATTAACACCATTCGAAAGGCTTGATGACAGCACTGGCGCGCTTTGAAGCAGAT	351
QY	456	CTGAAGGACAAGATGAGAGGCACTGATTTTGAAGAGCTCCGAGAGGCGAGGTTTAAAAAAA	515
Db	352	CTGAAGGACAAGATGAGAGGCACTGATTTTGAAGAGCTCCGAGAGGCGAGGTTTAAAAAAA	411
QY	516	GGCCGGGGGTGCAAGAAAGAAAAAGGGGTCCCGGGGCGGAGCGAGAGAGATACAGAGGA	575
Db	412	GGCCGGGGGTGCAAGAAAGAAAAAGGGGTCCCGGGGCGGAGCGAGAGAGATACAGAGGA	471
QY	576	GACACACCAAGAAAGAAAGAACACAAAGAGAGGCTGTGATTCACCTGACACATCTGTCC	635
Db	472	GACACACCAAGAAAGAAAGAACACAAAGAGAGGCTGTGATTCACCTGACACATCTGTCC	531
QY	636	GTGCACCCCTCTGTATGTCTGTGACATGCCGTGTGACCCAAAGCAACCCAGTACTGCTTG	695

Db	532	GTGCACCCCTGTGATGTGCTGAGATGATGCCCTGTGACCCAAACGAAACCCAGCTATGTGCTG	591
Qy	696	TGGCACCAAGTCTCTTAATGGGAGATGATTGGCTGTGACAAATCCAGACTGTCCATTTAG	755
Db	592	TGCCACCAAGTCTCTTAATGGGAGATGATTGGCTGTGACAAATCCAGACTGTCCATTTAG	651
Qy	756	TGCTTTTCACTTTCCTCGTGTGACCTTACCAAGAAACCCAAAGGAAA	803
Db	652	TGCTTTTCACTTTCCTCGTGTGACCTTACCAAGAAACCCAAAGGAAA	699

RESULT 3
US-09-006-783A-6

GENERAL INFORMATION:

APPLICANT: Garkavstev, Igor

APPLICANT: Riabowol, Karl
TITLE OF INVENTION: n32/INCI as a Modulator of n53 Chemical

TITLE OF INVENTION: Pathway

CORRESPONDENCE ADDRESS: NUMBER OF SEQUENCES: 7;

ADDRESSEE: McDonnell Boehnen Hulbert & Berghoff

STREET: 300 South Wacker Drive
CITY: Chicago

STATE: Illinois
COUNTY: Cook

ZIP: 60606

COMPUTER READABLE FORM:

COMPUTER: IBM PC compatible

```
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #10
```

```

; CURRENT APPLICATION DATA:

```

APPLICATION NUMBER: 05/09/006, /83A
FILING DATE: 15-JAN-1998

CLASSIFICATION: 435

NAME: NO. 6297366nan, Kevin E

REGISTRATION NUMBER: 35,303
REFERENCE / DOCKET NUMBER: 07 037

TELECOMMUNICATION INFORMATION:

TELEPHONE: 312-913-0000
TELEFAX: 312-913-0002

; INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:
LENGTH: 633 base pairs

TYPE: nucleic acid

TOPOLOGY: linear

MOLECULE TYPE: CDNA

NAME/KEY: CDS ;

LOCATION: 1..630
; NIS-09-006-783A-6

Query Match	11.8%	Score 113;	DB 4;	Length 633;
Best Local Similarity	72.68%	Pred. No. 1.1e-24;		
Matches 146; Conservative	0;	Mismatches 55;	Indels 0;	Gaps 0

[illegible]

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 22, 2003, 19:24:43 : Search time 69 Seconds
(without alignments)
4257.918 Million cell updates/sec

Title: US-09-442-013-7
Perfect score: 958
Sequence: 1 ttgtgtacctcagccctgc.....cgtgtactactagtaacaa 958

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 15338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

Issued_Patents_NA:*
1: /cgn2-6/ptodata/1/lna/5A_COMB.seq:*
2: /cgn2-6/ptodata/1/lna/5B_COMB.seq:*
3: /cgn2-6/ptodata/1/lna/6A_COMB.seq:*
4: /cgn2-6/ptodata/1/lna/6B_COMB.seq:*
5: /cgn2-6/ptodata/1/lna/PCtUS_COMB.seq:*
6: /cgn2-6/ptodata/1/lna/backfillseq1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	636.8	66.5	678	US-09-195-286-3	Sequence 3, Appli
2	636.8	66.5	699	US-09-195-286-2	Sequence 2, Appli
3	113	11.8	633	US-09-006-783A-6	Sequence 6, Appli
4	113	11.8	873	US-09-006-783A-4	Sequence 4, Appli
5	113	11.8	1902	US-09-258-257-1	Sequence 1, Appli
6	113	11.8	1902	US-09-258-371-1	Sequence 1, Appli
7	113	11.8	1902	US-08-568-721A-1	Sequence 1, Appli
8	113	11.8	1902	US-08-751-230-1	Sequence 1, Appli
9	113	11.8	1902	US-09-499-082-1	Sequence 1, Appli
10	113	11.8	1902	US-09-258-372-1	Sequence 1, Appli
11	113	11.8	2061	US-09-258-371-9	Sequence 9, Appli
12	113	11.8	2061	US-08-751-230-9	Sequence 9, Appli
13	113	11.8	2061	US-09-499-082-9	Sequence 9, Appli
14	113	11.8	2061	US-09-258-372-9	Sequence 9, Appli
15	113	11.8	2061	US-09-006-783A-2	Sequence 2, Appli
16	113	11.8	2061	US-09-159-871-1	Sequence 1, Appli
17	97	10.1	840	US-09-601-478-6	Sequence 6, Appli
18	97	10.1	1078	US-09-601-478-7	Sequence 7, Appli
19	97	10.1	1154	US-09-484-970B-81	Sequence 81, Appli
20	75.8	7.9	7218	US-08-232-463-14	Sequence 14, Appli
21	46.8	4.9	289	US-09-007-005-17	Sequence 17, Appli
22	46.8	4.9	289	US-09-244-796-17	Sequence 17, Appli
23	41.4	4.3	2338	US-08-425-069-1	Sequence 1, Appli
24	41.4	4.3	2338	US-08-317-844B-1	Sequence 1, Appli
25	40.2	4.2	277	US-09-007-005-3	Sequence 3, Appli
26	40.2	4.2	277	US-09-244-796-3	Sequence 3, Appli
27	39.8	4.2	248	US-09-007-005-32	Sequence 32, Appli

28	39.8	4.2	248	4	US-09-244-796-32	Sequence 32, Appli
29	39	4.1	451	4	US-09-370-838-146	Sequence 146, App
30	37.8	3.9	1995	2	US-08-425-069-3	Sequence 3, Appli
31	37.8	3.9	1995	2	US-08-317-844B-3	Sequence 3, Appli
32	37.4	3.9	3588	1	US-08-197-792-32	Sequence 32, Appli
33	37.4	3.9	3588	1	US-08-459-850-32	Sequence 32, Appli
34	37.4	3.9	3588	1	US-08-459-850-32	Sequence 32, Appli
35	36.2	3.8	51259	3	US-08-781-891-209	Sequence 209, App
36	35.8	3.7	3416	2	US-08-357-642A-2	Sequence 2, Appli
37	35.8	3.7	3416	2	US-08-460-626-2	Sequence 2, Appli
38	35	3.7	1926	4	US-09-249-585A-4	Sequence 4, Appli
39	35	3.7	1931	2	US-09-130-114-2	Sequence 2, Appli
40	35	3.7	2576	1	US-08-471-033-35	Sequence 35, Appli
41	35	3.7	2576	2	US-08-471-044-35	Sequence 35, Appli
42	35	3.7	2576	2	US-08-463-483A-35	Sequence 35, Appli
43	35	3.7	2576	2	US-08-471-046A-35	Sequence 35, Appli
44	35	3.7	2576	2	US-08-470-566B-35	Sequence 35, Appli
45	35	3.7	2576	2	US-08-469-334-35	Sequence 35, Appli

ALIGNMENTS

RESULT 1
US-09-195-286-3
Sequence 3, Application US/09195286
Patent No. 6066474
GENERAL INFORMATION:
APPLICANT: Marcu, Kenneth B.
TITLE OF INVENTION: Y2H56 A STRONG IKK BINDING PROTEIN
FILE REFERENCE: Docket No. 6066474 178-258
CURRENT FILING DATE: 1998-11-18
NUMBER OF SEQ ID NOS: 3
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 3
LENGTH: 678
TYPE: DNA
ORGANISM: Homo sapiens
US-09-195-286-3

Query Match 66.5%, Score 636.8; DB 3; Length 678;
Best Local Similarity 98.9%; Pred. No. 1.4e+183;
Matches 641; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY	156	CTGATAGTATTCGACACCTTCCTCGCACTTCGAGAGCACTTCACCTGATGCGAG	215
DB	31	CTGGACAGTATTCGACACCTTCCTCGCACTTCGAGAGCACTTCACCTGATGCGAG	90
QY	216	CTGGACAGAGGAGCGAAGATTAAGAAACAGAGATTCATCTGCTGCGAGATATC	275
DB	91	CTGGACAGAGGAGCGAAGATTAAGAAACAGAGATTCATCTGCTGCGAGATATC	150
QY	276	TCCACGAGTGAAGACGCTCTCCAGACGCGCTGAGCGCTGAGCAAGATCCAGAAC	335
DB	151	TCCACGAGTGAAGACGCTCTCCAGACGCGCTGAGCGCTGAGCAAGATCCAGAAC	210
QY	336	GCCTACACAGTATTCGACAGATTAAGAAAGTGCAGCTGCGATGCAAGCTTAC	395
DB	211	GCCTACACAGTATTCGACAGATTAAGAAAGTGCAGCTGCGATGCAAGCTTAC	270
QY	396	GAGATGGGTGAACACATTCGAGAGGCTGTGTCGAGACCTGGCGCTTTGAAGCAGAT	455
DB	271	GAGATGGGTGAACACATTCGAGAGGCTGTGTCGAGACCTGGCGCTTTGAAGCAGAT	330
QY	456	CTGAAGCAAGATGAGGAGGAGTATTTGAAGCTCCGAGGCGAGGGTTAAAAAAA	515
DB	331	CTGAAGCAAGATGAGGAGGAGTATTTGAAGCTCCGAGGCGAGGGTTAAAAAAA	390
QY	516	GGCGGGGTCAAGAAAGAAAGAGGCTCCGGGGCCAGGAGGAGGACATCAGAGGA	575
DB	391	GGCGGGGTCAAGAAAGAAAGAGGCTCCGGGGCCAGGAGGAGGACATCAGAGGA	450